Analyses of All Possible Point Mutations within a Protein Reveals Relationships between Function and Experimental Fitness: A Dissertation by Roscoe, Benjamin P.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2014-03-25 
Analyses of All Possible Point Mutations within a Protein Reveals 
Relationships between Function and Experimental Fitness: A 
Dissertation 
Benjamin P. Roscoe 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Biochemistry Commons, Cellular and Molecular Physiology Commons, Molecular Biology 
Commons, and the Molecular Genetics Commons 
Repository Citation 
Roscoe BP. (2014). Analyses of All Possible Point Mutations within a Protein Reveals Relationships 
between Function and Experimental Fitness: A Dissertation. GSBS Dissertations and Theses. 
https://doi.org/10.13028/M2G027. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/716 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 ANALYSES OF ALL POSSIBLE POINT MUTATIONS WITHIN A PROTEIN 
REVEALS RELATIONSHIPS BETWEEN FUNCTION AND EXPERIMENTAL 
FITNESS 
 
A Dissertation Presented 
 
By 
 
BENJAMIN PETER ROSCOE 
 
 
Submitted to the Faculty of the 
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
in partial fulfillment for the degree of 
 
 
DOCTOR OF PHILOSOPHY 
 
 
(March 25, 2014) 
 
BIOCHEMISTRY AND MOLECULAR PHARMACOLOGY   
  
ANALYSES OF ALL POSSIBLE POINT MUTATIONS WITHIN A PROTEIN 
REVEALS RELATIONSHIPS BETWEEN FUNCTION AND EXPERIMENTAL 
FITNESS 
 
A Dissertation Presented 
 
By 
 
BENJAMIN PETER ROSCOE 
 
The signatures of the Dissertation Defense Committee signify completion and approval 
as to style and content of the Dissertation 
 
 
Daniel N. Bolon, Ph.D., Thesis Advisor 
 
 
C. Robert Matthews, Ph.D., Member of Committee 
 
 
William E. Royer, Ph.D., Member of Committee 
 
 
Peter M. Pryciak, Ph.D, Member of Committee 
 
 
Douglas M. Fowler, Ph.D., Member of Committee 
 
 
The signature of the Chair of the Committee signifies that the written dissertation meets 
the requirements of the Dissertation Committee 
 
 
Reid Gilmore, Ph.D., Chair of Committee 
 
 
The signature of the Dean of the Graduate School of Biomedical Sciences signifies that 
the student has met all graduation requirements of the school 
 
 
Anthony Carruthers, Ph.D., 
Dean of the Graduate School of Biomedical Sciences 
 
 
iii 
 
Dedication 
  
This work is dedicated to my mother and father, Peter Jack Roscoe and  
Erika Maria Roscoe. 
  
iv 
 
Acknowledgements 
 Before matriculating in the UMass Medical School Graduate School of Biological 
Sciences, I believed a doctorate program was another hoop to jump through for a 
distinguished career in the biomedical sciences. I have found this outlook to be extremely 
shortsighted and cannot begin to quantitate my personal growth as a scientist and human. 
Most importantly, I now realize this growth should always be encouraged and pursued by 
all people. I could not have started this lifelong journey without the individuals 
acknowledged below: 
 I would like to thank my advisor, Daniel N. Bolon, Ph.D., for continually pushing 
me to always make concrete advances in any tasks I pursue, and for being a constant 
source of projects and ideas, as well as accepting and encouraging my ideas. Next, I 
would like to recognize all of my current and former Bolon lab members for constant 
personal and scientific interactions, Ryan Hietpas, Ph.D., Natalie Wayne Pursell Ph.D., 
Parul Mishra, Ph.D., Li Jiang, Pamela Cote, Aneth Laban, Lester Pullen, and Dan Virgil. 
 I would also like to thank my GSBS classmates Paul Nobrega, Kenneth Lloyd, 
and Sarah Grace Swygert for scientific discussions, support, and editing duties. 
 Additionally, I must recognize the incredible assistance of the UMass Medical 
school flow cytometry core staff that helped integrate flow cytometry and cell sorting 
into the middle of my thesis research almost seamlessly. Most of the work in chapter III 
would not have been possible without their expertise. 
  
v 
 
My thesis advisory committee members have given indespensible advice 
throughout my research, thank you to Reid Gilmore, William Royer, C. Robert 
Matthews, Francesca Massi and Peter Pryciak. I also want to give special thanks to Ken 
Knight, GSBS assistant Dean for lots of personal support, and Dean Anthony Carruthers 
for personal communications regarding my projects. 
 
  
  
  
vi 
 
Abstract 
The primary amino acid sequence of a protein governs its specific cellular 
functions. Since the cracking of the genetic code in the late 1950’s, it has been possible to 
predict the amino acid sequence of a given protein from the DNA sequence of a gene. 
Nevertheless, the ability to predict a protein’s function from its primary sequence remains 
a great challenge in biology.  In order to address this problem, we combined recent 
advances in next generation sequencing technologies with systematic mutagenesis 
strategies to assess the function of thousands of protein variants in a single experiment. 
Using this strategy, my dissertation describes the effects of most possible single point 
mutants in the multifunctional Ubiquitin protein in yeast. The effects of these mutants on 
the essential activation of ubiquitin by the ubiquitin activating protein (E1, Uba1p) as 
well as their effects on overall yeast growth were measured. Ubiquitin mutants defective 
for E1 activation were found to correlate with growth defects, although in a non-linear 
fashion. Further examination of select point mutants indicated that E1 activation 
deficiencies predict downstream defects in Ubiquitin function, resulting in the observed 
growth phenotypes. These results indicate that there may be selective pressure for the 
activity of the E1enzyme to selectively activate ubiquitin protein variants that do not 
result in functional downstream defects. Additionally, I will describe the use of similar 
techniques to discover drug resistant mutants of the oncogenic protein BRAFV600E in 
human melanoma cell lines as an example of the widespread applicability of our strategy 
for addressing the relationship between protein function and biological fitness. 
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Chapter I - Introduction 
Cellular function is mediated by biochemical interactions of all the molecules in a 
cell. The primary amino acid sequence of a given protein determines its cellular function 
via its structure1 and the biochemical interactions mediated by its amino acid side chains.. 
Since the cracking of the genetic code in the late 1950’s, it has been possible to predict 
the primary amino acid sequence of a given protein from the coding DNA sequence.2,3,4 
Although it remains difficult to predict the 3-dimensional structure of a folded protein 
from a DNA coding sequence, great advances in structural determination of proteins by 
x-ray crystallography, NMR, and electron microscopy have resulted in over 90,000 
solved protein structures deposited in the RCSB Protein Data Bank.5 Predicting protein 
function from primary amino acid sequence is an even more daunting task, with the 
primary methods being phylogenetic comparisons of DNA coding sequences and 
homology modeling of similar protein domains6. Therefore, experimental techniques to 
systematically determine the role of each amino acid position of a protein on biochemical 
and cellular function are proving to be very valuable to link protein function with 
sequence7. The following work describes insights gained from studying the consequences 
on biochemical function and cellular growth by high-throughput measurements of all 
possible point mutants of a protein.  
 
 
 
 
2 
 
Analysis of protein function using systematic mutagenesis 
 
Systematic mutagenesis (introducing amino acid substitutions at all positions of 
an entire protein or region of interest) of proteins has been achieved for many years 
through error prone PCR or replacing portions protein-coding genes with cassette-based 
oligonucleotides containing synthetically introduced randomized codons8,9. High 
throughput methods to screen mutants generated by these methods were previously 
limited by the ability to analyze the function of many variants at the same time. Previous 
methods included Sanger (inhibition of polymerization reactions with randomly 
incorporated dideoxy nucleotides) sequencing, amber-codon suppression in E. coli to 
screen for functional variants,10 and proteomic screens to detect mutant protein sequences 
after selection.11 The fairly recent advent of next generation DNA sequencing techniques 
now allows for the analysis of millions of DNA sequence reads from a single pool of 
DNA. Within the last 5 years, multiple investigators have reported high throughput 
analysis of large pools of protein variants using various selection techniques (e.g. growth 
competition, phage display) analyzed by deep sequencing.12–17 
 Recently, multiple strategies combining high-throughput mutagenesis coupled 
with deep-sequencing readouts have been developed and utilized by various researchers. 
Each strategy has inherent advantages and disadvantages that should be carefully 
considered for each experimental application. Some investigators, including Stan Fields 
et al,18 and Doug Fowler et al12 utilize error prone PCR and/or error prone 
oligonucleotide synthesis to generate tens to hundreds of thousands of variants within a 
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single library. This is a very powerful approach because of the massive number of 
mutants that can be screened simultaneously. Another advantage of this strategy is that 
both single and multiple mutations are generated in the library, so the effects of multiple 
substitutions can be determined. The study of epistatic mutations within a single protein 
is a current area of immense interest in the field of protein sequence evolution.19 The 
disadvantage to random mutagenesis techniques is that it is difficult to capture every 
single amino acid substitution within a library, as there is no way to prevent multiple 
substitutions when increasing the PCR or oligonucleotide synthesis error rate. Therefore, 
the library size would have to be untenably large to ensure all single mutants are covered. 
For applications such as screening for drug resistant mutants within a target protein, it is 
advantageous to screen for only single point mutations, as these are probabilistically the 
most likely mutations to occur in a clinical setting.20 
 Work in our lab and presented throughout this thesis systematically builds a 
mutant library containing every codon within a protein sequence with all 64 possible 
codons.13,14 This is achieved by generating a self-removable fragment from the region of 
the gene to be mutagenized by the addition of inverted type-II endonuclease (specifically 
BsaI) sites within the gene (Figure 1.1a,b). Type-II endonucleases cut outside of their 
DNA recognition sequence and allow for excision of the region to be mutagenized 
leaving 4 base pair overlapping ends that can then have cassette libraries containing 
randomized codons ligated within the gene (Figure 1.1c). These mutant libraries are then 
able to be tested in multiple types of high-throughput experiments, including the ability to 
support growth as a single copy in yeast (figure 1.2)13,14, or for specific biochemical 
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functions by harnessing display technologies such as yeast surface and phage display to 
display library variants on the surface of a yeast cell or phage particle, and screening for 
specific interactions. Deep sequencing can then be used to tabulate the overall abundance 
of point mutants in the initial library compared to specified experimental conditions, 
whether it is abundance in a cell population over time, or enrichment/depletion after a 
biochemical screen.   
This methodology provides multiple advantages, although less total mutants (and 
no multiple substitutions within the same protein) are screened than in the approaches 
described above:  One advantage is that by substituting every codon, all WT synonyms 
and stop codons (missense mutations) are sampled, resulting in a large number of internal 
controls for WT synonymous and truncated protein sequences that are useful for 
normalizing enrichment and depletion of point mutants. Another advantage of this 
strategy is that the effect of protein point mutations can be averaged across synonymous 
codons, giving a better handle on variation within a single experiment, and greater 
confidence in measurements.  An additional benefit is that this strategy has the potential 
to differentiate between activities between synonymous codons, although we have not 
observed this phenomenon within our experiments to date. Perhaps the most important 
advantage to this method is that by systematically substituting with all possible mutations 
at each position in a protein, we can obtain detailed information regarding the chemical 
and physical requirements of each amino acid within a protein. Chapters 2-4 will report 
on positions of the proteins ubiquitin and BRAF V600E where very modest substitutions 
(e.g. substitutions with residues of similar physical and chemical properties) at specific 
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amino acid positions are not tolerated, indicating specific biochemical interactions are 
perturbed. 
 
  
6 
 
Figure 1.1. Steps to generate plasmid libraries of point mutants. (a) Whole-plasmid PCR 
to generate inverted BsaI vector that can be fully excised with the BsaI endonuclease. (b) 
Digestion of this vector to generate directional sticky-ends. (c) Cassette ligation to 
introduce point mutants in frame with the gene. 
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Figure 1.1. Steps to generate plasmid libraries of point mutants. 
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Figure 1.2. Bulk competition of libraries of point mutants in yeast. (a) Plasmid libraries 
are transformed into yeast. (b) Yeast that have taken up a plasmid are selected for and 
amplified. (c) Selection pressure is applied to the library copy of the mutated gene and 
samples are collected over time in bulk-competition. 
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Figure 1.2. Bulk competition of libraries of point mutants in yeast. 
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Fitness measurements and application to experimental evolution 
 
Mutations allow adaptation of organisms under selective pressures through 
natural selection.21 While this theory has been extensively studied in population genetics 
studies of natural populations, until recently, there has been little experimental 
methodology available to scan the mechanisms of mutant accumulation in the laboratory 
setting. Recent work on hsp90 by Ryan Hietpas, et al from our group provided 
convincing experimental support for the nearly neutral theory of evolution posited by Dr. 
Mootoo Kimura based on predictions of population genetics models in 1983.22 This work 
examined the tolerance of the highly conserved multifunctional hsp90 protein to 
mutation, which resulted in a biphasic distribution of growth effects for point mutations 
depending on the position in the protein.13 Most mutations in this study were either well 
tolerated (nearly neutral), or highly deleterious. The work presented in chapter 2 of this 
dissertation demonstrates a similar result for all point mutations of residues 2-76 of 
ubiquitin in Saccharomyces cerevisae.  
 More insights from the research presented in chapter 2 of this thesis lend support 
to the theory proposed by Dr. Emile Zuckerlandl in 1976 that the functional density of 
proteins (i.e. the magnitude of molecular interactions of a given residue) correlates with 
mutational sensitivity of a given residue.23 There are over 40 distinct co-crystal structures 
of ubiquitin and binding partners in the Protein Data Bank, and we were able to strongly 
correlate the interaction density of Ubiquitin among all of these co-crystals with the 
mutational sensitivity of mutants at each residue in our screen. Interestingly, the most 
11 
 
sensitive mutants (and those with the most buried surface area in over 40 co-crystal 
structures) clustered on one side of the 3-dimensional structure of ubiquitin, indicating a 
common binding motif for many clients.    
 
High throughput analysis of specific function 
  
 Proteins contribute to cellular function through biochemical interactions. The 
specific amino acid composition of a protein dictates its structure and interaction with 
partner molecules by interaction surfaces created by the three dimensional location and 
physical properties of its amino acid side chains.1,24 The complexity of interactions that 
can be mediated by different combinations of the 20 common amino acids of proteins is 
staggering, especially with large proteins composed of hundreds or thousands of residues. 
This makes predicting the structure and function of the majority of proteins from amino 
acid sequences extremely difficult,25 and highlights the value of high-throughput 
approaches to determine the specific effects of amino acid substitutions within a given 
protein. 
 Coupling high-throughput mutagenesis techniques with protein display on the 
surface of phage26,27 (and later yeast surface display)28 has been used successfully since 
the early 1990’s to screen for protein variants with increased binding affinities to a 
particular target. Because of limitations in sequencing technology, these types of 
experiments were usually focused on mutants that were enriched after selection by 
repeated cycles of binding to a desired target, washing, and eluting. Alternatively, 
12 
 
proteins displayed on a cell surface could be separated by FACS and then sequenced in 
low/medium throughput (tens to hundreds of variants). Variants with the desired binding 
properties could then be identified by sequencing DNA from the enriched phage or yeast 
populations. The limitation of these strategies is that quantitative analysis in differences 
of interaction properties is difficult, making it difficult to detect variants with reduced 
affinity.  
 The advent of next generation nucleic acid sequencing technologies has made it 
possible to identify millions of DNA sequences from a single pool of DNA. This 
capability has made it possible for researchers to scan hundreds of thousands of protein 
variants in single display experiments and make quantitative estimates about relative 
binding properties. For example, Doug Fowler and Carlos Araya et al while in Stan 
Fields’ laboratory utilized phage display coupled with deep sequencing analysis in a 
technique they refer to as “deep mutational scanning,” to analyze the binding of >600,000 
amino acid variants of a human WW domain to its peptide substrate, and were able to 
report features important to binding that would not be evident from analysis of fewer 
mutations at each position (e.g. alanine scanning)12. These findings were then extended to 
determine the thermodynamic properties of the WW domain amino acid primary amino 
acid sequence that affected binding.16 This group was also able to screen thousands of 
mutants of the RRM domain of a poly-A binding protein and determine the epistatic 
effects of substitutions at multiple sites within the same protein. Further evidence of the 
synergy between these techniques is evidenced by the discovery of activity-enhancing 
mutations in an E3 ubiquitin ligase by Lea M. Starita et al.18 
13 
 
 It is a significant challenge to determine how a specific biochemical interaction of 
a given protein affects the overall function of a cell. Some proteins are not essential or 
only affect the phenotype of a cell under specific conditions (e.g. temperature stress, 
starvation, or DNA damage), while other proteins perform many functions, all of which 
can contribute to growth defects. The relationship between a specific biochemical activity 
and experimental fitness of a protein that performs a single function can be predicted 
from biochemical flux models.29,30 In these cases, there is a threshold of specific activity 
that can be reduced (elasticity function) before observing a decrease in growth rate, and 
then with further reduction of activity, a decrease in growth rate that can be fit to an 
exponential function and correlated to growth rate. Nevertheless, many proteins are 
involved in multiple cellular interactions, and the fitness effect of any given mutation can 
be explained by either the effect on one rate limiting step or a combination of multiple 
processes, making predictions of mutant effects from a single function extremely 
difficult. Therefore, high throughput measurements of mutant libraries for specific 
biochemical functions can be compared to experimental fitness data to determine the 
effect of a given function on experimental fitness. Chapters II+III of this dissertation 
report high-throughput measurements of the relative E1 reactivity of all ubiquitin point 
mutants, and insights into how this one essential activity correlates with the growth rate 
in yeast. 
  
Ubiquitin is a 76 amino acid protein that predominately acts as an intracellular 
signaling molecule by covalently attaching to substrates via its c-terminus or lysine (K) 
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sidechains.31,32 Ubiquitin can also form chains of varying length and structure by 
covalently attaching to other ubiquitin molecules through any of its seven lysines, as well 
as the amino and carboxyl termini. Many different structural orientations can be formed 
through the various polyubiquitin linkages mediated by E1, E2, and E3 ubiquitin ligases, 
and these structures can be specifically recognized by different binding partners and 
receptors (as reviewed by Daniel Finley in the 2009 Annual Review of Biochemistry).32 
For example, K48-linked tetrameric ubiquitin is required for efficient targeting of 
substrates to the 26S proteasome for degradation.33  Attachment of single molecules of 
ubiquitin to substrates via K63 has been shown to be involved in DNA repair, and 
multiple other linkages (including K63-linked polyubiquitin) are involved in everything 
from signaling proteins for protein trafficking to chromatin remodeling in the nucleus to 
control gene expression.34,35   
Ubiquitin interacts directly with hundreds of binding partners in the cell, even 
excluding substrates that are targeted for proteasomal degradation. Most of these 
interactions are mediated by ubiquitin binding domains (UBD) and ubiquitin interacting 
motifs (UIM) homology regions found in most binding partners.36,37 Activation of 
ubiquitin by the E1 ubiquitin activating enzyme (Uba1p is the sole E1 in yeast) is 
essential as the first step for the formation of polyubiquitin chains.  This activation 
consists of a two-step process where ubiquitin is first adenylated by E1, and then the 
catalytic cysteine of E1 forms a thioester bond with the C-terminus of ubiquitin. The 
attached ubiquitin can then be transferred to an E2 enzyme that associates with the E1 
(dozens in eukaoryotes). The different E2 molecules can then transfer ubiquitin to other 
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molecules with different linkages according to the specific E2 activity (although there is 
overlap between linkages formed within even the same E2 enzymes, an area of active 
research)38 Ubiquitin can then be transferred to specific substrates by multiple 
mechanisms. Ubiquitin can either be transferred to a thioster-linkage with an E3 ubiquitin 
ligase (hundreds in eukaryotes) which directly interacts with substrates and transfers the 
ubiquitin to the substrate, or alternatively, some E3’s interact with RING domains that 
mediate transfer of ubiquitin from E3 to the substrate.39 Some substrates also react 
directly with E2’s and ubiquitin transfer is mediated by transfer of the ubiquitin to a 
HECT-domain containing protein followed by transfer to the substrate.40   
 Ubiquitin is an essential protein in all eukaryotes and defects with the 
ubiquitination and proteasome pathway are associated in multiple human diseases, 
including cancer and neurodegenerative diseases.41 Because ubiquitin is involved in so 
many interactions, it is difficult to determine precisely which functions are perturbed by 
any defect in ubiquitin or its conjugation system. Any ubiquitin mutants that effect 
cellular function may be defective at any one or any combination of processes. To begin 
to determine how ubiquitin point mutants effect cellular function, we made a yeast library 
containing all ubiquitin point mutants, and determined the competitive growth rate of 
each single ubiquitin mutant (growth rate compared to wild type in the same culture) of 
each point mutant. This results from this study is reported in chapter II of this 
dissertation, with analysis of the mutational sensitivity of each residue of ubiquitin that 
correlates defects in growth rates with known interactions of many binding partners. To 
extend this study to determine how one essential interaction, activation of ubiquitin by 
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the sole E1 in yeast, we expressed the same ubiquitin mutant libraries on the surface of 
yeast and tested the ability of the yeast libraries to react with E1. By sorting reactive 
ubiquitin variants, we were able to quantitatively assess the reactivity of most point 
mutants (described in chapter III of this dissertation). Because E1 activation of ubiquitin 
is essential for yeast growth, we expected that variants that were not able to be activated 
would also be growth defective. Surprisingly, we found that the ability of ubiquitin 
variants to be activated could be reduced up to 50-fold compared to wild-type ubiquitin 
and still support yeast growth (figure 3.6). Another unexpected finding was that an 
overwhelming majority of variants that reacted efficiently with E1 did not exhibit growth 
defects, even with the potential for perturbation of hundreds of other interactions 
downstream and independent of E1 activation.  The combination of these two studies 
provides a unique examination into the effects of saturation mutagenesis of a whole 
essential protein that is involved in many cellular processes.    
 
Structural Insights 
 The primary amino acid sequence of a protein determines its final folded structure 
within a cell.1 Ubiquitin is an extremely stably folded small protein that can withstand 
temperatures of up to 90º C at pH 4.0 without melting.42 By analyzing the sensitivity of 
mutations to residues to the core of ubiquitin, we were able to determine which positions 
were especially sensitive to mutation, even with substitutions of other branched aliphatic 
residues (isoleucine, leucine, and valine). These substitutions were not predicted to cause 
unfolding (Figure 2.7d), and tended to be located at regions in the core that were 
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proximal to surface residues involved in many interactions (Figure 2.7). These findings 
demonstrate that high-resolution information about the sensitivity of core residues to 
mutation can give strong insights into protein function, and highlight regions of the 
protein that may be involved in local structural changes or protein dynamics. Another 
potential strength of this technique is to determine the requirements of protein folding in 
cell membranes, which are difficult to purify and crystallize.  
 
Determining drug resistance by systematic mutagenesis of a protein kinase 
Single point mutations that interfere with drug binding are a common mechanism 
of the development of drug resistance.43 In chapter IV, Using the overall systematic point 
mutant screening strategy described above, we were able to determine second site 
resistance mutants to the oncogenic protein BRAFV600E which is present in many 
human cancers and 80% of human melanomas. The valine to aspartic acid mutation 
causes BRAF to constitutively phosphorylate downstream targets in the MEK and ERK 
pathways.  We generated mutant libraries in the kinase domains of BRAFV600E, and 
were able to identify over a dozen resistance mutants that were resistant to a research-tool 
inhibitor (PLX4700) analogous to the FDA approved inhibitor Vemurafineb. One of 
these mutants, L505H, is attainable by a single base substitution, which is the most likely 
mutation in a single protein drug target43 and was independently discovered by Tian Xu 
and colleagues from a vemurafenib-resistant tumor cell line derived from a human 
melanoma patient (unpublished communications with Michael R. Green).  
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Summary 
 My main goal in this dissertation is to clearly communicate the value of direct 
measurements of the effects of systematic point mutations for the functional analysis of 
proteins. Especially in light of rich structural and biochemical data available for many 
protein systems, I believe that high-throughput functional characterization can be used to 
help solve many complex problems in biology that are difficult without applying new 
technology. Because it is difficult to predict function from amino acid sequence alone, I 
hope that systematically characterizing specific biochemical interactions and fitness 
effects of entire proteins will lead to better understanding of how protein sequences 
evolve to carry out specific functions. This quantitative information, when gathered 
across many different protein systems, will help synergistically in the efforts of 
phylogenetic reconstructions in evolution, as well as predictions of protein structure and 
function.  
 These approaches are also very powerful for studying mechanisms of drug 
resistance in human cancer as well as diseases caused by bacteria and viruses, as 
mutations at the DNA level that cause single amino acid protein variants are the most 
likely to cause resistance within a drug target. While mutations outside of protein drug 
targets can cause resistance as well, these methods are not limited to mutagenizing any 
one protein, and the fast increase in high-throughput sequencing technology may soon 
lead to being able to study mutations of many proteins within a system in parallel. 
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Chapter II – Analyses of the effects of all ubiquitin  
point mutants on yeast growth rate 
 
This work has been previously published as Roscoe, B. P., Thayer, K. M., Zeldovich, K. 
B., Fushman, D. & Bolon, D. N. A. Analyses of the effects of all ubiquitin point mutants 
on yeast growth rate. J. Mol. Biol. 425, 1363–77 (2013). 
 
The work presented in this chapter was a collaborative effort of all listed authors. Dr. 
Daniel N. Bolon designed the initial Ubiquitin mutant libraries. I performed all yeast 
selection, sequencing, and single mutant generation experiments. Dr. Kelly M. Thayer 
and Dr. Konstantin M. Zeldovich calculated average surface area of ubiquitin contacts 
from solved structures in the protein data bank. Dr. Daniel N. Bolon and I both analyzed 
all data and prepared the figures and initial manuscript. Dr. Daniel N. Bolon prepared the 
final manuscript.  
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Abstract 
The amino acid sequence of a protein governs its function.  We used bulk 
competition and focused deep sequencing to investigate the effects of all ubiquitin point 
mutants on yeast growth rate. Many aspects of ubiquitin function have been carefully 
studied, which enabled interpretation of our growth analyses in light of a rich structural, 
biophysical and biochemical knowledge base. In one highly sensitive cluster on the 
surface of ubiquitin almost every amino acid substitution caused growth defects. In 
contrast, the opposite face tolerated virtually all possible substitutions. Surface locations 
between these two faces exhibited intermediate mutational tolerance. The sensitive face 
corresponds to the known interface for many binding partners. Across all surface 
positions, we observe a strong correlation between burial at structurally characterized 
interfaces and the number of amino acid substitutions compatible with robust growth. 
This result indicates that binding is a dominant determinant of ubiquitin function. In the 
solvent inaccessible core of ubiquitin all positions tolerated a limited number of 
substitutions, with hydrophobic amino acids especially interchangeable. Some mutations 
null for yeast growth were previously shown to populate folded conformations indicating 
that for these mutants subtle changes to conformation caused functional defects. The 
most sensitive region to mutation within the core was located near the C-terminus that is 
a focal binding site for many critical binding partners. These results indicate that core 
mutations may frequently cause functional defects through subtle disturbances to 
structure or dynamics. 
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Introduction  
Analyses of protein sequence-function relationships provide a powerful approach 
to understand mechanism. Mutational studies provide information on the functional 
impact of specific chemical changes to the protein. Systematic analyses of point 
mutations provide a detailed map of chemical space that can be mined to infer 
mechanism. While it has been possible to generate libraries of point mutants for many 
years9, until recently it had only been feasible to analyze the function of systematic 
mutations using amber suppresser strains of E. coli.10 Functional analyses of mutant 
libraries in non-suppresser systems can now be performed in high-throughput by utilizing 
deep-sequencing to analyze mixtures of multiple mutants simultaneously. In this 
approach, sequence profiling, originally by microarray44 and now more commonly by 
deep sequencing is used to determine the relative abundance of mutants in response to 
selective pressures.12–17,45–47 
To measure the fitness effects in cells of all possible point mutants for regions of 
genes, we developed an approach we refer to as EMPIRIC.13,14 This approach utilizes 
systematic site saturation libraries that incorporate a single degenerate codon (NNN) in 
an otherwise wild type (WT) coding sequence. Thus, all possible point mutants are 
included in the library design and the vast majority can be observed above background in 
deep sequencing analyses. We analyze libraries of point mutants in conditional yeast 
strains that contain a second copy of the gene whose activity can be tightly regulated. 
This enables the amplification of mutant libraries in yeast under permissive conditions 
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where growth is not dependent on mutant function. Adjusting conditions to turn off the 
second copy of the gene then initiates growth competition based on mutant fitness. In 
previous work, we analyzed a nine amino acid loop in yeast Hsp90.13 Here, we report 
EMPIRIC fitness analyses for the entire yeast ubiquitin gene.   
Ubiquitin is essential in all eukaryotes where it serves multiple functions via its 
ability to covalently attach to substrate proteins.32 The covalent attachment of the C-
terminus of ubiquitin to lysine side-chains is mediated by a series of enzymes referred to 
as E1, E2, and E3.31 Multiple ubiquitin molecules can be linked through covalent 
attachment between the C-terminus of one ubiquitin chain and a lysine from another 
ubiquitin.  Lysine 48 in ubiquitin is the only lysine that is essential for yeast growth.34 
K48-linked poly-ubiquitin serves as a degradation signal48 with four K48-linked 
ubiquitins sufficient to target substrates for proteasome-mediated degradation.33 Protein 
degradation by the ubiquitin-proteasome system is an important regulator of the 
composition of the proteome.49  As such, the ubiquitin-proteasome system is required for 
homeostasis under constant conditions as well as rapid cellular responses to altered 
external conditions.50 Protein degradation is often a critical signal in cells. For example, 
destruction of cyclins serves as the signal for progression through each step of the cell 
cycle51; and degradation of IκB serves as a key signal in many immune responses.52 
Disruptions to protein degradation pathways can lead to a variety of disorders including 
neurodegeneration53 and cancer.50 Protein degradation pathways have emerged as 
promising targets for therapeutic drugs, including proteasome inhibitors that are currently 
in clinical use as anti-cancer agents.54 
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Because of its central role in mediating eukaryotic physiology, ubiquitin has been 
carefully analyzed by many approaches providing the opportunity to interpret fitness 
analyses in regards to a wealth of available structural and biochemical information. In 
particular, non-covalent binding interactions are critical to ubiquitin function. For 
example, the covalent attachment of ubiquitin depends on non-covalent interfaces 
between conjugating enzymes and ubiquitin.55–58 After covalent attachment to substrates 
most known functions of ubiquitin, including delivery of substrates to the proteasome, are 
mediated by non-covalent binding to ubiquitin-binding proteins.36,59,60 There are many 
different ubiquitin-binding proteins in all eukaryotes and binding to ubiquitin is 
frequently mediated by a set of modular ubiquitin-binding domains (UBDs). The most 
common UBDs in both yeast and humans36 are the ubiquitin-interacting motif61 (UIM) 
that consists of a single α-helix62, and the ubiquitin-associated63 (UBA) domain that 
forms a three-helix bundle.64,65 Many UBDs bind to a hydrophobic patch on the surface 
of ubiquitin that includes residues L8, I44 and V70.36,66,67  
Alanine scanning of the surface positions in ubiquitin successfully demarcated 
hotspots for ubiquitin binding partners by identifying 16 residues where substitutions 
prevented yeast growth, the majority of these positions located in the proximity of the L8, 
I44, V70 hydrophobic patch as well as the K48 and C-terminal sites of covalent linkage.67  
Of note, the alanine scan used a binary scoring of mutants (presence or absence of 
observed growth) and did not quantify potential intermediate growth defects nor did it 
sample the full diversity of possible mutations leaving many questions about the 
sensitivity of ubiquitin to surface mutations unknown. For example, are conservative 
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mutations (e.g. Ile to Val) to the L8, I44, V70 hydrophobic patch functional, and at 
positions where alanine substitutions are functional are more severe mutations also 
tolerated (e.g. Asp to Lys charge reversals)?  
In addition to binding, the thermodynamics of ubiquitin folding and unfolding 
have been subject to careful analysis. Ubiquitin is highly stable to temperature 
denaturation42 and predominantly populates a folded conformation even when subject to 
near boiling temperature (90 °C) at pH 4. Though it is a small protein of 76 amino acids, 
native conformations are sufficiently thermodynamically stabilized relative to unfolded 
conformations that folding is efficient even for many disruptive mutants in the solvent-
inaccessible hydrophobic core including all individual alanine substitutions68, mutations 
that increase bulk69 and some hydrophobic to polar substitutions.70,71 Compared to their 
influence on protein folding, the impact of core mutations on ubiquitin function has not 
been thoroughly investigated. Of the few core mutants that have been studied 
functionally, we have previously analyzed Leu to Ser mutations at positions 67 and 69 
near the C-terminus of ubiquitin. Both of these substitutions were capable of folding, but 
weakened binding affinity to proteasome receptors, resulted in increased accumulation of 
high molecular weight protein species in cells, and failed to support yeast growth.70 
These results indicated that small changes to the native structure or dynamics of ubiquitin 
can impair function. 
To comprehensively examine both the sensitivity of the ubiquitin surface to 
mutation and the impact of core mutations on function, we analyzed the impacts of all 
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ubiquitin point mutants on yeast growth rate. On the surface of ubiquitin, there were ten 
ultra-sensitive positions where only the wild type amino acid was observed to support 
robust growth. We also observed a cluster of ultra-tolerant positions on the α-helical face 
of ubiquitin where virtually all amino acid substitutions were compatible with robust 
growth. Structural analyses of 44 high-resolution co-crystal structures of ubiquitin bound 
to different partners indicated that burial at interfaces was a good predictor of sensitivity 
to mutation at surface positions. In the solvent-inaccessible core of ubiquitin hydrophobic 
substitutions were generally tolerated. Comparison of mutant effects on growth with 
previously determined effects on folding stability indicated that some mutants capable of 
folding were defective for growth. Functional sensitivity to mutation was asymmetrically 
distributed in the core. Core positions near the C-terminus where many critical binding 
interactions occur were the most sensitive to mutation. These findings indicate that 
binding interactions are a dominant contributor to ubiquitin function, which can be 
impacted by subtle conformational changes and/or dynamics in the folded state of 
ubiquitin. 
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Results and Discussion 
Bulk competition of ubiquitin mutants in a shutoff strain. 
To facilitate the analyses of mutants with varied fitness, we used the Sub328 
ubiquitin shutoff strain.34 In Sub328, the only copy of the ubiquitin gene is expressed 
from a galactose regulated promoter that generates sufficient ubiquitin protein to support 
robust growth in galactose media, but that is effectively turned off in dextrose media. 
These properties enable Sub328 cells to host libraries of ubiquitin mutants in galactose 
media where growth does not require mutant function, and subsequently switch to 
dextrose media where growth is directly related to mutant function (Figure 2.1a). To 
characterize the timing of the shutoff process, we examined the growth of Sub328 cells 
harboring either a rescue plasmid constitutively expressing WT ubiquitin (utilizing a 
promoter and plasmid system previously developed to analyze ubiquitin mutants in 
yeast34), or a control plasmid lacking ubiquitin (Figure 2.1b). Cells with the rescue 
plasmid grow rapidly in dextrose media, but cells with the control plasmid stall in growth 
after about 10 hours in dextrose media. Based on these results, we decided to analyze 
selection on mutant libraries starting after 12 hours in dextrose so that most cells without 
functional mutants would have stalled in growth. 
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Figure 2.1. Bulk competition analyses of the effect of ubiquitin mutants on yeast growth. 
(a) Experimental setup: systematic libraries of ubiquitin point mutants generated using 
saturation mutagenesis at sequential positions within a 9-10 amino acid window were 
generated on a plasmid with a constitutive promoter. These libraries were introduced into 
a ubiquitin strain whose only other source of ubiquitin was regulated by a galactose 
dependent promoter. Yeast libraries were amplified in galactose, and then competed in 
dextrose where growth relied on the mutant ubiquitin library. (b) Growth of the ubiquitin 
shutoff strain is rescued by constitutive expression of WT ubiquitin. (c) Positions 40-48 
of ubiquitin were selected for initial method development. (d-e) Sequence based analyses 
of bulk competition of libraries of ubiquitin point mutants at positions 40-48. (d) Stop 
codons were rapidly depleted indicating that they were unable to support growth, while 
silent substitutions that change the nucleotide sequence without altering the protein 
sequence persisted in shutoff conditions. (e) Correlation between measured growth 
effects of mutants (selection coefficient) from full experimental repeats. 
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Figure 2.1. Bulk competition analyses of the effect of ubiquitin mutants on yeast growth. 
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We examined the robustness of bulk competitions by analyzing a nine amino acid 
region (Figure 2.1c) of ubiquitin that included K48, the essential lysine involved in 
forming poly-ubiquitin chains that target substrates to the proteasome. The size of this 
region enabled it to be efficiently interrogated by Illumina short read (36 base) 
sequencing. We generated site saturation libraries for each position in the region, mixed 
libraries to create a combined library for the region and used focused deep sequencing14 
to analyze the relative abundance of each point mutant in the combined library.  The 
library was introduced into yeast, expanded in galactose media for 48 hours, and then 
switched to dextrose media for 50 hours. Samples from the library of yeast were saved at 
different time points in the competition and the relative abundance of mutants over time 
determined by sequencing, providing a direct measure of relative mutant fitness13. The 
fitness effects of WT synonyms (silent mutations) and stop codons (nonsense mutations) 
served as important internal positive and negative controls (Figure 2.1d).  WT synonyms 
persisted in the bulk competition consistent with the near-neutral expectation for silent 
mutations.  In contrast, stop codons rapidly decreased in relative abundance consistent 
with the critical function of the C-terminus of ubiquitin in conjugation to substrates.72 
The slope of mutant to WT ratio versus time in WT generations was calculated and 
represents the selection coefficient (s) where s=0 indicates wild type growth and s= -1 
indicates a null mutant. The rapid drop off in abundance of strongly deleterious mutants 
meant that this class of mutant could not be quantified as precisely as mutants that 
persisted in the culture. We performed a full experimental repeat to judge the 
reproducibility of our bulk fitness measurements. Excluding strongly deleterious mutants 
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(s<-0.5), we observed a strong correlation between repeat measures of the effects of 
ubiquitin amino acid substitutions on yeast growth rate (Figure 2.1e). Compared to fit 
mutants, strongly deleterious mutants (s<-0.5) showed larger differences in the 
experimental repeat (Figure 2.2A). Excluding strongly deleterious mutants, the 
correlation between repeat measurements indicates that we can accurately resolve growth 
differences of about 7%. This level of resolution is valuable for investigating the physical 
constraints on ubiquitin function. However, it is not sufficient to distinguish the full 
spectrum of selection that would act on natural populations where fitness effects on the 
order of the inverse of the effective population size (estimated at 10-7 in yeast)73,74 are 
subject to effective selection. 
Analyzing mutants across the ubiquitin coding sequence 
By investigating multiple different regions in parallel (Figure 2.3), we were able 
to analyze all positions in ubiquitin at the same time. We separated the ubiquitin gene 
into eight regions each encoding 9-10 amino acids that were amenable to our sequencing-
based approach (Figure 2.3a and Supplementary Table 2.1).  For each region, we 
generated site saturation libraries that we introduced into shutoff yeast and analyzed by 
bulk competition and sequencing. Utilizing this approach, we determined fitness effects 
across the ubiquitin coding sequence (Figure 2.3b). In order to assess reproducibility and 
selection in each region we analyzed both WT synonyms and stop codons (Figure 2.2B). 
In all regions, WT synonyms were consistently highly  
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Figure 2.2. Growth properties of select mutants. (A) Correlation between full 
experimental repeat for amino acids 40-48 across all measurements. (B) EMPIRIC 
measurements of stop codons and WT synonyms in each region. Error bars indicate 
standard deviation (N=22-29 for stop codons; N=16-34 for WT synonyms). (C) Growth 
rate in monoculture measured by changes in optical density over time. SUB328 cells 
harboring ubiquitin variants on 417GPD plasmids were pre-grown in shutoff conditions 
for 16 hours, and then monitored for the following 12 hours in shutoff conditions. A total 
of 17 point mutants were analyzed as well as a positive control (wt) and a negative 
control (G75D/G76D). 
 
 
 
 
 
 
 
 
 
 
32 
 
Figure 2.2. Growth properties of select mutants. 
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Figure 2.3. Analyses of the growth effects of mutants across the ubiquitin gene. (a) The 
gene was subdivided into eight regions of 9-10 amino acids and each region was subject 
to saturation mutagenesis, bulk competition in yeast, and deep sequencing analyses. (b) 
Heat map representation of the effects of ubiquitin mutants on yeast growth. Mutants that 
were below a conservative detection limit at the beginning of the competition were 
omitted from fitness analyses. (c) Bi-modal distribution of observed mutant effects on 
yeast growth indicates that most mutants supported either WT-like or null growth in yeast 
(d) Distribution of growth effects for mutations that depleted by more than 2-fold during 
outgrowth in galactose media, but remained sufficiently abundant to quantify fitness. 
Most depleted mutants had null-like fitness and none were WT-like (s>-0.1). (e) 
Correlation between the growth rate of a panel of individually analyzed mutants relative 
to fitness measures from bulk competitions. 
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Figure 2.3. Analyses of the growth effects of mutants across the ubiquitin gene. 
 
 
  
35 
 
fit (s≈0) with narrow distributions (standard deviations ranging from 0.005 to 0.03). 
These observations indicate that highly fit mutants are accurately interrogated by our 
procedure as expected because they persist in the culture and are sampled throughout the 
competition experiment. The average fitness effects of stop codons is similar in each 
region (Supplementary Figure S2.1B), but with increased measurement variation. In all 
regions the average stop codon is highly deleterious (s<-0.65) indicating that selection is 
strong across all regions. Because highly deleterious mutants rapidly deplete from the 
culture, they are not sampled as extensively as other mutants and measurement accuracy 
has an increased dependence on the synchronization of selection pressure across the yeast 
culture and the number of sequence reads at the early selection time points. The variation 
in measurements of stop codons is approximately ten times greater than WT synonyms 
(standard deviation ranging from 0.07 to 0.1 for seven of the regions). Because of 
unintended variations in sequencing depth, one region (positions 49-58) had markedly 
lower number of reads for the early timepoints (Supplementary Table 2.1). In this region, 
the average stop codon was strongly deleterious (s=-0.75), but as expected, measurement 
variation was large (standard deviation of 0.37).  With the exception of this region, the 
experimental measure of highly deleterious mutants is reasonably precise across the 
dataset.   
For amino acids encoded by multiple codons, we calculated fitness as the average 
over all synonyms (Supplementary Table 2.2). Across the entire data set, the fitness 
effects of all nucleotide changes that encode the same amino acid were similar indicating 
that protein sequence had a dominant impact on fitness compared to nucleotide sequence.  
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We were able to directly analyze selection coefficients for the majority of possible amino 
acid substitutions (85% - colored in Fig 2.3b). These quantified mutants exhibited a bi-
modal distribution of fitness effects (Figure 2.3c), which has been commonly observed in 
many different fitness studies.10,75–78 
At the first time point analyzed in shutoff selection, the relative abundance of 
some mutants was below our threshold for accurate analysis (colored grey in the heat 
map).  We considered two potential explanations for this low mutant abundance: poor 
representation in the saturation mutagenesis, and/or depletion during growth in galactose 
where WT ubiquitin was co-expressed. We deep sequenced the plasmid pool and found 
that virtually all point mutants (99%) were represented in the plasmid library at relative 
abundances above our threshold for analysis (Supplementary Table 2.3). Sequencing of 
yeast samples obtained immediately following amplification in galactose media revealed 
that many mutations were depleted, indicating that they had a dominant negative growth 
defect. We observed greater than 2-fold depletion for 95% of mutants that were below the 
threshold level for fitness analysis (grey boxes in Figure 2.3b). We took advantage of 
mutants that were highly represented in the plasmid library to provide a dataset of 
mutants that depleted during co-expression with WT ubiquitin, but whose relative 
abundance after outgrowth was sufficient to enable accurate fitness measurements. These 
depletion-prone mutations are universally unfit (Figure 2.3D), indicating that depleted 
mutations that were not over-represented in the plasmid library (solid grey boxes in 
Figure 2.3b) are likely unfit. The dominant negative growth effects of ubiquitin mutants 
are both intriguing and mechanistically unclear as they occur at multiple different 
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structural locations. Experiments focused on these mutants will likely be an exciting area 
of future research. As indicated in Figure 2.3b, a small number of mutations were low in 
abundance in the plasmid library or introduced an internal restriction site that interfered 
with sample processing (further described in the Methods section).  
The bulk fitness measurements are in agreement with the known function of 
ubiquitin. For example positions 48 and 76 are sites of critical for covalent ubiquitin-
ubiquitin linkages and are known to be sensitive to mutation.32 In our EMPIRIC analyses, 
only the WT amino acids at positions 48 and 76 (outlined in dashed red lines in Figure 
2.3b) are compatible with robust growth.  There are three amino acid substitutions 
between the yeast and human versions of ubiquitin (outlined in maroon in Fig 2.3b). 
Consistent with the strong functional conservation in ubiquitin, all of these substitutions 
support robust yeast growth. To further probe the accuracy of our bulk competition 
measurements, we constructed 17 individual point mutations spread across the ubiquitin 
coding sequence and analyzed their growth rate in monoculture (Figure 2.2). We find that 
monoculture growth rate was strongly correlated with EMPIRIC fitness measurements 
(Figure 2.3e).  
Sensitivity to mutation on the surface of ubiquitin 
We examined the tolerance of each position by quantifying the number of amino 
acids compatible with robust growth, defined here as having less than a 10% growth 
defect. This cutoff definition was chosen both because it is larger than our measurement 
precision and because it encompasses the main peak of near-WT fitness mutants (Figure 
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2.1c). This definition should include essentially all experimentally fit mutants in the 
robust class and minimize the number of mutants whose classification would switch with 
a small change in the cutoff. For amino acids located at or near the solvent-accessible 
surface, the observed tolerance was bimodal (Figure 2.4a). The majority of positions 
permitted either greater than 16 amino acids (and were classified as tolerant), or less than 
5 amino acids (and were classified as sensitive). Of note, position 12 was classified as 
intermediate despite having only four fit amino acids because unusually poor mutant 
representation in the plasmid library hindered fitness quantification of 10 amino acids.  
Mapping to the mono-ubiquitin structure revealed that sensitive and tolerant positions 
clustered completely on opposite faces (Figure 2.4b). The fitness-sensitive positions are  
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Figure 2.4. Effects of mutants on the solvent-accessible surface of ubiquitin on yeast 
growth. (a) Distribution of the number of amino acids observed to support growth within 
90% or greater of wild type ubiquitin. Many positions in ubiquitin are either highly 
sensitive to mutation (4 or less amino acids support robust growth), or highly tolerant (17 
or more amino acids support robust growth). (b) Space filling representations of ubiquitin 
structure (based on 1UBQ.PDB67) with sensitive positions colored blue, tolerant yellow, 
and intermediate green. (c) Heat map representations of sensitive, intermediate and 
tolerant positions on the ubiquitin surface. One-dimensional maps on the bottom compare 
our analyses with a previous alanine scan37. At positions where the WT amino acid is 
alanine, glycine substitutions are shown for both the EMPIRIC and previous alanine scan. 
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Figure 2.4. Effects of mutants on the solvent-accessible surface of ubiquitin on yeast 
growth.  
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located on the β-sheet face, which contains the hydrophobic patch66 including L8, I44, 
and V70. This region is known to bind to many ubiquitin receptors.  
We compared the EMPIRIC fitness map for sensitive, intermediate and tolerant 
positions on the surface of ubiquitin to a previous alanine scan of the ubiquitin surface67 
(Figure 2.4c). Overall, the EMPIRIC results correspond very well to the previous alanine 
scan. Of the 16 alanine scan mutants identified as growth defective, all have at least a 
20% growth deficiency in our analyses. Of the 41 alanine scan mutants identified as 
supporting growth, 36 exhibited robust growth in our analyses while five exhibited 
growth defects ranging from 11% to 47%. The small number of discrepancies could be 
due to differences in experimental detail including the strains analyzed and the growth 
conditions.  The alanine scan effectively identified sensitive sites, but did not distinguish 
tolerant sites from sites with intermediate sensitivity. By quantifying the effects of 
mutants and examining all possible substitutions, the EMPIRIC analyses presented here 
defines a continuous spectrum of mutational sensitivity from ultra-sensitive to ultra-
tolerant. 
The most tolerant positions in ubiquitin can accommodate almost any amino acid 
substitution without disturbing the observed function (Figure 2.4c). These ultra-tolerant 
positions cluster on one side of ubiquitin. The only mutations other than stop codons 
observed to reduce function were proline mutations within the α-helix that are known to 
disrupt helical structure, as well as minor defects for a small fraction of the possible 
hydrophobic substitutions (S28F, S28I, Q31I, P37W, P37F, P37Y, D39W, T55W) and a 
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small number of charge reversals (D21K, D21R, D39R). Charge reversals are generally 
well tolerated on this face of ubiquitin (e.g. E16, E18, D39, D52, R54, and K63). The 
tolerance to charge reversal mutants, which dramatically change the interaction potential 
of a protein surface, suggests that this face of ubiquitin is not involved in critical binding 
interactions. The entire amino acid sequence of ubiquitin is highly conserved (there are 
only three substitutions between yeast and human ubiquitin), indicating that mutations 
throughout the protein impact fitness on a magnitude that is selectable in natural 
populations. Of note, the WT residues at the ultra-tolerant positions are never aliphatic or 
aromatic. Based on these properties (polar and tolerant of individual mutations) we 
speculate that this region of ubiquitin may perform a solubility promoting role as similar 
properties have been observed in solubility promoting regions of the Hsp90 
chaperone79,80. These studies in Hsp90 support the idea that stringent natural selection for 
stability can result in highly optimized sequences that are so soluble that they are robust 
to individual mutations when measured with experimentally limited sensitivity. Ubiquitin 
is highly soluble (>100 mg/ml) and has been shown to impart solubility on genetically 
fused partner proteins.81 In principle, ubiquitin solubility could provide a functional 
benefit by influencing the solubility of covalent complexes with substrates. The ultra-
tolerance of this surface of ubiquitin to our experimental analyses is notable and 
motivated our discussion of solubility, which we acknowledge is highly speculative. 
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At the most sensitive positions to mutation (G10, R42, G47, K48, H68, R72, L73, 
R74, G75, G76), only the WT amino acid was observed to support robust growth. All ten 
ultra-sensitive positions are located on the surface of the ubiquitin structure. Seven of 
these positions are either at or adjacent in primary sequence to the sites of critical 
covalent attachment (G47, K48, R72, L73, R74, G75, G76) consistent with the known 
role of these positions in conjugation to substrates and promoting recognition by the 
proteasome.32 Of the other three ultra-sensitive positions, G10 is located in a β-turn in 
structural proximity to the C-terminus and has a positive main chain φ angle that is 
incompatible with other amino acids. The other two (R42 and H68) are both structurally 
adjacent to the hydrophobic patch formed by L8, I44, and V70 that is at the interface with 
many ubiquitin receptors. L8, I44, and V70 can all tolerate conservative substitutions 
(e.g. Leu to Ile) in our assay. These results are consistent with both the binding of partner 
proteins to this patch as well as the relatively low specificity of hydrophobic interactions 
relative to polar interactions such as hydrogen bonds that are highly directional. Of note, 
the contributions of H68 to function was unclear from alanine scanning as it has only a 
partial (20%) growth defect in our analyses (Figure 2.4c) and was positive for growth in 
plasmid swap experiments.67 
Mapping fitness sensitivity to interfaces 
Analyzing the effects of all ubiquitin mutants combined with the available 
structural information on interfaces with many different binding partners provides a 
unique opportunity to investigate how binding interactions influence sensitivity to 
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mutation. Based on chemical intuition, it has long been posited that interaction surfaces 
will impose evolutionary constraints based on the prediction that many mutations located 
at interfaces will disrupt binding.82 Consistent with previous observations, the most 
sensitive sites to mutation map to known binding interfaces including those with UBA 
and UIM domains (Figure 2.5a,b). To further examine the relationship between binding 
interfaces and sensitivity to mutation, we analyzed the surface area buried by each 
position in ubiquitin across 44 high resolution crystal structures (Supplementary Table 
S2.4). The average fraction of surface area buried was greater for positions that were 
sensitive to mutation in our screen compared to positions that were tolerant to mutation 
(Figure 2.5c). Across all surface positions, the fraction of surface area buried at 
structurally characterized interfaces predicted about 60% of the variance in observed 
tolerance to mutation (Figure 2.5d). Of note, the relationship between surface burial and 
tolerance to substitution appears to have multiple phases. At low fraction surface burial 
many mutations are tolerated and at a threshold around 0.3, amino  
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Figure 2.5. Relating fitness sensitivity on the surface of ubiquitin to binding interfaces. 
Structural representations of ubiquitin bound to common binding domains: (a) UBA 
domain (2OOB.PDB71), and (b) UIM domain (1QOW.PDB72). Top images show 
binding domains in magenta and ubiquitin as space-filled spheres with fitness sensitive 
positions in blue, fitness tolerant positions in yellow, and intermediate positions in green. 
Bottom images illustrate the underlying ubiquitin secondary structure. (c) Fraction of 
surface area buried per sensitive or tolerant residue on the surface of ubiquitin in 44 high-
resolution co-crystal structures. Error bars represent standard deviations (N=18 and 19 
respectively) (d) Correlation between fitness tolerance to amino acid substitution and 
burial at structurally characterized interfaces. 
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Figure 2.5. Relating fitness sensitivity on the surface of ubiquitin to 
binding interfaces. 
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acid tolerance tends to decrease. Positions with a fraction of surface area buried greater 
than 0.4 are universally sensitive in our analyses. Consistent with these observations, the 
data fit well to a transition switching model related to those used in chemical denaturation 
of proteins (Figure 2.5d). These observations demonstrate that binding is a dominant 
determinant of sensitivity to mutation for ubiquitin and provide quantitative support for a 
long-standing intuition in molecular evolution. 
We further analyzed how sensitive and tolerant positions mapped to the structure 
of K48-linked tetra-ubiquitin because this is the minimal signal for proteasome-
targeting.33 The structure of tetra-ubiquitin in the proteasome-bound state is currently 
unavailable, as is the structure of poly-ubiquitin attached to a substrate. However, the 
structure of unanchored K48-linked tetra-ubiquitin representing the predominant 
conformation at physiological conditions is available.83 Structural analyses of this 
“closed” conformation of tetra-ubiquitin showed that fitness-sensitive positions all cluster 
on the interior of tetra-ubiquitin, while fitness-tolerant positions all cluster on the exterior 
(Figure 2.6).  This result suggests that the structural arrangement mediated by inter-
ubiquitin contacts in closed tetra-ubiquitin may be biologically important. For example 
by presenting a molecular surface that is almost entirely polar, the closed conformation of 
tetra-ubiquitin may enhance solubility. In addition, the sequestration of binding sites for 
UBDs in the closed conformation may be important for modulating access to these 
interfaces by different effectors.84 This potential mechanism is consistent with both an 
observed “open” conformation of K48-linked tetra-ubiquitin56 and from NMR studies 
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demonstrating that binding by UBDs can require access to interfaces unavailable in the 
“closed” conformation. 84 
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Figure 2.6. Relating fitness sensitivity to structure of tetra-ubiquitin (a) Structural image 
of K48-linked tetra-ubiquitin (2O6V.PDB54). Top images show space-filling 
representation with fitness sensitive positions colored blue, tolerant positions yellow, and 
intermediate positions grey. Different color shades were used to distinguish subunits. 
Bottom image illustrates the underlying secondary structure. (b) Fractoin surface area 
buried per sensitive or tolerant residue in tetra-ubiquitin. Error bars represent standard 
deviations (N=18 and 19 respectively) 
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Figure 2.6. Relating fitness sensitivity to structure of tetra-ubiquitin 
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Effects of Mutations in the Solvent-inaccessible Core. 
The majority of positions (10 of 16) located in the core of ubiquitin tolerated 3-6 
mutations (Figure 2.7a,b) with substitutions between hydrophobic amino acids of 
different geometry frequently resulting in robust growth at all positions. This distribution 
of tolerated mutations is consistent with solvent-inaccessible residues contributing to a 
well-packed, largely hydrophobic core to energetically distinguish the native state from 
unfolded conformations. Aliphatic (Val, Leu, Ile) to aromatic (Phe, Tyr, Trp) 
substitutions that increase core bulk were generally poorly tolerated. For example, we did 
not observe any aliphatic to Trp substitutions that were compatible with robust growth. In 
the core mutations to Trp were only tolerated at positions where the WT amino acid was 
aromatic (F45, Y59). These observations indicate that large increases in core over 
packing, which are likely to alter the native conformation and dynamics, commonly result 
in functional defects to ubiquitin. 
Polar amino acids in the core are generally incompatible with efficient ubiquitin 
function. Q41 is the only polar WT amino acid in the core. The side-chain of Q41 
hydrogen bonds to a solvent-inaccessible and otherwise unsatisfied main-chain carbonyl 
oxygen. While most polar substitutions at position 41 exhibited a strong growth defect, 
multiple aliphatic substitutions (Leu, Ile, Met) were tolerated. These findings are 
consistent with the energetic penalty for burying unsatisfied hydrogen bonding atoms in 
the core of proteins as well as the energetic benefit from burial of hydrophobic atoms.85,86  
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Figure 2.7. Mutant effects in the solvent-inaccessible core of ubiquitin. (a) Heat map 
indicating the fitness of mutations at core positions indicates that substitutions among 
aliphatic amino acids are generally well-tolerated. (b) Positions in the core exhibit an 
intermediate tolerance to mutation with most positions having 3-6 different amino acids 
that support growth rates similar to the wild type sequence (s>-0.1). (c) Structural 
representation of ubiquitin showing the wild type side chains of core positions. Positions 
that tolerate more than eight amino acids (s>-0.1) are colored in yellow. (d) Relationship 
between core mutant impacts on folding stability39; 42 and yeast growth. Previously 
measured effects on ∆∆G of folding are plotted such that negative numbers represent 
destabilization. The amount of destabilization estimated to abolish folding is indicated as 
a dashed grey line on the left. Mutations to Q41, the only WT core polar amino acid, are 
shown in grey. All mutations in this panel are estimated to populate the unfolded state 
less than 1% in the absence of elevated temperature or denaturant based on the stability 
of wild type ubiquitin39. Mutants that are destabilized by more than 2 kcal/mol are 
shown in orange if they are highly fit (s>-0.12), blue if they are strongly deleterious (s<-
0.49), or purple for those with intermediate fitness. (e) Structure of ubiquitin indicating 
the location of destabilized and highly fit (yellow) as well as destabilized and deleterious 
(cyan) mutations. 
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Figure 2.7. Mutant effects in the solvent-inaccessible core of ubiquitin. 
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The energetic penalty for burial of charged amino acids with unsatisfied hydrogen bonds 
in the core of proteins is especially severe and we observe growth defects at all core 
positions for substitutions to R, K, D, or E. The general trends that we observe in the core 
are consistent with a large body of work demonstrating that the interior of proteins is 
important for governing protein folding and dynamics.87 
Within the core of ubiquitin, we observe that the sensitivity to mutation is 
unevenly distributed with the most tolerant positions (L15, V17, I23, F45) all clustered in 
one structural region (Figure 2.7c). We considered two potential explanations for this 
observation. First, protein folding may be a dominant determinant of the function of 
ubiquitin core mutants and the tolerant regions are less important for folding. Second, 
core mutations may impact ubiquitin function by subtle changes to the folded 
conformation and/or dynamics that affect critical binding interactions. The contribution 
of core positions to ubiquitin folding has been determined by φ analysis, which uses 
alanine mutations to identify residues that contribute to the folding transition state.68 Of 
note, a broader folding transition state of ubiquitin was reported in studies using 
engineered double histidine substitutions and divalent metals as probes.88 By φ analysis, 
the transition state for folding was found to occur in the same core region where we 
observe relatively high functional tolerance to mutation. In particular L15, V17, and I23 
all have φ-values ≥ 0.5 (F45 was not analyzed) indicating that they have a large energetic 
contribution to the folding transition state. In contrast positions located near the C-
terminal tail in the structure of ubiquitin all were observed to have φ-values close to zero 
indicating that they provide minimal energetic contributions to the folding transition 
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state. These observations indicate that critical positions for ubiquitin folding can 
functionally tolerate more mutations than other core positions. Because protein folding to 
native conformations of ubiquitin should be required for function, this finding indicates 
either that the transition state for folding does not correlate with mutant effects on folding 
efficiency, or that ubiquitin core mutants may also have important impacts on protein 
behavior other than folding (e.g. binding).  
We compared growth effects of core mutations to previously reported68,71 
observations of individual ubiquitin mutant impacts on the thermodynamic stability 
difference between folded and unfolded conformations (Figure 2.7d and Supplementary 
Table S2.5). All of the mutants in this panel were able to fold efficiently and populated 
native conformations under physiologically relevant conditions, but exhibited growth 
rates from WT to null in our assays. This observation indicates that some core ubiquitin 
mutants able to fold efficiently are functionally defective. Our previous work 
demonstrated that the L67S and L69S core mutations are capable of folding under 
physiological conditions, but are defective for binding to proteasome receptors and do not 
support yeast growth.89 Thus core ubiquitin mutations capable of folding can be defective 
for binding to important receptors.  In future studies, it will be interesting to determine 
the specific biochemical defects in core ubiquitin mutants that impair function. Of note, 
mutations that resulted in less than a 2 kcal/mol destabilization of the folded relative to 
unfolded states exhibited small to no observable growth defects. Within this stability 
region, mutations at Q41 had more pronounced functional defects than mutations at 
positions where the WT amino acid was hydrophobic. This observation is consistent with 
56 
 
the observation that polar interactions in protein interiors can have a large influence on 
protein dynamics.86  
Among the analyzed panel of core mutations that destabilized the folded state by 
2 kcal/mol or greater there was a large variance in functional effects spanning from null 
to WT growth rates (Figure 2.7d). Within this stability regime, we mapped mutants with 
either minimal or severe growth effects onto structure (Figure 2.7e). The destabilized 
mutants that supported the most efficient growth included substitutions at three of the 
most functionally tolerant positions (L15A, V17N, I23A – mutants at F45 were not in the 
stability dataset). Mutations with a similar range of destabilization that exhibited severe 
growth defects were clustered near the β-sheet surface and C-terminus in the structure of 
ubiquitin (Figure 2.7e). Thus, core positions that are relatively sensitive to mutation were 
located adjacent to surface positions that make critical binding interfaces while tolerant 
core positions were located distant to known binding interfaces. Based on these 
observations, we speculate that many core ubiquitin mutations may impact function by 
affecting binding affinities. Interestingly, NMR studies have demonstrated that the C-
terminal region of ubiquitin exhibits uncorrelated conformational dynamics90,91 
suggesting that it is capable of sampling many different conformations that could be 
important for binding to diverse UBDs. Indeed, recent reports indicate that distinct 
ubiquitin conformations mediated by core amino acids are important for affinity with 
different binding partners.92 NMR studies on linked ubiquitin also observed 
conformational dynamics in the C-terminal region91, consistent with a potential role in 
mediating receptor binding to poly-ubiquitin. 
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Conclusions 
The comprehensive analysis of ubiquitin mutants presented here provides a 
rigorous examination of the physical constraints at each position in the protein. 
Consistent with previous observations, our results strongly support binding as a dominant 
functional constraint for ubiquitin both for surface positions as well as for many core 
positions. Indeed, location at structurally characterized interfaces alone is a good 
predictor of the tolerance of surface positions to mutation. One face of ubiquitin that is 
not commonly at structurally characterized interfaces, tolerates almost all substitutions 
without causing detectable growth defects. The experimental tolerance that we observed 
for this surface indicates that its contribution to function is relatively insensitive to 
mutation. This mutational profile together with the polar composition of this region is 
consistent with a role in promoting solubility. We also find that the functional sensitivity 
to core mutations is asymmetrically distributed. Sites involved in the folding transition 
state are the most tolerant to mutation while sites in structural proximity to critical 
binding sites are the most sensitive. These results are consistent with an important role 
for ubiquitin conformational dynamics in mediating binding to critical partner molecules. 
The structural separation of folding centers and regions important for dynamics that 
influence binding events may be a design principle utilized by other proteins to balance 
the requirement for both folding and dynamics required for function.   
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Materials and Methods 
High-throughput EMPIRIC Fitness Measurements 
We constructed ubiquitin mutant libraries in a KanMX4-marked yeast high copy 
shuttle vector (p427) with ubiquitin expression driven by the GPD1 promoter. To aid in 
cloning, the ampicillin-resistance gene was removed from the vector, and selection 
during bacterial cloning was performed with kanamycin (resistance provided by the 
KanMX4 marker). Of note, this high copy plasmid system is important for expressing 
ubiquitin at near-physiological levels because the ubiquitin gene is present at multiple 
chromosomal locations in wild type yeast. Libraries of saturated single codon 
substitutions in yeast ubiquitin were generated using a cassette ligation strategy in 
p427GPD as previously described.14 To facilitate cloning and subsequent sequencing 
analyses, the ubiquitin gene was subdivided into eight regions of 9-10 amino acids. Pools 
of saturated point mutants within each region were generated that could be accurately and 
efficiently interrogated with short-read Illumina sequencing. To distinguish the growth 
properties of ubiquitin mutants, we utilized the Sub328 yeast strain.34 The sole ubiquitin 
in these cells is supplied from a galactose regulated promoter. 
Pooled plasmid libraries of mutants for each region of ubiquitin were transformed 
separately into the same batch of Sub328 cells as described.93 In order to minimize 
doubly transformed cells94, a total of 1 µg of plasmid DNA was transformed per 100 µL 
competent yeast cells, and after recovery the cells were grown for 48 hours at 30° C in 30 
mL of liquid SRGal (synthetic 1% raffinose, 1% galactose) media supplemented with 
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G418 (200 µg/mL). Cultures were diluted to maintain log-phase growth. After 48 hours 
of selection for G418 resistance in SRGal media, late-log cells were collected by 
centrifugation, then washed and resuspended in SD (synthetic 2% dextrose) media with 
G418 and ampicillin (50 µg/mL) to hinder bacterial contamination. Cultures of 100 mL 
were grown in a shaking incubator at 30 °C for 3 days with dilution to maintain the 
culture in logarithmic growth. Time point samples were collected throughout this period 
by centrifuging 2*108 cells, resuspending with 1 mL of water, transferring to a 
microfuge, pelleting, removing the supernatant and freezing the pellet at -80 °C. Fitness 
analyses were performed on samples isolated after 12, 15, 19, 23, 29, and 45 hours in 
dextrose. These fitness analyses were performed over 11 generations as the doubling time 
of the yeast harboring the WT rescue plasmid was 3 hours under these conditions.  A full 
experimental repeat was performed for the ubiquitin region encompassing amino acids 
40-48, including preparation of competent yeast from a separate colony, transformation, 
growth, and time point sampling. 
Plasmid DNA was isolated from yeast pellets and processed for deep sequencing. 
Frozen pellets were thawed, lysed using zymolyase, and plasmid DNA isolated and 
prepared for sequencing as previously described 6. An initial PCR reaction was 
performed to amplify the library version of ubiquitin utilizing primers specific to the 
p427GPD vector. This PCR product was separated on an agarose gel, excised and 
purified using a silica column (Zymo Research). A second round of PCR was performed 
with region-specific primers that added a MmeI cut site immediately upstream of the 
randomized region and a universal primer binding site 250 bases downstream. The 
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resulting PCR product was purified on a silica column, digested with MmeI and purified 
again on a silica column. Barcoded adapters were then ligated and samples processed and 
analyzed as previously described.14 
Adapter cassettes with a sticky-end complementary to the resulting MmeI 
overhang were attached using T4 DNA ligase (New England Biolabs). Ligation adapters 
included a binding site for universal Illumina primers and a barcode to distinguish the 
time point and sample. Ligation reactions were separated on an agarose gel and the 
ligation product excised and purified. A final round of PCR was performed with Illumina 
primers. To minimize PCR errors, cycles were limited and the high-fidelity Pfusion 
enzyme (New England Biolabs) was utilized throughout. For each region, a processing 
control was included that started with a purified plasmid with wild type ubiquitin and was 
processed identical to time point samples (same number of PCR cycles, etc.). To 
distinguish mis-reads during sequencing, a sequencing control was also included in all 
deep sequencing samples. The sequencing control consisted of a region of the Sec61 gene 
cloned into a plasmid with flanking Illumina primer binding sites. Eight cycles of PCR 
from this plasmid generated a deep sequencing sample with minimal sequence 
heterogeneity. 
Short-read (36 base) Illumina sequencing was utilized to analyze all time point 
samples. The resulting FastQ files were analyzed as previously described14 in order to 
determine the fitness effects of mutants. Processing and sequencing errors were directly 
estimated in each sequencing reaction from the number of apparent mutants observed in 
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the internal processing and sequencing controls. The average per base error rate including 
PCR processing and sequencing was 0.005 per base. The majority of these errors (~90%) 
result in apparent double mutants that were filtered out of the data resulting in accurate 
abundance measurements of the underlying distribution of mutants in the library. Mutants 
with a relative abundance (mutant/WT) below 2-10 at the initial time point (12 hours in 
dextrose) under selection were deemed too noisy for accurate fitness measurements based 
on visual inspection of mutant versus time trajectories and were omitted from further 
analysis. In addition, mutants that created an internal MmeI site that would complicate 
processing were omitted from fitness analyses. The first three time points during library 
selection (corresponding to 12, 15, and 19 hours in dextrose) were utilized to analyze the 
rapid drop-off in stop codons and other null-like mutants. For mutations that persisted in 
the population, fitness effects were determined using all time points in selection. The 
residuals for each fit were determined to identify problematic mutants that were 
subsequently plotted, and eliminated from consideration if they showed multi-phasic 
behavior (< 1% of the data was eliminated using this approach). Depletion ratios were 
calculated from the relative abundance of mutants observed in sequencing of the plasmid 
library compared to cells collected at the end of growth in galactose. Mutants with a 
relative abundance (mutant/WT) below 2-8 in the plasmid library were deemed too noisy 
for depletion analyses based on visual inspection of trajectories.  
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Growth Rate of Individual Mutants in Monoculture 
We measured the growth rate of 19 different point mutants in monoculture after 
shutoff in dextrose (Figure 2.2).  These mutants were chosen to span a range of EMPIRIC 
fitness values, and were from regions spanning the entire ubiquitin gene.  Single mutants 
were generated in p427GPD and transformed into Sub328 yeast.  Growth rates were 
determined by monitoring the OD600 during growth under identical conditions to the 
EMPIRIC bulk competitions (SD media with G418 and ampicillin at 30° C). 
Structural Analyses of Ubiquitin 
Ubiquitin positions were characterized as at or near the solvent-accessible surface 
or in the solvent-inaccessible core based on the crystal structure of mono-ubiquitin 
(1UBQ.PDB67) and the classification algorithm of Mayo and colleagues.95 We analyzed 
ubiquitin interfaces by quantifying the surface area buried96 by each amino acid in atomic 
resolution structures in the protein data bank. We searched the Protein Data Bank (PDB) 
for entries with high sequence identity to ubiquitin, at least 2 chains in the biological 
assembly, and X-ray resolution of 2.5 Å or better. We identified PDB files that had a 
BLAST E-value of less than 10-20, and length of alignment between 50 and 100 residues 
as the selection criteria. We manually curated this list to exclude structures of identical 
protein complexes (keeping only the highest resolution structure in each case) and 
structures of mono-ubiquitin, resulting in 117 ubiquitin chains in 44 PDB structures. We 
used areaimol from the CCP4 v.6.2 package97 to calculate ASA for each residue of every 
ubiquitin molecule both in the complex and in isolation. The resulting changes in ASA 
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upon complex formation are provided as a supplementary table to this dissertation 
(Supplementary Table S2.4).  
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ABSTRACT 
The complexity of biological interaction networks poses a challenge to 
understanding the function of individual connections in the overall network. To address 
this challenge, we developed a high throughput reverse engineering strategy to analyze 
how thousands of specific perturbations (encompassing all point mutations in a central 
gene) impact both a specific edge (interaction to a directly connected node) as well as 
overall network function. We analyzed the effects of ubiquitin mutations on activation by 
the E1 enzyme and compared these to effects on yeast growth rate. Using this approach, 
we delineated ubiquitin mutations that selectively impacted the ubiquitin-E1 edge. We 
find that the elasticity function relating the efficiency of ubiquitin-E1 interaction to 
growth rate is non-linear and that a greater than 50-fold decrease in E1 activation 
efficiency is required to reduce growth rate by two fold. Despite the robustness of fitness 
to decreases in E1 activation efficiency, the effects of most ubiquitin mutations on E1 
activation paralleled the effects on growth rate. Our observations indicate that most 
ubiquitin mutations that disrupt E1 activation also disrupt other functions. The 
structurally characterized ubiquitin-E1 interface encompasses the interfaces of ubiquitin 
with most other known binding partners, and we propose that this enables E1 in wild-type 
cells to selectively activate ubiquitin protein molecules capable of binding to other 
partners from the cytoplasmic pool of ubiquitin protein that will include molecules with 
chemical damage and/or errors from transcription and translation.  
66 
 
INTRODUCTION 
 
Determining how genes function together as biological systems is a defining 
challenge of the genomic era. While genome sequences reveal the DNA blueprint of 
organisms, deciphering how this blueprint leads to biological function is challenging due 
in large part to genetic interaction complexity.98,99 For example, many phenotypes are 
mediated by multiple genes100, and numerous genes exhibit pleiotropy.101 Tremendous 
progress has been made in mapping the connections (aka edges) between genes and gene 
products by both genetic102–104 and biochemical approaches.105,106 Epistatic analyses of 
gene knockout combinations have provided a broad understanding of the impacts of node 
deletions on network function.102 In addition, approaches have been developed to analyze 
the effects of disrupting individual network edges by identifying mutations that disrupt a 
specific interaction.107–109 However, for most complex biological networks, the elasticity 
function110,111 relating network edge strength (e.g. the affinity of a specific protein-
protein interaction) to overall network function is poorly understood. To address this 
challenge, we developed a high throughput strategy to analyze how all point mutations in 
a central gene impact both an edge to a directly connected node in its network as well as 
overall network function. Here we report experiments with ubiquitin and the E1 enzyme 
that provide fundamental insights into regulated protein degradation in eukaryotes. 
Systematic investigations of the relationships between gene or protein sequence, 
function and fitness provide new opportunities to bridge molecular, systems, and 
evolutionary biology.7,19,112,113 While a wealth of studies demonstrate that the fitness 
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effects of mutations are mediated by biochemical changes,10,29,114–118 most systematic 
studies of mutants have focused predominantly on either growth effects (e.g. Chapter II 
of this dissertation)13,111or biochemical effects.12,15,16,108 The relationships between mutant 
effects on biochemical properties and experimental fitness under defined conditions have 
been studied using traditional approaches for a handful of genes, almost all of which 
encode enzymes that catalyze a single critical chemical transformation. In many of these 
systems,117,119–121 the experimental fitness effects of a set of mutants can be accurately 
predicted based on both the proficiency of the mutant enzyme and physiological models 
of biochemical fluxes.29 However, for the majority of genes (particularly those that 
perform multiple functions, or whose functions are not fully appreciated) the 
relationships between a mutation’s impact on biochemical properties and fitness remain 
unclear. In theory, each activity of a multi-functional protein may contribute 
independently to fitness and be predicted based on flux models, or the contributions of 
each activity to function may be interdependent, likely depending on the molecular and 
evolutionary context of each particular central network node. Distinguishing these 
possibilities provides insights into network function and can be accomplished by 
systematically investigating mutant effects on both biochemical function and 
experimental fitness. 
We determined the effects of all possible point mutants in ubiquitin on activation 
by the E1 enzyme and compared this functional map to a corresponding map of 
experimental fitness effects in yeast (Figure 2.2). Through its ability to covalently link to 
other proteins, ubiquitin contributes to multiple important cellular processes including 
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regulated protein degradation.31 The covalent attachment of ubiquitin is mediated by a 
series of enzymes, with E1 activation serving as the first step in this process. E1 activates 
ubiquitin by first adenylating the C-terminus of ubiquitin and subsequent covalent 
attachment via a catalytic cysteine in E1.56,122 We find that most ubiquitin variants that 
were deficient for E1 activation failed to support robust yeast growth, consistent with the 
essential role of this reaction.123 However, our results also demonstrate that activation of 
wild-type ubiquitin is far more efficient than required to support robust growth and that 
the relationship between the E1 reactivity of a ubiquitin mutant and yeast growth rate is 
non-linear. Despite this non-linear elasticity function,110,111 the effects of most ubiquitin 
mutants on E1 activation were similar to their effects on yeast growth rate. These 
observations suggest that most ubiquitin mutations that lead to defects in E1 activation 
also lead to defects in other ubiquitin-network edges (e.g. binding to the proteasome), and 
that the combined biochemical defects of these ubiquitin mutants are responsible for the 
observed fitness defect.  
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RESULTS AND DISCUSSION 
Investigating E1 reactivity 
We developed a bulk competition approach to interrogate the E1 reactivity of all 
possible point mutants in ubiquitin (Fig. 3.1). Comprehensive site saturation libraries of 
ubiquitin point mutants in eight pools of 9-10 consecutive amino acid positions (Figure 
2.2)14 were transferred to a yeast display system. Importantly, this yeast display setup 
(Fig. 3.1a) presents ubiquitin molecules with a free C-terminus, which is required for 
activation by E1. For initial method development, we focused on a region of ubiquitin 
encoding amino acids 40-48 that form a close contact with E1 in the co-crystal structure56 
(Fig. 3.1b). Display cells were reacted with a limiting concentration of yeast E1 (Uba1) 
(Fig. 3.2), labeled with fluorescent antibodies targeted to E1 as well as an HA epitope 
used to control for display level, and separated by flow cytometry into pools of E1 
reactive cells and HA displaying cells (Fig. 3.1c). Cells from each pool were subjected to 
focused deep sequencing38 and the difference in observed mutant frequency used to 
assess the E1 reactivity of each ubiquitin point mutant. 
 
 
 
 
 
70 
 
Figure 3.1. E1 reactivity of ubiquitin mutants assessed using yeast display and FACS. (a) 
Experimental setup: the C-termini of displayed ubiquitin variants are free to react with E1 
and the upstream HA-tag enables normalization for display level. (b) in amino acids 40-
48 that were chosen as an initial test. (c) FACS analysis of pools of ubiquitin point 
mutants in the test region. Cells in the sort windows were independently collected and 
analyzed by focused deep sequencing in order to estimate the E1 reactivity of each 
mutant. (d) E1 reactivity estimates are reproducible in a full experimental repeat. 
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Figure 3.1. E1 reactivity of ubiquitin mutants assessed using yeast display and FACS. 
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In order to achieve the throughput required to systematically scan all ubiquitin 
point mutants we utilized a display system that enabled a FACS and deep sequencing 
readout to report on E1 activation efficiency. This provides a reasonable approximation 
of the E1 activation process that occurs in cells, but reactions that occur on a cell surface 
are not perfect mimics of reactions in solution. E1 contains multiple domains and can 
bind two ubiquitin molecules at the same time: one that is adenylated (through strong 
non-covalent association between E1 and adenosine) and one that is covalently attached 
to the catalytic cysteine of E1. In our bulk competitions, E1 attachment to the displaying 
yeast cells requires adenylation, but we do not experimentally interrogate the transfer and 
attachment of displayed ubiquitin to E1’s catalytic cysteine. In addition, the display of 
multiple copies of the same ubiquitin molecule on the surface of each display cell will 
constrain E1 to primarily react with two ubiquitin molecules of the same sequence (i.e., 
in the assay E1 should preferentially bind two ubiquitins of the same sequence, one 
covalently and one non-covalently). 
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Figure 3.2. Flow cytometry controls. Yeast displaying a wild type ubiquitin construct 
were reacted with a saturating concentration of purified biotin-E1 and analyzed by flow 
cytometry following antibody labeling directed towards the HA epitope only (a), E1 only 
(b), or both HA and E1 (c). Control yeast that do not display ubiquitin on the cell surface 
show negligible antibody labeling (d). As is commonly observed with yeast display, there 
is a population of cells that do not effectively express this ubiquitin construct on the cell 
surface. (e) Fraction of yeast displaying wild type ubiquitin in the double positive 
window as a function of E1 concentration. All further experiments used E1 at sub-
saturating concentrations (100 nM). 
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Figure 3.2. Flow cytometry controls. 
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We developed the system to interrogate the kinetics of covalent activation of 
ubiquitin mutants with high sensitivity. To develop a sensitive assay for this rapid kinetic 
process we utilized a limiting amount of E1 enzyme mixed into a suspension of display 
cells and quenched with free ubiquitin such that displayed mutants were in competition 
with each other. While quenching with free ubiquitin serves to provide a final stop to the 
reaction, the limiting concentration of E1 means that depletion of E1 during the 
competition phase can vary depending on the relative activation efficiency of library 
variants, leading to potential distinctions in the sensitivity of our assay for regions of 
ubiquitin analyzed in different pools. Region to region consistency could be achieved by 
using conditions of ultra-limiting E1 (e.g., by including an equivalent concentration of 
soluble ubiquitin to E1 in the competitions, or by using rapid mixing techniques to 
quench reactions before E1 is depleted). Of note, experiments using ultra-limiting E1 
conditions would be strongly influenced by mixing conditions, introducing additional 
sources of potential experimental variation. 
Given the caveats of our experimental approach, we performed a number of 
control analyses to assess the quality of our data. The site saturation ubiquitin libraries 
include all 64 codons at each position and thus encode many wild type synonyms and 
stop codons. Across all measurements, wild type synonyms exhibit similarly robust E1 
reactivity and stop codons exhibit baseline levels of E1 reactivity (Fig. 3.1d), consistent 
with selection on the ubiquitin amino acid sequence in our screen and the known 
requirement of the C-terminus of ubiquitin for E1 reactivity. This approach resulted in 
highly reproducible (R2=0.96) measurements in a full experimental repeat (Fig. 3.1d), 
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and was used to interrogate the E1 reactivity of mutants across all of ubiquitin (Fig. 3.3a, 
Supplementary Tables S3.1 and S3.2). We also developed an independent assay using 
purified proteins to measure the E1 reactivity of individual mutants relative to wild type 
(Fig. 3.4). Multiple factors may contribute to distinctions in E1 activation observed in the 
yeast display and purified protein analyses including: noise in each experiment, variations 
in selection strength for different regions of ubiquitin in the yeast display experiments, 
and biochemical distinctions due to yeast surface versus solution reaction conditions. 
Analyses of a panel of mutants indicated that yeast display E1 reactivity measurements of 
ubiquitin mutants in different regions correlate (R2=0.6) with measurements made with 
purified proteins. Based on these analyses, we conclude that the bulk yeast display 
studies distinguish highly active from weakly active variants, but that smaller distinctions 
in relative activation efficiency may not be determined with confidence from the bulk 
competitions (Fig. 3.4). 
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Figure 3.3. Mapping the effects of ubiquitin mutants on E1 reactivity to structure. Heat 
map representation of E1 reactivity for ubiquitin mutants normalized to wild type 
synonyms and stop codons. (a) Map of entire ubiquitin sequence except for the initiating 
methionine. Of note, we did not observe any ubiquitin mutants present in our plasmid 
libraries that failed to efficiently display the HA epitope. (b) Sensitivity of ubiquitin 
surface positions for E1 reactivity assessed by measuring the number of amino acids 
compatible with proficient E1 activation within 20% of wild-type ubiquitin. (c) Mapping 
sensitive (purple) and tolerant (blue) positions on the ubiquitin surface onto the 
structurally 36 characterized complex with E1 (shown in transparent grey). (d) Correlation 
between the average impact of substitutions at each ubiquitin position on E1 activation 
and the fraction of wild-type side-chain surface area buried at the E1 interface. Positions 
11, 27, and 35 (colored green in panel d) stand out as sensitive for E1 activation despite 
not burying side chain surface at the binding interface. (e) The wild-type amino acids at 
these positions (K11, K27, and G35) all form intra-molecular interactions that likely 
contribute to the ground state structure and/or dynamics of ubiquitin.  
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Figure 3.3. Mapping the effects of ubiquitin mutants on E1 reactivity to structure.  
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Figure 3.4. Comparison of E1 reactivity estimates from bulk competitions with 
independent measurements made using purified proteins. Individual mutants from three 
regions analyzed in separate bulk competitions are distinguished by colors: green squares 
(K33A, E34G, G35N), blue circles (Q40A, I44M, I44V, K48R), and red diamonds 
(H68N, H68Q, H68S, L69S, R72S, G75D). Overall estimates from bulk competitions 
positively correlate (R2=0.6) with those using purified proteins. Of note, E1 contains two 
ubiquitin binding sites that would be constrained to interact with identical ubiquitin 
variants in the bulk competitions, but that would be able to independently access wild 
type ubiquitin and a mutant in the experiments with purified proteins. Thus, distinctions 
between surface display and freely diffusible conditions may explain some of the 
observed discrepancy between E1 reactivity estimates by these two approaches. 
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Figure 3.4. Comparison of E1 reactivity estimates from bulk competitions with 
independent measurements made using purified proteins.  
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Mapping mutant effects on E1 activation to structure 
Structural mapping indicates a general correspondence between E1 reactivity and 
contact surfaces observed56 between E1 and ubiquitin. To estimate the sensitivity of each 
ubiquitin position, we calculated the fraction of mutations at each position in ubiquitin 
that were proficient for E1 activation (within 20% of the average wild type synonym). Of 
note, 90% of wild type synonyms, but no stop codons classify as E1 proficient under this 
definition. Most positions on the surface of ubiquitin either tolerated almost every amino 
acid substitution or were highly sensitive to mutation (Fig. 3.3b, Fig. 3.5a). Mapping the 
tolerant surface ubiquitin positions to the structure indicates that sensitive positions were 
located almost exclusively at the interface with E1 and tolerant positions remained 
predominantly solvent accessible (Fig. 3.3c). The fraction of ubiquitin side chain surface 
area buried at the interface with E1 correlates with the observed variation in the average 
effect of ubiquitin mutations on E1 reactivity (Fig. 3.3d), indicating that surface area 
burial is a major determinant of mutational sensitivity. All ubiquitin positions that bury 
greater than 60% of their side chain surface area at the E1 interface are strongly sensitive 
to mutation. Conversely, the majority of ubiquitin positions that do not bury any side 
chain surface area at the E1 interface are almost completely tolerant to mutation. Three 
ubiquitin positions that do not bury side chain surface area at the E1 interface exhibit 
mutational sensitivity that stands out (positions 11, 27, and 35 shown in Fig. 3.3d&e). 
The side chains at these three positions all make intramolecular contacts that may impact 
ubiquitin structure and dynamics: K11 and K27 both form salt bridges between different 
secondary structure elements, and G35 is part of a turn structure and has a main chain 
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conformation (positive phi angle) energetically disfavored for non-glycine amino acids 
(Fig. 3.3e). These structural analyses are consistent with the chemical intuition that the 
functional sensitivity of a position to mutation is primarily determined by direct binding 
interfaces82 as well as structural integrity124 and dynamics.70 
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Figure 3.5. Representations of E1 reactivity for ubiquitin mutants normalized to wild 
type synonyms and stop codons. (a) Heatmap representation of positions on the solvent 
accessible surface of ubiquitin separated into tolerant positions (left panel) and sensitive 
positions (right panel). (b) Heatmap representation of solvent inaccessible core positions. 
(c) Distribution of sensitivity to mutation for core positions. Positions 17, 45, and 69 
stand out as the most tolerant core positions (colored blue). (d) Structural representation 
of ubiquitin and E1 illustrating the location of core ubiquitin amino acids (colored purple 
or blue as in panel c). 
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Figure 3.5. Representations of E1 reactivity for ubiquitin mutants normalized to wild 
type synonyms and stop codons.  
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In the solvent inaccessible core of ubiquitin, most positions exhibited a similar 
pattern of mutational tolerance for E1 reactivity (Fig. 3.5b-d). 13 of the 16 core positions 
have aliphatic side chains in wild-type ubiquitin (six Leu, four Ile, and three Val) that 
form a hydrophobic cluster known to be a driving force for stabilizing native protein 
structures.125,126 Consistent with observations that the protein folding stability of wild-
type ubiquitin is far greater than required for yeast growth (Figure 2.6)127, we observe 
that modest substitutions to other aliphatic side chains are generally well tolerated for 
activation by E1 (Fig. 3.5b). In contrast, substitutions to polar amino acids are poorly 
tolerated, suggesting that these substitutions likely disrupt the ground state structure or 
the dynamics of ubiquitin. Three positions that are exceptions to this rule are all located 
at the edge of the solvent inaccessible core (Fig.3.5c&d) where long polar amino acid 
side chains may be able to access solvent without disrupting the structure.  
Relationship between ubiquitin mutant effects on E1 activation and experimental 
fitness. 
The fitness effects of ubiquitin mutants integrate over impacts on the entire 
ubiquitin interaction network. For this reason, ubiquitin mutants with identical impacts on 
E1 activation can have different fitness effects  (e.g., due to different effects of each 
mutant on binding to and recycling by the proteasome).70,125,128,129 Comparing the upper-
bound of fitness effects to E1 reactivity (see dashed red line in Fig. 3.6a) provides an 
estimate of the underlying elasticity relationship demarcated by ubiquitin mutations that 
primarily impact E1 activation. Our systematic scan of ubiquitin mutants indicates that 
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this elasticity relationship is non-linear and that E1 reactivity can be reduced to baseline 
levels under the conditions of our screen with minimal impacts on fitness. 
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Figure 3.6 Relating the effects of ubiquitin mutations on E1 reactivity to experimental 
fitness. (a) Comparison of ubiquitin mutant effects on E1 reactivity and yeast 
experimental fitness for all positions in ubiquitin. (b-f) Ubiquitin mutations at four 
positions located at the E1 interface were analyzed further using purified components. (b) 
Illustration indicating the location of ubiquitin amino acids E34, G35, R72 and G75. E34 
and G35 are located at the periphery of interface between ubiquitin and E1. R72 is 
located in a deep cavity on the surface of E1 and forms multiple hydrogen bonds across 
the interface. G75 is located in a narrow cleft adjacent to the active site. (c) E1 reactivity 
for a panel of mutants at these positions was determined using purified proteins and 
binary competitions with wild-type. (d) The experimental fitness of this panel of mutants 
was analyzed by monitoring the growth rate of each mutant in isolation. (e) The E1 
activation potential of purified wild-type (WT), R72S and G75D ubiquitin variants 
analyzed without competition by Western blotting for high molecular weight ubiquitin. 
(f) The accumulation pattern of epitope tagged ubiquitin variants expressed in yeast co-
expressing endogenous untagged ubiquitin. 
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Figure 3.6 Relating the effects of ubiquitin mutations on E1 reactivity to experimental 
fitness.  
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To further assess the minimum level of E1 reactivity for a ubiquitin mutant 
required to support yeast growth, we investigated a panel of individual ubiquitin mutants 
(Fig. 3.6b-f). We chose non-conservative mutations located at the structurally determined 
interface with E1 (Fig. 3.6b) that exhibited activation defects in display competitions. We 
independently determined the E1 reactivity of each mutant in our panel using purified 
proteins (Fig. 3.7). Consistent with our bulk experiments, each mutant exhibited reduced 
E1 reactivity compared to wild type (Fig. 3.6c). The E34G and G35N ubiquitin mutants 
both reduce E1 activation by roughly 40% but both support yeast growth rates as the sole 
ubiquitin in cells that are indistinguishable from wild-type (Fig. 3.6c&d). The R72S and 
G75D mutants were both severely defective (~50-fold) for E1 reactivity relative to wild 
type. Of these two severely E1 deficient mutants, R72S supported yeast growth albeit at a 
rate 30% slower than wild type and G75D exhibited null-like growth based on 
monoculture experiments (Fig. 3.6d, Fig. 3.8). 
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Figure 3.7. E1 reactivity of ubiquitin variants estimated with purified proteins. (a) 
Experimental setup: under conditions of limiting E1, fluorescently labeled ubiquitin and 
unlabeled ubiquitin compete for E1 activation. Titrations of unlabeled competitor 
ubiquitin variants, separation of reaction products by SDS-PAGE and fluorescent 
imaging were used to quantify the amount of fluorescent label in E1 conjugates. The 
resulting plots of fluorescently conjugated E1 as a function of unlabeled competitor were 
fit to a simple kinetic model in order to estimate reactivity relative to wild type ubiquitin. 
(b) Fluorescent scan of SDS-PAGE gel with competition between fluorescently labeled 
and unlabeled wild type ubiquitin. The star denotes a minor contaminant in the FL-UB 
preparation. (c) Plots of binary competitions for a panel of unlabeled competitor ubiquitin 
variants. The impacts of these mutants on experimental fitness in yeast are noted on the 
right side of the panel. (d) Coomassie stained gel of purified unlabeled ubiquitin variants 
with intervening lanes removed for clarity (indicated with white space). (e) Reactivity 
measures with purified proteins are highly reproducible for replicate experiments using 
unlabeled wild type ubiquitin (mean = 0.95, standard deviation = 0.07, N=3). 
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Figure 3.7. E1 reactivity of ubiquitin variants estimated with purified proteins.  
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Figure 3.8. Monoculture yeast growth rate supported by a panel of ubiquitin point 
mutants as the sole expressed ubiquitin. 
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Figure 3.8. Monoculture yeast growth rate supported by a panel of ubiquitin point 
mutants as the sole expressed ubiquitin. 
 
  
94 
 
To further investigate the E1 activation potential of R72S and G75D, we tested 
them individually with varying concentrations of E1 (Fig. 3.6e). At low E1 
concentrations, both R72S and G75D reacted poorly with E1 compared to wild-type 
ubiquitin providing an additional confirmation of the activation defects of these mutants. 
At higher concentrations, R72S was capable of reacting with E1. We did not observe 
reaction of G75D with E1 even at concentrations 100-fold greater than those where we 
observed reaction with wild type, or 10-fold greater than for R72S. G75D was recently 
recovered in a phage display selection for E1 reactivity,130 which may be due to the use 
of non-covalent and unstable131 Fos-Jun mediated association between ubiquitin and 
phage particles, or other distinctions between the experimental setups. Our observations 
with purified proteins show that G75D ubiquitin is severely defective for E1 reactivity. 
The ability of R72S ubiquitin to support yeast growth, albeit with an 
approximately 30% defect relative to wild type, was unexpected as position 72 is the 
main determinant of activation specificity for ubiquitin-like proteins.55,57,132 Consistent 
with the importance of R72 in E1 activation, our binary competitions with purified 
proteins (Fig. 3.6c) indicate that R72S ubiquitin is activated by E1 approximately 2% as 
efficiently as wild type. This represents an upper estimate on the E1 reactivity of a 
ubiquitin mutant required to support yeast viability, as we cannot rule out the possibility 
that the R72S mutation impacts other ubiquitin functions.  
To examine how the E1 reactivity that we observed in vitro extends to in vivo 
utilization of ubiquitin, we measured the accumulation pattern of the R72S and G75D 
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ubiquitin variants in yeast cells. In cells, ubiquitin exists primarily in two pools: free 
ubiquitin monomers of low molecular weight, or covalent conjugates of far greater 
molecular weight (depending on the mass of the targeted protein and the number of 
ubiquitin molecules attached). To examine how ubiquitin variants accumulate in these 
two pools, we co-expressed untagged wild-type ubiquitin with mutant versions tagged 
with an epitope tag that is compatible with in vivo function.34 The separation of denatured 
cell lysates by gel electrophoresis followed by Western blotting for the epitope tag 
enabled estimation of the fraction of the tagged ubiquitin variant incorporated into 
conjugates while in competition with wild type ubiquitin in cells. These experiments 
provide a valuable examination of ubiquitin and E1 in the complex cellular environment, 
but they do not distinguish E1 activation from contributions of other enzymes (e.g. E2’s 
and E3’s) in the conjugation process. While epitope tagged wild type ubiquitin readily 
accumulated as conjugated species, we did not observe appreciable accumulation of 
conjugates of either R72S or G75D (Fig. 3.6e), consistent with our observations that both 
of these mutants are at severe competitive disadvantage for E1 activation relative to wild-
type ubiquitin.  
Investigating activation potential of ubiquitin mutants with excess E1. 
To delineate ubiquitin effects on E1 activity near the threshold required to support 
robust yeast growth rates, we performed display experiments under conditions of excess 
E1 for two ubiquitin regions encompassing amino acids 40-48 and 68-76 located at the 
E1 interface (Fig. 3.9a). Excess E1 in these experiments provides the opportunity for each 
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displayed mutant to react with minimal competition from other variants and distinguishes 
ubiquitin mutants with severe E1 activation defects from those with competitive 
activation defects that may not compromise fitness on their own. The regions we chose to 
study in these experiments are located at structurally characterized interfaces  with other 
ubiquitin binding partners36 including ubiquitin-associated domains (UBA) and ubiquitin-
interacting motifs (UIM) as illustrated in Fig. 3.9b&c.  
The relationship between fitness and activation efficiency with limiting E1 in 
these two regions (Fig. 3.9d) is similar to the pattern observed across all positions in 
ubiquitin (Fig. 3.6a). In particular, these regions contain many mutations that cause 
deficient E1 activation with limiting E1, including some that exhibit growth rates 
approaching wild-type (Fig. 3.9d). Of note, R72 forms extensive contacts with E1, but is 
largely exposed in complexes with UBA or UIM proteins such that mutations at this 
position may primarily impact E1 activation. The contact between arginine 72 and E1 has 
previously been demonstrated to be important for efficient ubiquitin activation.55,56,132 As 
expected based on these previous observations, only the wild-type amino acid at position 
72 was compatible with proficient E1 activation under limiting conditions (Fig. 3.9d). In 
terms of fitness effects, all point mutations at position 72 were deleterious, though they 
ranged from roughly 40% growth defects to null in estimates from bulk competitions 
(Fig. 3.9d).  
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Figure 3.9. Distinguishing the E1 reactivity of ubiquitin mutants near the threshold 
required to support yeast growth. Two regions of ubiquitin encompassing amino acids 
40-48 and 68-76 were analyzed using bulk competitions performed with excess E1. (a) 
Molecular illustration highlighting the contacts between these two ubiquitin regions 
(shown in light grey) and E1 (shown in dark green) based on 3CMM.PDB.56 (b&c) 
Illustrations of contacts between ubiquitin and two common ubiquitin binding domains 
(UBA and UIM) based on 1QOW.PDB133 and 2OOB.PDB134 respectively. (d&e) The 
impacts of ubiquitin mutants in these two regions on experimental fitness compared with 
effects on reactivity with either limiting E1 (d), or excess E1 (e). Ubiquitin mutants 
deficient for activation with limiting E1 are shown as purple squares and mutations at 
position 72 are highlighted with a light blue diamond in panels d&e. (f) For ubiquitin 
mutants deficient for reactivity with limiting E1, the distribution of E1 reactivity 
observed in experiments with excess E1. 
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Figure 3.9. Distinguishing the E1 reactivity of ubiquitin mutants near the threshold 
required to support yeast growth.  
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With excess E1, the relationship between ubiquitin mutant effects on activation 
and fitness shifted distinctly (Fig. 3.9e, Supplementary Tables 3.3&3.4). Excess E1 
caused an increase in the E1 reactivity observed for many ubiquitin mutants. All ubiquitin 
mutants with severe activation defects with excess E1 also exhibited deficient growth in 
yeast, suggesting that E1 activation in this set of ubiquitin mutants is below the level 
required for growth. While this class of ubiquitin mutants likely has fitness limiting E1 
activation defects, they may also have defects in other critical ubiquitin functions due to 
the structural location of many of these residues at contact sites with other ubiquitin 
binding domains (Fig 3.9b&c). 
We observed many ubiquitin mutants that were activation deficient at limiting E1, 
but were capable of activating with excess E1 (Fig. 3.9e&f). This class of ubiquitin 
mutant exhibits competitive activation defects that are not severe enough on their own to 
prohibit yeast growth, but that would competitively hinder activation in the presence of 
ubiquitin molecules that are more E1 reactive. Most ubiquitin mutants with competitive 
activation defects exhibited severely impaired fitness, suggesting that these mutants also 
caused biochemical defects in other critical ubiquitin properties.  
Amino acid substitutions at position 72 resulted in activation efficiencies with 
excess E1 that correlated positively with fitness effects (Fig. 3.9e). The location of R72 in 
a deeply buried cleft in the structure with E1 (Fig. 3.9a) and at the periphery of structures 
of ubiquitin with other binding domains (Fig. 3.9b&c) suggests that mutations at position 
72 may primarily impact E1 activation within the ubiquitin interaction network. 
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Consistent with this structural inference, the activation observed with excess E1 of 
ubiquitin mutants at position 72 disproportionately correlate with fitness effects 
compared to mutants at other positions. 
Correspondence between ubiquitin mutant effects on E1 activation and fitness. 
The overall distribution of ubiquitin mutant effects on E1 reactivity under 
conditions of limiting E1 is similar to the distribution of experimental fitness effects (Fig. 
3.10a). Both distributions are bi-modal with a main peak near wild type (defined as 1) 
and null (defined as 0). These profiles indicate the magnitudes of mutant effects on 
fitness and this E1 function are similar. In principle, this could be due to a strong or linear 
relationship where E1 activation is rate-limiting for yeast growth, but this idea is 
incompatible with our observation that R72S ubiquitin reduces E1 activation 50-fold 
while impairing growth rate less than two fold. As an alternative hypothesis, we propose 
that the similar observed distributions of ubiquitin mutant effects may be due to parallel 
biochemical impacts of many ubiquitin mutants on E1 activation and other ubiquitin 
functions.  
For both experimental fitness and E1 reactivity, we classified each mutant as 
proficient (within 20% of the average wild type synonym), deficient (within 20% of the 
average stop codon), or intermediate (Fig. 3.10a&b). To assess the reasonableness of 
these cutoffs we examined wild type synonyms and stop codons as positive and negative 
controls. We observe that greater than 90% of wild type synonyms classify as proficient 
and greater than 90% of stop codons classify as deficient. In addition, these control sets 
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exhibited no full misclassifications (e.g., proficient misclassified as deficient). The 
majority of E1 deficient ubiquitin mutations were deficient for yeast growth; and the 
preponderance of E1 proficient mutations supported robust yeast growth (Fig. 3.10b). 
The large number of mutants that exhibit robust yeast growth and E1 reactivity indicates 
that most ubiquitin variants that react efficiently with E1 tend to also function well in all 
other essential ubiquitin activities. The strong correspondence between E1 reactivity and 
fitness is consistent with the structurally characterized interfaces between ubiquitin and 
many binding partners that often center on the isoleucine 44 of ubiquitin.36 
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Figure 3.10. Similar impacts of ubiquitin mutations on E1 reactivity and experimental 
fitness. (a) Distribution of ubiquitin mutant effects on E1-reactivity with limiting E1 (top) 
and previously determined27 effects on yeast growth rate (bottom). Stop codons were not 
included in the E1 or fitness panels, and four severely depleted reactivity measurements 
were excluded in order to focus on the main features of the distribution. (b) Contingency 
table describing the observed overlap of ubiquitin mutants effects on E1-reactivity and 
yeast growth. All observed frequencies were statistically skewed compared to 
expectations from independent binomial distributions, which are shown in italics. (c) 
Analyses of the side-chain surface area buried between ubiquitin and many different 
binding partners in 45 high resolution co-crystal structures indicate that I44 and V70 are 
almost always fully buried at the binding interface. Positions surrounding I44 and V70 
are buried in a large fraction of interfaces depending on the orientation of the binding 
partner relative to ubiquitin. (d) The adenylation domain of E1 (shown in gray) almost 
completely encompasses ubiquitin surfaces that were structurally determined to 
contribute to binding interfaces with other proteins. (e&f) Domains that commonly 
mediate binding to ubiquitin bind to smaller surface regions of ubiquitin than E1. 
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Figure 3.10. Similar impacts of ubiquitin mutations on E1 reactivity and experimental 
fitness. 
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Common ubiquitin binding interface 
Structural analyses indicate that ubiquitin almost universally contacts partner 
proteins via a common binding surface (Fig. 3.10c-f). Our own analyses of 45 high 
resolution co-crystal structures of ubiquitin with a variety of binding partners indicate 
that the side-chains of I44 and V70 in ubiquitin are almost always fully buried at the 
interface (Fig. 3.10c) and surrounding positions are buried in a fraction of these structures 
depending on the shape and orientation of the binding partner (Fig. 3.10d-f, 
Supplementary Table S3.5). The adenylation domain of E1 forms a very large contact 
surface with ubiquitin that encompasses nearly all of the structurally characterized 
contacts between ubiquitin and other common binding domains including ubiquitin-
associated domains (UBA) and ubiquitin-interacting motifs (UIM) as illustrated in Fig. 
3.10d-f. 
One third (3300 Å2) of the total surface area of ubiquitin is buried by contact with 
E1,56 including the hydrophobic patch formed by L8, I44, and V70 that is required for 
binding to proteasomal66 and many other ubiquitin receptors.36 This large interface is not 
a chemical prerequisite for activation, as the chemistry of this reaction is localized to the 
C-terminal carboxyl group of ubiquitin. The same chemical mechanism is utilized to 
activate SUMO (a ubiquitin like protein) despite a far smaller interface (1600 Å2)55. The 
strong evolutionary conservation of E1, whose protein sequence is 50% identical between 
human and yeast36, suggests that the large ubiquitin-E1 interface has been subject to 
stringent purifying selection in nature. The structural interface between ubiquitin and E1 
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is among the surfaces that exhibit the strongest evolutionary conservation in these 
proteins (Fig. 3.11). Our results indicate that the large E1-ubiquitin interface enables E1 
to preferentially activate ubiquitin variants that are functional across the majority of the 
ubiquitin interaction network. 
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Figure 3.11. Sequence conservation across species of ubiquitin and E1. (a) Sequences of 
ubiquitin from diverse eukaryotes. The protein sequence of ubiquitin is ultra-conserved 
with amino acid substitutions at four positions that are colored red. (b) Illustration of the 
contacts between ubiquitin and the adenylation domain of E1. Ubiquitin side chains at 
positions that vary in nature are colored red and cluster away from the interface with E1. 
(c) Illustration of the structure of E1 and ubiquitin. Ubiquitin is colored green and the E1 
is colored based on amino acid conservation observed among diverse fungi [alignment 
from Wapinski I, Pfeffer A, Friedman N, Regev A (2007) Natural history and 
evolutionary principles of gene duplication in fungi, Nature 449:54-61] 
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Figure 3.11. Sequence conservation across species of ubiquitin and E1. (a) Sequences of 
ubiquitin from diverse eukaryotes.  
  
108 
 
While E1 poorly activates most ubiquitin mutants that are growth deficient, we 
observed a small fraction of ubiquitin mutants that were activated efficiently by E1, but 
that were incompatible with robust growth. Of the 939 ubiquitin point mutants that were 
E1 proficient (Fig. 3.10b), only 59 (6%) were growth deficient (Fig. 3.12). These poorly 
filtered ubiquitin point mutants were frequently located at the periphery of the interface 
between ubiquitin and the adenylation domain of E1 (Fig. 3.12), consistent with the 
chemical intuition that peripheral contacts have smaller contributions to binding and 
reactivity than central contact points.135 
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Figure 3.12. Ubiquitin point mutants with robust E1 activation, but strong fitness defects. 
(a) Histogram illustrating the number of point mutants at each position in ubiquitin that 
were proficient for activation with limiting E1, but that were deficient for yeast growth. 
Positions are color coded based on the number of poorly filtered substitutions (>3 red; 2-
3 blue; 1 yellow). (b) Location of these ubiquitin mutants relative to the interface with the 
adenylation domain of E1 (shown in grey). Positions are color coded as in panel a. 
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Figure 3.12. Ubiquitin point mutants with robust E1 activation, but strong fitness defects.  
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Discriminating Activation by E1 
We investigated the effects of ubiquitin mutations at two positions (I44 and K48) 
that are both critical for many downstream functions, but whose mutational sensitivity for 
E1 reactivity was not predicted nor discussed in the description of the ubiquitin-E1 
crystal structure.56 I44 is at the center of a hydrophobic patch on the surface of ubiquitin 
that forms central contacts with most structurally characterized ubiquitin binding 
domains,36,66 and K48 is the site of covalent linkage to form ubiquitin polymers that 
target substrates for proteasome mediated degradation.33 In the structurally characterized 
complex with E1, I44 of ubiquitin forms hydrophobic contacts with multiple side chains 
of E1, while K48 forms a partially solvent accessible salt bridge with E892 from E1 (Fig. 
3.13a). While hydrophobic contacts stabilize interfaces, they tend to tolerate slight 
changes to geometry and often permit conservative substitutions (see Chapter II, Figure 
2.6).12,13,15 Using binary competitions with purified proteins, we observed that E1 
reactivity was sensitive to even the most conservative substitutions of Ile to Val at 
position 44 (Fig. 3.13b and Fig. 3.7). Similarly, partially solvent exposed salt bridges 
such as the one formed by K48 of ubiquitin with E1 often fail to stabilize protein 
structures and complexes due to the cost of displacing water molecules from unbound 
states.136 However, the ubiquitin K48 mediated salt bridge to E1 is critical for efficient 
activation as mutations that remove the positive charge at position 48 reduce competitive 
reactivity with E1 (Fig. 3.13b and Fig. 3.7).  
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Figure 3.13. E1 inefficiently activates ubiquitin variants with known biochemical defects 
in downstream pathways. (a) Molecular illustration of contacts between ubiquitin amino 
acids I44 and K48 with the adenylation domain of E1. Covalent linkage by the ubiquitin 
K48 side chain is a critical signal for proteasome mediated degradation, and I44 forms 
direct binding contacts with almost all structurally characterized ubiquitin binding 
partners. Conservative substitutions to I44 as well as substitutions that removed the 
positive charge at K48 exhibited decreased E1 reactivity in purified form (b) and a 
reduced ability to conjugate to other proteins in cells co-expressing wild-type ubiquitin 
(panel c and Supplementary Fig. S8). (d) The capability of E1 to preferentially activate 
ubiquitin protein molecules functional in downstream pathways provides the potential for 
post translational quality control over the pool of ubiquitin protein in wild-type cells that 
will include ubiquitin protein molecules with errors from synthesis and/or chemical 
damage. (e) Selection model indicating that pressure for E1 to quality filter ubiquitin 
protein molecules could lead to parallel selection for downstream processes to function 
with the pool of ubiquitin variants efficiently activated by E1. This hypothesis is 
consistent with the correspondence we observe between ubiquitin mutant effects on 
competitive fitness and E1 activation as well as the extensive binding interface between 
E1 and ubiquitin that encompasses the interfaces of ubiquitin with other binding partners.    
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Figure 3.13. E1 inefficiently activates ubiquitin variants with known biochemical defects 
in downstream pathways. 
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While ubiquitin mutations at position 44 and 48 almost universally cause strong 
activation defects with limiting E1, many are capable of activation with excess E1. With 
excess E1, eight substitutions at isoleucine 44 (Q, H, T, A, V, L, M, W) and all 
substitutions except D and E at lysine 48 could be activated in experiments with excess 
E1 (Supplementary Table S3.4). These observations indicate that the fitness defects of 
most mutations at positions 44 and 48 are caused by biochemical defects other than E1 
activation, consistent with the known biochemical function of K48 in forming critical 
polymers and I44 in binding to essential receptors.36,66 
We investigated how mutants at positions 44 and 48 accumulated in vivo. We 
observed that ubiquitin mutants at I44 or K48 exhibited decreased accumulation as 
conjugated species in cells co-expressing wild type ubiquitin (Fig. 3.13c, Fig. 3.14). 
Together with our observation that these mutants exhibit a competitive E1 defect in vitro, 
we infer that E1 contributes to the limited conjugation of these ubiquitin variants in vivo. 
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Figure 3.14. Accumulation pattern of epitope tagged ubiquitin variants expressed in 
yeast co-expressing endogenous untagged ubiquitin. Yeast lysates were analyzed by 
Western blotting with anti-His antibody. The star denotes a minor background band 
present in yeast lysates that cross reacted with the anti-His antibody. 
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Figure 3.14. Accumulation pattern of epitope tagged ubiquitin variants expressed in 
yeast co-expressing endogenous untagged ubiquitin. 
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Post translational quality filtering model 
Based on our observations, we propose that E1 can discriminately activate 
ubiquitin protein molecules that are capable of binding to other partners from the pool of 
ubiquitin protein in cells that will include molecules with synthetic errors137 and/or 
chemical damage (e.g. deamination of glutamine to glutamate)138 (Fig. 3.13d). Of note, 
the E1 quality filtering that we propose occurs on the protein pool of ubiquitin generated 
from the wild-type ubiquitin gene. Estimates of the rate of transcription and translational 
errors139 suggest that ~0.1% of ubiquitin protein molecules generated from the wild-type 
gene will contain an amino acid substitution error. The average observed fitness effect of 
an amino acid substitution in ubiquitin (savg = -0.25) leads to a potential fitness benefit 
from E1 quality filtering of 0.025% (s=0.00025) under the simplifying assumption that 
all amino acid substitutions are equally probable. In natural populations, selection 
coefficients above ≈0.0001% (s≈10-6) would be subject to natural selection based on 
estimates of the effective population size of yeast140 and the nearly neutral model.141 Of 
note, it is possible that some ubiquitin variants that were efficiently activated by E1, but 
that were unfit (Fig. 3.10B) may not have been subject to strong selection for filtering 
due to the amino acid substitution in these variant having a low probability to occur from 
synthesis errors. These rough approximations of protein synthesis errors and fitness costs 
indicate that quality filtering by E1 could impact fitness by a magnitude sufficient for 
selection in natural populations of yeast. 
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The tendency for partner proteins to bind to a similar ubiquitin surface is 
consistent with our quality filtering hypothesis, but does not rule out alternative 
explanations. For example, the ubiquitin surface that binds to E1 has biophysical 
properties (exposed hydrophobic side chains including I44) that favor macromolecular 
interactions and likely contribute to this surface serving as a common target of other 
binding partners. However, the observed biophysical diversity at protein-protein 
interfaces24 makes it unlikely that biophysical preferences alone would lead to a near-
universal ubiquitin binding surface that is encompassed by the E1-ubiquitin interface, 
while the quality filtering model would.  
In addition, the quality filtering model provides a rationale for the impacts of 
mutations to K48 on E1 activation efficiency.  Our display studies as well as follow up 
studies with individual ubiquitin mutants demonstrate that E1 selectively filters ubiquitin 
protein molecules with substitutions at position 48 that cause known biochemical defects 
when activated and attached to substrates.33 In future studies, it will be important to 
further test the quality filtering model. In particular, this model makes the potentially 
testable prediction that loss of quality filtering by E1 would lead to fitness defects. 
The quality filtering model provides a possible rationale for the large contact area 
observed between E1 and ubiquitin: to enable E1 to extensively interrogate the properties 
of ubiquitin molecules and discriminate functional ubiquitin variants. All positions at an 
interface can contribute to relative affinity (e.g. ΔΔG of binding compared to wild-type) 
and this in turn contributes directly to competitive or relative reactivity for systems under 
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equilibrium control.23,82 Thus, all positions at interfaces have the potential to contribute 
strongly to competitive affinity and reactivity. Consistent with this idea, the interface 
between ubiquitin and E1 is conserved relative to other surfaces on these proteins (Fig. 
3.11). This type of interface-mediated quality filtering may reduce potential toxic 
consequences from flawed macromolecules in other systems with large contact surfaces 
(e.g. ribosome assembly). Of note, the expression of flawed proteins can impose a fitness 
cost even in the absence of aberrant function142 that is of sufficient magnitude to be under 
selection in natural populations.141 Quality filtering of ubiquitin pools by E1 may be 
particularly important because proteasome-mediated surveillance, an important quality 
control component for the majority of the proteome,143 may be unavailable for ubiquitin 
due to the inherent ubiquitin recycling function of the proteasome.144,145 
The selection we propose for quality filtering of ubiquitin protein pools by E1 
predicts feedback selection such that ubiquitin mutants will often have similar 
biochemical effects across many ubiquitin functions (Fig. 3.13e). In this model, 
downstream ubiquitin functions impose selection pressure for quality filtering by E1, and 
quality filtering imposes feedback selection on downstream ubiquitin functions to be 
efficient with the set of ubiquitin variants that pass E1 quality filtering. Quality filtering 
and feedback selection provide a plausible evolutionary rationale for the structurally 
observed large ubiquitin E1 interface that encompasses interfaces of ubiquitin with other 
binding partners. 
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Conclusions 
Understanding the connections between function and fitness is a primary goal of 
many biological disciplines including systems biology and molecular evolution. While 
sound approaches have been developed to understand the connections between function 
and fitness for proteins that perform a single function,29,117,119–121 investigating potential 
interdependencies in multi-functional proteins had posed daunting technical challenges. 
Systematic investigations of mutant effects provide a powerful approach to delineate 
mutations that primarily impact a single network edge from mutations with broad 
network impacts. Using this approach we find that the activation of ubiquitin by E1 is far 
greater than required for robust yeast growth, but that most ubiquitin mutations that 
disrupt E1 activation also disturb other ubiquitin functions. This study demonstrates that 
systematic mutant analyses provide a powerful approach to investigate how edge-rich 
protein interaction networks contribute to overall biological function. 
MATERIALS AND METHODS 
Libraries of ubiquitin point mutants were displayed on the surface of yeast as C-
terminal fusions with Aga2-HA similar to previous descriptions.28,146 Pools of yeast 
displayed mutants were reacted with E1, labeled with fluorescent antibodies directed to 
either E1 or the HA tag. FACS was used to isolate E1-reactive cells (E1 and HA positive) 
and/or HA-displaying (HA positive) cells. Deep sequencing14 was used to determine the 
enrichment or depletion of each mutant in E1 reactive cells compared to HA displaying 
cells. The relative E1 reactivity of a panel of individual ubiquitin variants was 
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independently determined relative to wild type ubiquitin using purified proteins. The 
accumulation pattern of His6-ubiquitin variants in yeast harboring untagged wild type 
ubiquitin was monitored by inducing expression of the epitope tagged variant followed 
by Western blotting. 
Expression and purification of E1 (Uba1) 
The yeast E1 (Uba1) open reading frame was cloned with a biotin ligase acceptor 
peptide147,148 encoded at the far C-terminus into a pAC-T7, an expression vector with a 
T7 promoter and a chloramphenicol resistance marker. This expression plasmid was co-
transformed into BLR(DE3) E. coli together with pET24-birA to co-express biotin ligase. 
Cells were grown at 37 °C in 2x YT media to an OD600 of 0.8.  Cells were then induced 
with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 25° C for 6 hours, harvested 
by centrifugation, and resuspended in IMAC binding buffer (20 mM potassium 
phosphate, pH 7.2, 300 mM sodium chloride, 10 mM imidazole). Bacterial pellets were 
lysed with a combination of lysozyme, DNAse I, and sonication in the presence of 1 mM 
phenylmethanesulfonyl fluoride (PMSF) to inhibit proteolysis. Biotinylated Uba1 was 
then purified by Cobalt immobilized metal affinity chromatography followed by anion 
exchange chromatography. Active E1 concentration was estimated by titration with 
purified wild type ubiquitin, and was routinely 20-40% of the E1 concentration estimated 
by absorbance at 280 nm. E1 concentrations based on absorbance at 280 nm were more 
precise and are used throughout the text and figures. 
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Yeast surface display of ubiquitin point mutants 
Systematic libraries of ubiquitin point mutants were generated in the pCTCON2 
yeast display plasmid28 with a galactose dependent promoter driving a fusion of Aga2 
with HA followed by a glycine rich linker and ubiquitin with its native C-terminus. 
Libraries of ubiquitin point mutants were generated in eight pools.  Each pool contained 
mutants in 9-10 consecutive amino acids as described in chapter II (Fig. 2.3). Ubiquitin 
mutant libraries were transferred into pCTCON2 using SLIC.149 To facilitate transfer a 
modified pCTCON2 destination plasmid was constructed with the sequence 
GCTAGCGATTCTAGAACTAGTAATATGCATGCTCGAGTCATGTAATTAGTTAG
GATCC immediately following the HA tag and glycine rich sequence in pCTCON2. This 
vector was prepared for SLIC by digestion with SphI and treatment with T4 DNA 
polymerase as described.149 SLIC inserts were prepared by 8 cycles of PCR with 
ubiquitin libraries in p427GPD (described in chapter II) as template and forward 
(GATTCTAGAACTAGTAATATG) and reverse primers 
(TAACTAATTACATGACTCGAG) that bind immediately upstream and downstream of 
the ubiquitin open reading frame in this template, followed by treatment with T4 DNA 
polymerase as described.149 After annealing of prepared vector and inserts, samples were 
transformed into competent bacteria and plasmid libraries prepared in bulk as previously 
described.14 The library generation procedures were developed to maximize the fraction 
of the library with relevant point mutations and minimize chances for secondary 
mutations, especially those outside of the regions directly sequenced and hence 
undetectable to our enrichment analyses. The starting ubiquitin libraries were generated 
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using a cassette ligation strategy (described in chapter II) such that all regions outside of 
those directly sequenced were copied entirely in bacteria where fidelity should virtually 
eliminate the probability of secondary mutations. In transferring the libraries to the 
display plasmid, we performed 8 cycles of PCR using Pfusion DNA polymerase (New 
England Biolabs). According to the manufacturer’s estimated error rate for this 
polymerase (4.4×10-7) and the amplification details, we estimate that less than 1 in 10,000 
molecules would have a secondary mutation outside the region that we sequence. 
Pooled mutant libraries of each region were transformed separately into the 
EBY100 yeast-display strain as described in chapter II.  Following plasmid 
transformation, yeast cells were pelleted and washed three times in 1X Tris buffered 
saline (TBS) to remove extra-cellular plasmid.  Each pellet was then resuspended in 50 
mL of synthetic dextrose (SD) media lacking tryptophan and uracil to select for 
transformed cells. Cells were grown for 48 hours (to an OD600 of about 1) at 30 °C in a 
shaking incubator.  Aliquots of approximately 108 cells were collected for each library 
and stored in 20% glycerol at -80°C. Aliquots for each library region were thawed and 
used to inoculate 50 mL of casamino acid and dextrose media (CAAD).  These cultures 
were grown at 30 °C to near-saturation for 24 hours, and then diluted 50-fold into 50 mL 
of fresh CAAD.  Yeast proliferation was then monitored by OD600 reading and kept in 
mid-log growth by dilution with fresh CAAD for 16 hours.  Cells in log phase were 
collected by centrifugation and washed 3 times with CAA-RG media (casamino acids 
media with 1% raffinose and 1% galactose), resuspended in CAA-RG media to an 
OD600 of 0.5, and grown at 30°C for a further 16 hours. As a control for non-displaying 
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cells, cultures were also grown in CAAD to repress expression from the gal-inducible 
promoter. 
Labeling and sorting of yeast display cells 
 For each ubiquitin region, a sample of 107 display cells were collected in a 
microfuge tube, washed twice with TBS, and resuspended in 100 μL of TBS.  A 2x E1 
reaction mixture was made in a separate tube (50 mM Tris pH 7.5, 5 mM magnesium 
chloride, 2.5 mM ATP, and 200 nM total E1 enzyme for limiting conditions or 2000 nM 
total E1 for excess conditions). 100 μL of E1 reaction mixture was mixed with cells, 
incubated at room temperature for 1 minute, and the reaction quenched with an excess of 
free ubiquitin. Following reaction, yeast cells were washed twice with 500 μL of TBS 
containing 0.1 % bovine serum albumin (TBSB).  Cells were resuspended in 100 μL of 
TBSB and incubated for 30 minutes on ice with a 1:100 dilution of both α-HA rabbit 
polyclonal (Abcam 13834-100) and mouse monoclonal α-biotin (Jackson Immuno 
Research 200-002-211) antibodies.  Cells were then collected by centrifugation, washed 
twice with TBSB and incubated in a 100 μL volume on ice with α-rabbit-IgG-FITC and 
α-mouse-IgG-phycoerytherin (PE) (Sigma F0382 and P9287). Labeled cells were diluted 
to 106 cells/mL and transferred to polystyrene FACS tubes. 
 Labeled samples were sorted for display efficiency and E1 reactivity on a BD 
FACSVantage DV-1 cell sorter by collecting all FITC-positive cells as one population 
(HA-display positive), followed by double-positive FITC+PE cells (HA-display positive 
and E1 reactive).  To ensure adequate library coverage, at least 150,000 cells of each 
population were sorted and collected into sterile SD media.  Sorted yeast were amplified 
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in 50 mL of SD-U-W media (display off) for 24 hours at 30 °C to an OD600 of 
approximately 1.  These yeast samples were collected by centrifugation, washed with 
TBS, and cell pellets stored at -80 °C.  
Quantifying mutant responses to selection by sequencing 
 Plasmid DNA from yeast pellets was prepared for deep-sequencing as previously 
described in chapter II. Briefly, plasmid DNA was isolated from yeast and the display 
ubiquitin open reading frame amplified with primers specific to the pCTCON2 promoter 
and terminator regions. A second PCR step was used to focus on the randomized region 
of each library, including adding an MmeI site adjacent to the mutated region.  Three-
base barcodes each differing by at least two bases were ligated to MmeI-digested samples 
to differentiate between unsorted cells, HA-positive displaying cells, and double positive 
E1 and HA-displaying cells. FastQ files from deep sequencing were analyzed as 
previously described.14 Raw counts of each mutant were normalized to the wild type 
ubiquitin sequence count.  The relative enrichment or depletion of each mutant in E1 
reactive cells to HA displaying cells was calculated in log scale.  Because the last amino 
acid of ubiquitin is strictly required for E1 activation, stop codons at each position should 
be biochemically null. To normalize for small differences in observed raw enrichment 
and depletion values for different regions, the apparent E1 reactivity’s of mutants in each 
region were linearly scaled such that the average stop codon was 0 and the average wild 
type synonym was 1. Of note, analyses of unsorted and HA-displaying cells indicated 
that all mutations (including stop codons and cysteine substitutions throughout ubiquitin) 
were displayed with similar efficiency. As described in chapter II, mutations that were 
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low in abundance in our libraries (mutant:WT ratio less than 2-8) or that introduced an 
internal MmeI site were omitted from analysis. For wild type amino acids where 
synonyms were not available or analyzed, E1 reactivity was set to the average of all wild 
type synonyms in the region (1 by definition). 
Monoculture growth rate of yeast with individual ubiquitin mutations 
 Growth of yeast supported by ubiquitin variants was determined as previously 
described in chapter II.70 Briefly, plasmid (p427GPD) encoded ubiquitin variants driven 
by a constitutive promoter were transformed into a ubiquitin shutoff strain (Sub32852).   
Growth rates at 30 °C were determined in synthetic dextrose media by following the 
change in OD600 after 12 hours of pre-equilibration in shutoff conditions.   
Quantification of ubiquitin activation by E1 using purified proteins 
 We developed a binary competition assay to determine the E1 reactivity of 
ubiquitin mutants relative to wild type using purified proteins.  We generated and purified 
wild type ubiquitin with a His6 tag and a unique cysteine at the N-terminus 
(MGHHHHHHCGG). Purified protein was reacted with fluorescein iodoacetamide, and 
fluorescently labeled ubiquitin (FL-UB) further purified by size exclusion 
chromatography using a superdex-200 column. Competition experiments between 
fluorescently labeled wild type ubiquitin and unlabeled competitors were setup with 100 
nM total E1, 500 nM FL-UB, and a range of competitor concentrations. Reactions were 
performed at room temperature in E1 reaction buffer (25 mM Tris, pH 7.2, 50 mM 
sodium chloride, 5 mM magnesium chloride, 5 mM ATP) supplemented with 0.1 mg/mL 
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bovine serum albumin. After 1 minute, reactions were halted by the addition of sodium 
dodecyl sulfate to 2%. Reaction products were separated on a non-reducing SDS-PAGE 
and imaged on a fluorescent imager. The intensity of the FL-UB-E1 band was quantified 
using the program Multigauge (Fuji) and plotted as a function of the concentration of 
unlabeled competitor. These plots were fit to a simple kinetic model (Fig. 3.7) to estimate 
relative E1 reactivity. Relative E1 reactivity was log transformed and normalized (wild 
type set to 1 and the null mutant G75D set to 0) in order to facilitate comparison to 
reactivity estimates from display experiments. 
Analyzing ubiquitin accumulation in yeast 
 To examine the accumulation profile of ubiquitin mutants in yeast, we generated 
inducible epitope tagged ubiquitin constructs. Selected ubiquitin mutants with an N-
terminal His6-Myc epitope were cloned with a galactose inducible promoter
150 into p427 
plasmids.  These constructs were transformed into W303 yeast cells that express wild 
type ubiquitin from endogenous loci. Following transformation, single colonies were 
grown to saturation at 30 °C in synthetic dextrose media, and then grown at 30 °C for 16 
hours in synthetic media with 2% raffinose to an OD600 of 1.  At this point, a sample of 
control (uninduced) cells were collected and frozen at -80 °C. The remaining culture was 
grown in synthetic media with 1% galactose and 1% raffinose for 2 hours at 30 °C.  
Samples were collected by centrifugation, washed once with TBS and stored at -80 °C.  
Frozen samples were lysed by vortexing with glass beads and treatment with 2% SDS 
buffer with 1 mM PMSF at 95 °C for 5 minutes. After removing cell debris by 
centrifugation, the protein concentration in each sample was determined using a BCA 
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assay (Pierce).  Samples (20 μg of total protein from each lysate) were analyzed by 
Western blotting with anti-HisG antibody (Invitrogen 46-1008). Multigauge (Fuji) 
densitometry software was used to quantify both free and conjugated ubiquitin species.  
Structural analyses. 
Structural analyses were performed with Pymol (Schrödinger) or Chimera 
(UCSF), and these programs were also used to generate all molecular images. The 
average surface area buried at structurally characterized ubiquitin interfaces was 
calculated from surface area measurements described in chapter II (table 2.4). 
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Chapter IV - Resistance to vemurafenib resulting from a novel 
mutation in the BRAFV600E kinase domain 
 
This chapter has been published by Timothy R. Wagenaar*, Leyuan Ma*, Benjamin 
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Summary 
Resistance to the BRAF inhibitor vemurafenib poses a significant problem for the 
treatment of BRAFV600E-positive melanomas. It is therefore critical to prospectively 
identify all vemurafenib resistance mechanisms prior to their emergence in the clinic. The 
vemurafenib resistance mechanisms described to date do not result from secondary 
mutations within BRAFV600E. To search for possible mutations within BRAFV600E 
that can confer drug resistance, we developed a systematic experimental approach 
involving targeted saturation mutagenesis, selection of drug-resistant variants, and deep 
sequencing. We identified a single nucleotide substitution (T1514A, encoding L505H) 
that greatly increased drug resistance in cultured cells and mouse xenografts. The kinase 
activity of BRAFV600E/L505H was higher than that of BRAFV600E, resulting in cross-
resistance to a MEK inhibitor. However, BRAFV600E/L505H was less resistant to 
several other BRAF inhibitors whose binding sites were further from L505 than that of 
PLX4720. Our results identify a novel vemurafenib-resistant mutant and provide insights 
into the treatment for melanomas bearing this mutation. 
Significance 
The oncogenic BRAF kinase mutation BRAFV600E is found at high frequency in 
melanomas. Vemurafenib, a BRAF kinase inhibitor, has shown remarkable clinical 
efficacy in the treatment for BRAFV600E-positive melanoma. Inevitably, however, 
resistance emerges. Therefore, prospectively identifying possible vemurafenib resistance 
mechanisms is critical for developing more effective therapeutic approaches. Toward this 
end, we developed a systematic saturation mutagenesis approach to search for second-site 
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mutations within BRAFV600E that could confer drug resistance. Using this method, we 
identify and characterize a novel vemurafenib-resistant BRAFV600E mutant, which 
arises by a single nucleotide substitution, and provide insights into the potential treatment 
of melanomas bearing this mutation. 
Introduction 
BRAF is a serine–threonine kinase that functions as an immediate downstream 
effector of RAS (reviewed in Dhomen and Marais, 2007).151 BRAF activates the MAP 
kinase extracellular signal-regulated kinase (MEK), which in turn phosphorylates and 
activates extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2). Oncogenic 
BRAF mutations are found in a significant number of human cancers, with a particularly 
high frequency (50–70%) occurring in melanomas.152 The most frequent oncogenic 
mutation occurs within the BRAF kinase domain and is the substitution of a valine for 
glutamic acid at amino acid 600 (V600E). The mutation leads to unchecked kinase 
activity and constitutive activation of the downstream MEK and ERK kinases. 
Vemurafenib (also called PLX4032) is a selective inhibitor of BRAFV600E that 
can elicit marked melanoma tumor regression, resulting in improved progression-free and 
overall survival in patients with metastatic disease.153,154 However, the durability of the 
vemurafenib response is limited by acquired drug resistance.155 Thus, elucidating the 
basis of resistance to vemurafenib, and other BRAF inhibitors, is essential to developing 
more effective therapies for the treatment of melanoma. 
A common mechanism of resistance to small molecule protein kinase inhibitors is 
the acquisition of a second-site mutation that interferes with drug binding.43 Such drug-
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resistant variants, isolated from patients or in cell- or animal-based experiments, typically 
arise from a single, non-synonymous nucleotide mutation within the protein kinase 
domain. Several vemurafenib resistance mechanisms have been described and, in most 
cases, are due to alternative activation of MEK-ERK signaling .155 Other vemurafenib 
resistance mechanisms include amplification of the BRAFT1799A allele (encoding 
BRAFV600E)156 and generation of aberrantly spliced BRAFV600E variants.157 
Surprisingly, however, drug-resistant amino acid substitution mutants within the 
BRAFV600E protein-coding region have not been isolated from vemurafenib-resistant 
melanomas or melanoma cell lines, suggesting that they are either impossible or 
improbable relative to other resistant pathways. Here, we describe a systematic, structure-
based saturation mutagenesis approach to identify single, second-site nucleotide 
substitutions within BRAFV600E that can confer vemurafenib resistance. 
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Results 
A structure-based, targeted, saturation mutagenesis screen identifies PLX4720-
resistant BRAFV600E mutants 
Our experimental strategy is summarized in Figure 4.1(A) and discussed below. 
Guided by the structure of BRAFV600E bound to PLX4720 (PDB: 3C4C and Figure 
4.1B), a tool compound for vemurafenib that elicits comparable actions to its clinical-
grade counterpart158, we performed targeted saturation mutagenesis of 77 amino acids 
surrounding the PLX4720-binding site. Eight mutant pools were generated—
corresponding to amino acids 458–466, 467–476, 477–486, 501–510, 511–520, 527–536, 
579–587, and 588–596—in which each amino acid was mutated to all possible 64 
codons. The mutant pools were transferred into a retroviral vector containing 
BRAFV600E and then stably transduced into the human melanoma cell line A375, which 
is homozygous for BRAFV600E and highly sensitive to PLX4720.159 Cells were cultured 
for 3 weeks in the presence of 10 μM PLX4720, at which point resistant clones emerged 
for six of the eight pools (Figure 4.1C). Pools encoding mutants corresponding to amino 
acids 458–466 and 467–476 did not result in any detectable PLX4720-resistant colonies 
above background. 
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Figure 4.1. A structure-based, targeted, saturation mutagenesis screen identifies 
PLX4720-resistant BRAFV600E mutants. (A) Schematic summary of the PLX4720 
resistance screen. (B) Structure of BRAF complexed with PLX4720 (yellow); amino 
acids surrounding the drug-binding site are colored magenta. (C) Images of A375 cells 
transduced with retroviruses expressing BRAFV600E or pools of mutagenized 
BRAFV600E and grown in media containing PLX4720. Cells were fixed and stained 
with crystal violet. (D) Scatter plot showing enriched BRAFV600E mutants after 
PLX4720 selection from two independent biological replicates. Mutants that occur due to 
single nucleotide substitution are indicated by a red dot. (E) Amino acid sequence of the 
mutagenized region of human BRAFV600E showing the PLX4720-resistant mutants 
isolated from the screen showing a >fivefold enrichment. Mutants that occur by single 
nucleotide substitution are indicated by a red dot. (F) Location of the amino acids whose 
mutants are enriched >fivefold (shown in pink, except for L505 in red) in the BRAF–
PLX4720 structure. 
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Figure 4.1. A structure-based, targeted, saturation mutagenesis screen identifies 
PLX4720-resistant BRAFV600E mutants. 
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To identify the mutated amino acid(s) that conferred PLX4720 resistance, cells 
from the resistant cell populations were pooled, genomic DNA was isolated, and 
BRAFV600E variants were identified by massively parallel sequencing. We anticipated 
that, following drug selection, the sequences of PLX4720-resistant BRAFV600E mutants 
would be enriched relative to PLX4720-sensitive BRAFV600E variants. To control for 
possible unequal representation of the variants in the starting population, deep sequencing 
was also performed on genomic DNA isolated from transduced cells prior to drug 
selection. Figure 4.1(D) displays the relative enrichment of BRAFV600E variants 
following PLX4720 selection from two independent biological replicates. The use of 
replicate experiments enabled us to distinguish between reproducible enrichment, 
resulting from a drug-resistant mutation, and non-reproducible enrichment, resulting from 
a random variation in the sequence pool. For example, silent substitutions that did not 
alter the BRAFV600E protein sequence were occasionally enriched in one replicate, but 
rarely in both (Figure 4.2). Mutations that were enriched in both replicates across all 
measured synonymous codons with a net false discovery rate of < 1% were considered 
statistically significant. The results, summarized in Table S1, identified 25 different 
amino acids encompassing 55 variants, 18 of which could arise by a single-base 
substitution; mutants that were enriched >fivefold are shown in Figure 4.1(E). Figure 
4.1F displays the positions of the 10 amino acids, whose substitutions were enriched 
>fivefold, on the BRAF–PLX4720 structure. 
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Figure 4.2. Drug enrichment of silent mutations that did not change the parental 
BRAFV600E protein sequence. 
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Figure 4.2. Drug enrichment of silent mutations that did not change the parental 
BRAFV600E protein sequence. 
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Sensitivity of the BRAFV600E/L505H mutant to BRAF and MEK inhibitors 
 
We analyzed the 12 most enriched mutants and a subset of less enriched mutants, 
by stable expression in A375 cells followed by determination of the cellular PLX4720 
median inhibitory concentration (IC50). Figure 4.3(A) shows that the strongest PLX4720 
resistance was associated with substitutions at amino acids L485, L505, and F516. 
Notably, there was an excellent correlation between the normalized enrichment obtained 
from deep sequencing and the relative IC50. 
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Figure 4.3. Sensitivity of the BRAFV600E/L505H mutant to BRAF and MEK inhibitors. 
(A) Relative cellular IC50 of A375 cells transduced with a subset of candidate PLX4720-
resistant mutants plotted against their relative deep sequencing enrichment. (B–E) 
Immunoblots showing levels of phospho-MEK (p-MEK), total MEK (t-MEK), phospho-
ERK1/2 (p-ERK1/2), and total ERK1/2 (t-ERK1/2) in A375 cells transduced with a 
retrovirus expressing BRAFV600E, BRAFV600E/L505H, BRAFV600E/F516G, or 
BRAFV600E/T529N and treated with increasing doses of PLX4720 (B), SB590885 (C), 
RAF265 (D), or U0126 (E). α-Tubulin (TUBA) was monitored as a loading control. 
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Figure 4.3. Sensitivity of the BRAFV600E/L505H mutant to BRAF and MEK inhibitors. 
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We elected to further characterize BRAFV600E/L505H, which was the single 
nucleotide substitution mutant most resistant to PLX4720 (see Supplementary Table 
S4.1). For comparison, we also analyzed the most PLX4720-resistant mutant identified in 
our screen, BRAFV600E/F516G (Figure 4.3A), which arises from multiple nucleotide 
substitutions, and BRAFV600E/T529N, a previously characterized mutant derived by 
directed mutagenesis of the gatekeeper residue.160 As expected, the cellular proliferation 
assay of Figure 4.4 shows that A375 cells expressing BRAFV600E/L505H, 
BRAFV600E/F516G, or BRAFV600E/T529N were all more resistant to PLX4720 
compared with A375 cells expressing BRAFV600E. As expected, in the absence of 
PLX4720, proliferation of A375 cells expressing BRAFV600E was comparable to that of 
A375 cells expressing BRAFV600E/L505H, BRAFV600E/F516G, or 
BRAFV600E/T529N (Figure 4.4). 
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Figure 4.4. PLX4720 resistance of A375 cell lines expressing BRAFV600E, 
BRAFV600E/L505H, BRAFV600E/F516G or BRAFV600E/T529N. 
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Figure 4.4. PLX4720 resistance of A375 cell lines expressing BRAFV600E, 
BRAFV600E/L505H, BRAFV600E/F516G or BRAFV600E/T529N. 
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We next confirmed the relative sensitivity of the various BRAFV600E mutants to 
PLX4720 by monitoring phosphorylation of the downstream signaling components, MEK 
and ERK1/2. Figure 4.3(B) shows, as expected, that in A375 cells, PLX4720 potently 
inhibited BRAFV600E with marked reduction in phosphorylated MEK and ERK1/2 
(phospho-MEK and phospho-ERK1/2, respectively) by 0.8 μM PLX4720. By contrast, 
BRAFV600E/L505H and BRAFV600E/F516G required an approximately 100–150-fold 
higher concentration of PLX4720 to obtain similar reduction in phospho-MEK and 
phospho-ERK1/2 (Figure 4.3B and Figure 4.5A). Notably, the PLX4720 sensitivity of 
BRAFV600E/T529N was comparable to that of BRAFV600E, which likely explains why 
this mutant was not isolated in our screen. By comparison with the results with PLX4720, 
the BRAFV600E/L505H mutant had only a modest (5–7-fold) effect on resistance to two 
other BRAF inhibitors: SB590885 (Takle et al., 2006) and RAF265 (Amiri et al., 2006) 
(Figure 4.3C, D and Figure 4.5B, C). 
 
  
146 
 
Figure 4.5. Phospho-MEK or phospho-ERK1/2 IC50 curves for the immunoblots shown 
in Figure 2B–E. 
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Figure 4.5. Phospho-MEK or phospho-ERK1/2 IC50 curves for the immunoblots shown 
in Figure 2B–E. 
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A possible approach for treatment of vemurafenib-resistant melanomas is the use 
of a MEK inhibitor.155,161 We therefore analyzed the sensitivity of BRAFV600E/L505H 
to the MEK inhibitor U0126.162 Notably, BRAFV600E/L505H exhibited increased 
resistance to U0126 compared with BRAFV600E, as evidenced by elevated phospho-
ERK levels (Figure 4.3E and Figure S4.5D). By contrast, relative to BRAFV600E, the 
BRAFV600E/F516G mutant was comparably sensitive and the BRAFV600E/T529N 
mutant was actually more sensitive to U0126 (Figure 4.3E and Figure 4.5D). 
To determine whether the differences in MEK/ERK signaling were biologically 
relevant, we performed two additional experiments. First, we monitored expression of 
three representative ERK target genes (FOSL1, SPRY2, and DUSP6), a biologically 
relevant output of the BRAF-MEK-ERK signaling pathway.163 Gene expression was 
measured by quantitative RT-PCR (qRT-PCR) following treatment of A375 cells with a 
drug concentration that differentially affected the various BRAFV600E mutants. 
Consistent with the results of Figure 4.3(B), at a PLX4720 concentration of 20 μM, 
expression of FOSL1, SPRY2, and DUSP6 was greatly reduced in cells expressing 
BRAFV600E or BRAFV600E/T529N compared with cells expressing 
BRAFV600E/L505H or BRAFV600E/F516G (Figure 4.6). Similarly, treatment with 
SB590885 (0.8 μM) or U0126 (4 μM) reduced FOSL1, SPRY2, and DUSP6 expression 
to a greater extent in cells expressing BRAFV600E or BRAFV600E/T529N relative to 
cells expressing BRAFV600E/L505H or BRAFV600E/F516G. Finally, treatment with 
RAF265 (2.4 μM) reduced ERK target gene expression to a greater extent in cells 
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expressing BRAFV600E, BRAFV600E/F516G, or BRAFV600E/T529N relative to cells 
expressing BRAFV600E/L505H. 
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Figure 4.6. Analysis of ERK target gene expression following drug treatment in A375 
cell lines expressing BRAFV600E, BRAFV600E/L505H, BRAFV600E/F516G or 
BRAFV600E/T529N. 
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Figure 4.6. Analysis of ERK target gene expression following drug treatment in A375 
cell lines expressing BRAFV600E, BRAFV600E/L505H, BRAFV600E/F516G or 
BRAFV600E/T529N. 
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In a second set of experiments, we measured the relative drug resistance of A375 
cells expressing the various BRAFV600E mutants. Figure 4.7A–D shows that cells 
expressing either BRAFV600E/L505H or BRAFV600E/F516G were relatively more 
resistant to PLX4720, SB590885, RAF265, and U0126 than cells expressing 
BRAFV600E or BRAFV600E/T529N. Collectively, these results indicate that the 
differences in MEK-ERK signaling (Figure 4.3B) correlated well with both ERK target 
gene expression (Figure S4) and relative drug resistance (Figure 4.7A–D) of cells 
expressing the mutants. 
Finally, we also confirmed the PLX4720 resistance of the BRAFV600E/L505H 
mutant in an additional BRAFV600E-positive human melanoma cell line, MALME-3M. 
The results show that MALME-3M cells expressing BRAFV600E/L505H were 
substantially more resistant to PLX4720 than cells expressing BRAFV600E (Figure 
4.7E). 
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Figure 4.7. Relative drug resistance of BRAFV600E mutants in A375 cells, and 
confirmation of PLX4720 resistance of the BRAFV600E/L505H mutant in an additional 
BRAFV600E-positive human melanoma cell line. 
 
  
154 
 
Figure 4.7. Relative drug resistance of BRAFV600E mutants in A375 cells, and 
confirmation of PLX4720 resistance of the BRAFV600E/L505H mutant in an additional 
BRAFV600E-positive human melanoma cell line. 
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Characterization of the BRAFV600E/L505H mutant in 293T cells and Ba/F3 cells 
 
As described above, the initial characterization of BRAFV600E/L505H was 
performed in the A375 cell line. However, we found that A375 cells transduced with 
BRAFV600E were approximately six-fold more resistant to PLX4720 compared with 
parental A375 cells (Figure 4.8). Consistent with our results, previous reports have shown 
that BRAFV600E amplification leads to vemurafenib resistance.156 We therefore 
considered that the elevated levels of endogenous BRAFV600E in A375 cells might 
confound an accurate determination of the resistance conferred by PLX4720-resistant 
alleles, and elected to analyze the BRAFV600E/L505H mutant in two other cell lines that 
lacked BRAFV600E. 
First, we transiently expressed BRAFV600E/L505H in human embryonic kidney 
293T cells, which contain wild-type BRAF and have relatively low levels of phospho-
MEK and phospho-ERK1/2. As expected, the expression of BRAFV600E resulted in the 
activation of MEK-ERK signaling, as evidenced by increased levels of phospho-MEK 
and phospho-ERK1/2 (Figure 4.9A). Interestingly, 293T cells expressing 
BRAFV600E/L505H had substantially higher levels of phospho-MEK and phospho-
ERK1/2 compared with 293T cells expressing BRAFV600E, despite similar levels of 
BRAF protein, indicating that the L505H substitution increases BRAFV600E kinase 
activity. Even in the absence of the V600E mutation, the L505H substitution 
(BRAFL505H) led to elevated levels of phospho-MEK (Figure 4.9A). 
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Figure 4.8 Increased PLX4720 resistance of A375 cells expressing BRAFV600E. 
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Figure 4.8. Increased PLX4720 resistance of A375 cells expressing BRAFV600E. 
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Figure 4.9. Characterization of the BRAFV600E/L505H mutant in 293T cells. (A) 
Immunoblots showing levels of p- and t-MEK, p- and t-ERK1/2, and myc-tagged BRAF 
in 293T cells transfected with empty vector, wild-type BRAF, BRAFL505H, 
BRAFV600E, or BRAFV600E/L505H. (B, C) Immunoblots showing levels of p- and t-
MEK, p- and t-ERK1/2, and myc-tagged BRAF in 293T cells transiently transfected with 
BRAFV600E or BRAFV600E/L505H and treated with PLX4720 (B) or U0126 (C). 
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Figure 4.9. Characterization of the BRAFV600E/L505H mutant in 293T cells. 
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Treatment of 293T cells expressing BRAFV600E with PLX4720 resulted in dose-
dependent inhibition of MEK phosphorylation, with phospho-MEK levels being nearly 
undetectable by 2 μM PLX4720 (Figure 4.9B). By comparison, 293T cells expressing 
BRAFV600E/L505H displayed persistent phospho-MEK levels even at a PLX4720 
concentration of 50 μM (see also Figure S4.10A). Finally, consistent with the results in 
A375 cells, BRAFV600E/L505H was substantially more resistant to U0126 compared 
with BRAFV600E (Figure 4.9C and Figure 4.10B). 
Previous studies have shown that stable expression of BRAFV600E renders 
Ba/F3 cells, a BRAF wild-type, interleukin-3 (IL-3)-dependent pro-B cell line, dependent 
on BRAF-MEK-ERK signaling following IL-3 deprivation.160 To examine the effects of 
PLX4720 on cellular proliferation, we stably expressed BRAFV600E and 
BRAFV600E/L505H in Ba/F3 cells, to generate Ba/F3-BRAFV600E and Ba/F3-
BRAFV600E/L505H cells, respectively. As expected, expression of either BRAFV600E 
or BRAFV600E/L505H led to robust activation of MEK-ERK signaling (Figure 4.11A). 
Interestingly, total levels of BRAF were reduced in Ba/F3-BRAFV600E/L505H cells 
compared with Ba/F3-BRAFV600E cells, perhaps due to cytotoxicity of the 
BRAFV600E/L505H mutant. Nonetheless, MEK-ERK signaling was comparable or 
higher in Ba/F3-BRAFV600E/L505H cells compared with Ba/F3-BRAFV600E cells, 
again indicating that the BRAFV600E/L505H mutant has elevated kinase activity. As in 
293T cells, even in the absence of the V600E mutation, the L505H substitution 
(BRAFL505H) led to elevated levels of phospho-MEK (Figure 4.11B). Treatment of 
Ba/F3-BRAFV600E cells with PLX4720 resulted in a dose-dependent reduction in 
161 
 
phospho-MEK and phospho-ERK1/2 levels (Figure 4.11C). Notably, Ba/F3-
BRAFV600E/L505H cells required a ~20- to 25-fold higher concentration of PLX4720 
to achieve similar reduction in phospho-MEK and phospho-ERK1/2 compared with 
Ba/F3-BRAFV600E cells (Figure 4.11C and Figure 4.12). 
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Figure 4.10. Phospho-MEK or -ERK1/2 IC50 curves for the immunoblots shown in 
Figure 4.9B, C. 
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Figure 4.10. Phospho-MEK or -ERK1/2 IC50 curves for the immunoblots shown in 
Figure 4.9B, C. 
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Figure 4.11. Characterization of the BRAFV600E/L505H mutant in Ba/F3 cells. (A) 
Immunoblots showing levels of p- and t-MEK, p- and t-ERK1/2, and myc-tagged BRAF 
in parental Ba/F3 cells [(−); cultured with IL-3] or Ba/F3 cells stably expressing 
BRAFV600E or BRAFV600E/L505H (cultured without IL-3). (B) Immunoblots showing 
levels of p- and t-MEK, p- and t-ERK1/2, and myc-tagged BRAF in Ba/F3 stably 
expressing empty vector, wild-type BRAF or BRAFL505H (cultured with IL-3). (C) 
Immunoblots showing levels of p- and t-MEK, p- and t-ERK1/2, and myc-tagged BRAF 
in Ba/F3 cells cultured without IL-3, stably expressing BRAFV600E or 
BRAFV600E/L505H and treated with PLX4720. (D) Growth of parental Ba/F3 cells (−) 
or Ba/F3 cells stably expressing BRAFV600E or BRAFL505H/V600E and cultured with 
(+) or without (−) IL-3. (E, F) Cellular IC50 of parental Ba/F3 cells [(−); cultured with 
IL-3] and Ba/F3 cells stably transduced with BRAFV600E or BRAFV600E/L505H 
(cultured without IL-3) and treated with PLX4720 (E) or vemurafenib (F). Error bars 
indicate SEM. 
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Figure 4.11. Characterization of the BRAFV600E/L505H mutant in Ba/F3 cells. 
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Figure 4.12. Phospho-MEK IC50 curve for the immunoblots shown in Figure 4.11(C). 
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Figure 4.12. Phospho-MEK IC50 curve for the immunoblots shown in Figure 4.4(C). 
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Consistent with previous studies160, stable expression of BRAFV600E or 
BRAFV600E/L505H in Ba/F3 cells conferred IL-3-independent proliferation (Figure 
4.11D), enabling determination of the effect of PLX4720 on cellular proliferation. 
Notably, the cellular PLX4720 IC50 was 40-fold higher for Ba/F3-BRAFV600E/L505H 
cells compared with Ba/F3-BRAFV600E cells (Figure 4.11E). As expected, similar 
resistance was observed when vemurafenib was used instead of PLX4720 (Figure 4.11F). 
 
Sensitivity of the BRAFV600E/L505H mutant to PLX4720 in mouse xenografts and 
to other BRAF inhibitors in cell culture 
To determine whether the BRAFV600E/L505H mutant also conferred resistance 
to PLX4720 in vivo, we performed mouse xenograft experiments. Ba/F3-
BRAFV600E/L505H cells or Ba/F3-BRAFV600E cells were injected into the flanks of 
immunocompromised mice, and PLX4720 or control vehicle was administered 
intraperitoneally. PLX4720 markedly reduced growth of Ba/F3-BRAFV600E tumors, as 
expected, whereas Ba/F3-BRAFV600E/L505H tumors were resistant to PLX4720 
(Figure 4.13A, B). Notably, even in the absence of PLX4720, the growth of Ba/F3-
BRAFV600E/L505H tumors was faster than that of Ba/F3-BRAFV600E tumors (Figure 
4.13), which is likely due to the elevated kinase activity of BRAFV600E/L505H. 
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Figure 4.13. Sensitivity of the BRAFV600E/L505H mutant to PLX4720 in mouse 
xenografts and to other BRAF inhibitors in cell culture. (A) Tumor growth in mice 
subcutaneously injected with Ba/F3-BRAFV600E or Ba/F3-BRAFV600E/L505H cells 
and then intraperitoneally injected daily with either vehicle or PLX4720. For 
BRAFV600E ± PLX4720, P < 0.05; for BRAFV600E/L505H ± PLX4720, P > 0.05; for 
BRAFV600E versus BRAFV600E/L505H (vehicle), P < 0.05 at day 27. (B) Tumor 
weight after the final injection of either vehicle or PLX4720. Results are plotted with 
group mean, and SEM indicated by the horizontal and vertical lines, respectively. For 
BRAFV600E ± PLX4720, P < 0.05; for BRAFV600E/L505H ± PLX4720, P > 0.05; for 
BRAFV600E versus BRAFV600E/L505H (vehicle), P < 0.05. 
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Figure 4.13. Sensitivity of the BRAFV600E/L505H mutant to PLX4720 in mouse 
xenografts and to other BRAF inhibitors in cell culture. 
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Finally, the BRAFV600E/L505H mutant conferred a much lower level of 
resistance to several other BRAF inhibitors in Ba/F3 cells. For example, the cellular 
IC50s for SB590885 and GDC0879 were only fourfold higher (Figure 4.14A, B) and the 
cellular IC50 for RAF265 was only threefold higher (Figure 4.14C) in Ba/F3-
BRAFV600E/L505H cells compared with Ba/F3-BRAFV600E cells. 
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Figure 4.14. Sensitivity of the BRAFV600E/L505H mutant to other BRAF inhibitors can 
be explained by differences in steric clash imposed by the L505H substitution. (A–C) 
Cellular IC50 of parental Ba/F3 cells [(−); cultured with IL-3] and Ba/F3 cells stably 
transduced with BRAFV600E or BRAFV600E/L505H (cultured without IL-3) and 
treated with SB590885 (A), GDC0879 (B), or RAF265 (C). Error bars indicate SEM. (D, 
E) Position of the α-C helix of BRAFV600E bound to SB590885 (blue; D) or the 
GDC0879 analog (green; E) superimposed on the structure of the BRAFV600E kinase 
domain (gray) bound to PLX4720 (black). The position of the L505 residue is shown in 
red. 
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Figure 4.14. Sensitivity of the BRAFV600E/L505H mutant to other BRAF inhibitors can 
be explained by differences in steric clash imposed by the L505H substitution. 
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Discussion 
The comprehensive identification of drug-resistant mutations in cancers is an 
important step toward the development of improved therapeutic strategies. Here, we 
describe a systematic, structure-based experimental strategy to identify drug-resistant 
mutants within the oncogenic protein kinase BRAFV600E to its inhibitor vemurafenib. 
This method can be broadly applied for evaluating resistance to inhibitors of other 
proteins and has several important advantages over previous experimental approaches. 
Traditional drug resistance studies generate mutants by either (i) random methods (e.g., 
error prone PCR) that produce undesired mutants with multiple amino acid substitutions 
and do not necessarily generate all relevant single mutants (because of sampling 
limitations and biases in random mutagenesis), or (ii) directed mutagenesis based on 
results from related targets (e.g., gatekeeper mutations in protein kinases) that do not 
broadly sample sequence space164. Using systematic, structure-based saturation 
mutagenesis, we experimentally generate all relevant mutants without complications from 
undesired multiple amino acid substitutions. Furthermore, coupling the mutagenesis with 
a comprehensive deep sequencing readout directly quantifies the enrichment of each 
mutant in response to drug treatment. Thus, our systematic approach not only broadly 
samples sequence space but also quantifies the contribution of each mutant to drug 
resistance. 
Using this method, we have shown that vemurafenib resistance can occur by a 
novel second-site mutation, T1514A (encoding L505H), within the BRAFV600E kinase 
domain. A series of cell proliferation and biochemical assays were used to demonstrate 
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the PLX4720 resistance of the BRAFV600E/L505H mutant in three human melanoma 
cell lines, human 293T cells, and mouse Ba/F3 cells. The similarity of the results 
obtained in diverse cell lines indicates that the PLX4720 resistance of the 
BRAFV600E/L505H mutant, which is the major focus of our study, is independent of 
cell type. The L505H mutant increased the kinase activity of both wild-type BRAF and 
BRAFV600E. Interestingly, a search of the Catalogue of Somatic Mutations in Cancer 
(COSMIC) database165 revealed that the T1514A mutation was recently found in an 
individual with prostate cancer,166 suggesting that the elevated kinase activity of 
BRAFL505H may contribute to cancer development. 
We found that BRAFV600E/L505H was relatively resistant to MEK inhibition, 
which is likely due its increased kinase activity. By contrast, the BRAFV600E/L505H 
mutant had a lesser effect on sensitivity to several other BRAF inhibitors, such as 
SB590885, RAF265, and GDC0879. Inspection of the crystal structure of the 
BRAFV600E kinase domain bound to PLX4720 reveals that the propyl group of the 
sulfonamide moiety of the drug extends toward L505 in the BRAF α-C helix (Figure 4.1E 
and Figure 4.14D, E). By contrast, the crystal structure of BRAFV600E bound to 
SB590885 (PDB: 2FB8)167 (Figure 4.14D) or an analog of GDC0879 (PDB: 3D4Q)168 
(Figure 4.14E) reveals that neither drug is proximal to L505. Thus, resistance of the 
BRAFV600E/L505H mutant to PLX4720, but not SB590885 or GDC0879, can be 
explained by differences in steric clash imposed by the L505H substitution. Collectively, 
these results indicate that such BRAFV600E/L505H-containing melanomas will be more 
responsive to other BRAF inhibitors than to a MEK inhibitor. 
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It is important to prospectively identify the various mechanisms that can result in 
vemurafenib resistance prior to their emergence in the clinic. This information is essential 
both to accurately assess the growing population of treated patients that will become 
drug-resistant and to develop better drugs or drug combinations to overcome diverse 
resistance mechanisms. Based upon our results, we predict that the L505H mutant will be 
found in some vemurafenib-resistant melanomas particularly if the BRAFV600E-
independent resistance pathways can be inhibited. Consistent with this prediction, Tian 
Xu and colleagues have recently described the isolation of the BRAFV600E/L505H 
mutant in a melanoma cell line derived from an individual with vemurafenib-resistant 
melanoma (Choi J., Landrette S., Wang T., Evans P., Bacchiocchi A., Bjornson R., 
Cheng E., Stiegler A.L., Gathiaka S., Acevedo O., Boggon T.J., Krauthammer M., 
Halaban R., Xu T., unpublished data). These findings clearly demonstrate the power of 
our experimental approach for the prospective identification of drug-resistant mutants. 
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Methods 
Cell culture 
A375 and Ba/F3 cells were cultured in RPMI-1640 (Sigma-Aldrich, St. Louis, 
MO, USA) supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, 
Flowery Branch, GA, USA), 1 mM sodium pyruvate, and Pen/Strep (Sigma). Media for 
Ba/F3 cells were additionally supplemented with 10 ng/ml murine IL-3 (Peprotech, 
Rocky Hill, NJ, USA). The identity of the Ba/F3 cell line was confirmed by IL-3 
withdrawal experiments and fluorescence-activated cell sorting (FACS) analysis (Figure 
S9). 293T cells were cultured in DMEM (Sigma) with 10% FBS, 1 mM sodium pyruvate 
and Pen/Strep. 
Transient and stable transfections 
Retroviruses expressing BRAFV600E (Addgene, Cambridge, MA, USA) and all 
variants were generated by transient transfection of 293T cells using Effectene (Qiagen, 
Valencia, CA, USA). Retroviral supernatants were collected 48 h post-transfection, 
filtered, and supplemented with 5 or 10 μg/ml polybrene for infection of Ba/F3 or A375 
cells, respectively. For infection of Ba/F3 cells, cells were centrifuged for 90 min at 1000 
× g. At 24 h post-infection, cells were selected with puromycin at 2 μg/ml. Transient 
transfections of 293T cells were performed using Effectene. 
Mutagenesis screen 
Saturation mutagenesis was used to generate point mutant libraries for individual 
amino acids. To facilitate mutagenesis, a portion of BRAFV600E (nucleotides 1270–
1900) was cloned into pRNDM14, a minimal cloning plasmid, bracketed by SacI and SphI 
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restriction sites. Cassette mutagenesis was performed on this plasmid as previously 
described.13,14 The mutant pools were then transferred into the retroviral vector pBABE-
Puro-BRAFV600E (Addgene #15269) by sequence and ligation-independent cloning 
(SLIC).149 Briefly, the mutagenized cassette was excised using SacI and SphI, treated 
with T4 DNA polymerase to create 5′ single-stranded overhangs (approximately 30 nt) 
and then purified on a silica column. A pBABE-Puro-BRAFV600E SLIC vector was 
created by replacing BRAF nucleotides 1300–1870 with an ApaI restriction site. The 
construct was linearized and treated with T4 DNA polymerase as described above. The 
treated mutagenized cassette library and pBABE SLIC vector were annealed, and the 
entire reaction transformed into bacteria. Based on plating of a small fraction of the 
bacteria, this procedure routinely resulted in > 30 000 transformants, which was sufficient 
to transfer our libraries without compromising diversity. Focused deep sequencing was 
used to determine the representation of each mutation in the pBABE plasmid libraries 
and indicated that all mutations were present well above noise level. Individual mutations 
were generated by the same method and confirmed by Sanger sequencing. 
Retroviral particles were generated by transient transfection of 293T cells using 
Effectene as described above. A375 cells (3 × 106) were transduced at a multiplicity of 
infection of three with the retroviral BRAFV600E mutant pools in 100-mm plates, 
selected for stable integration with puromycin, and cultured in the presence of 10 μM 
PLX4720 for 3 weeks. Drug-resistant colonies were isolated and pooled, and genomic 
DNA was extracted. 
 
179 
 
The library version of BRAF was PCR-amplified from genomic DNA and 
prepared for Illumina sequencing as described.14 Briefly, PCR was used to introduce an 
MmeI site immediately 5′ to randomized regions and a 3′ Illumina primer binding site 
250 bases downstream. This product was digested with MmeI and ligated to adapters that 
included a barcode and a 5′ Illumina primer binding site. This product was PCR-
amplified with Illumina Sequencing Primers, gel-purified, and submitted for short single-
read (36 bases) analysis using a Solexa-Illumina GA Massively Parallel Deep Sequencer. 
Raw sequencing files in fastq format were processed essentially as described.14 All 
sequences were subjected to quality filtering requiring a PHRED score of ≥20 at all read 
positions. In addition, sequence reads where more than one codon differed from the 
parental construct were eliminated from analysis. The remaining sequences were 
analyzed to determine the number of reads for each point mutant in the plasmid library, 
as well as in transduced cells prior to and following treatment with drug. Mutations that 
created internal MmeI sites or that were severely under-represented in cells (100-fold 
relative to median wild-type synonym) without drug were omitted from analysis. Of the 
1160 possible protein point mutations (58*20), all but five (478A, 486D, 486E, 511W, 
and 580W) were successfully analyzed. The ratio of each codon substitution from cells 
after and before treatment with drug was used as a metric of drug resistance. The median 
enrichment of silent substitutions was used to normalize the data (resulting in the median 
synonymous substitution having an enrichment score of 1). Based on the distribution of 
enrichments for synonymous substitutions, we set a false discovery threshold for each 
codon observation. Amino acid substitutions were considered enriched in drug if all 
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observed synonymous substitutions were above a statistical cutoff such that the net P-
value was < 0.01. 
 
Structural images 
Images of BRAF bound to PLX4720 were generated from Protein Data Bank 
(PDB) entry 3C4C158 using the Pymol software package (Delano Inc., San Carlos, CA, 
USA) 
 
Drug treatment 
PLX4720 (Selleckchem, Houston, TX, USA), SB590885 (Tocris, Minneapolis, 
MN, USA), RAF265 (Selleckchem), U0126 (Cell Signaling, Beverly, MA, USA), 
GDC0879 (Selleckchem), and vemurafenib/PLX4032 (Selleckchem) were prepared in 
DMSO at 20 mM. 1 × 103 A375 or 1.5 × 104 Ba/F3 cells were plated per well of a 96-
well plate in 100 μl volume, and 24 h later, 50 μl of drug was added to the cells. 
 
Cellular and pMEK IC50 determination 
 
Cells expressing BRAFV600E or BRAFV600E mutants were cultured in the 
presence of serially diluted drug for 72 h, and viability was measured by Alamar Blue 
assay (Invitrogen, Grand Island, NY, USA). In Figure 2A, Trp and Met mutants were 
excluded from consideration. For Figures 2F, 4E, F and 6A–C, data were plotted in 
GraphPad Prism and a dose–response curve was fit with nonlinear regression. To 
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determine p-MEK IC50, the phospho-MEK immunoblots were quantified in ImageJ 
(NIH) and the densitometry used to plot the data. 
 
Immunoblotting 
Cells were lysed with cell lysis buffer [1%NP-40, 10% glycerol, 150 mM NaCl, 
50 mM Tris–HCl (pH 7.4), 1 mM EDTA] supplemented with complete protease inhibitor 
tablet (Roche, Indianapolis, IN, USA) and phophatase inhibitor cocktails 2 and 3 
(Sigma). Cell extract was quantified with bicinchoninic acid (Pierce, Rockford, IL, USA), 
and equal amounts of protein were loaded in each lane. Blots were probed with the 
following primary antibodies: phosphorylated MEK (S217/221), total MEK, 
phosphorylated ERK1/2 (T202/Y204), total ERK1/2, myc (all from Cell Signaling 
Technology), and tubulin. 
 
Cell growth assays 
Parental Ba/F3 cells or Ba/F3 cells stably transduced with BRAFV600E or 
BRAFV600E/L505H and cultured in the presence or absence of 10 ng/ml IL-3 were 
assessed for growth by counting. 
 
qRT-PCR analysis 
Total RNA was isolated from A375 cells treated in the presence or absence of 
drug using TriPure Isolation Reagent (Roche). Reverse transcription was performed using 
SuperScript II Reverse Transcriptase (Invitrogen) followed by qPCR using Fast SYBR 
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Green Master Mix (Applied Biosystems, Foster City, CA, USA) using the following 
primers: FOS1L forward (5′-CACTCCAAGCGGAGACAGAC-3′) and reverse (5′-
AGGTCATCAGGGATCTTGCAG-3′); SPRY2 forward (5′-
ATGGCATAATCCGGGTGCAA-3′) and reverse (5′-
TGTCGCAGATCCAGTCTGATG-3′); and DUSP6 forward (5′-
AGCTCAATCTGTCGATGAACG-3′) and reverse (5′-GCGTCCTCTCGAAGTCCAG-
3′). The expression level of each gene was normalized to that of three internal control 
genes, B2M forward (5′-CGCTCCGTGGCCTTAGC-3′) and reverse (5′-
AATCTTTGGAGTACGCTGGATAGC-3′); TBP forward (5′-CACAG 
GAGCCAAGAGTGAAG-3′) and reverse (5′-CAAGGCCTTCTAACCTTATAGG-3′); 
and GUSB forward (5′-TTGAGCAAGACTGATACCACCTG-3′) and reverse (5′-
TCTGGTCTGCCGTGAACAGT-3′). The qRT-PCR data were normalized to the three 
internal control genes individually and then combined. 
 
Tumor formation assays 
Balb/c nu/nu mice (NCI; n = 5 per group) were injected subcutaneously with 6 × 
106 Ba/F3 cells transduced with BRAFV600E or BRAFV600E/L505H. Tumors were 
allowed to form for 14 days at which point animals received daily intraperitoneal 
injections of vehicle (water + 5% DMSO) or PLX4720 (50 mg/kg). Tumor dimensions 
were measured every 3–4 days, and tumor volume was calculated using the formula π/6 × 
(length) × (width)2. After the final dose, animals were sacrificed and tumors were 
excised and weighed. For statistical analysis, Wilcoxon rank sum test was performed in R 
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(www.r-project.org). Animal experiments were performed in accordance with the 
Institutional Animal Care and Use Committee (IACUC) guidelines. 
 
Probability determinations 
The probabilities of mutation types for idealized libraries were calculated based 
on independent probabilities (Bayesian theory). For random mutagenesis, these 
probability estimates assume ideal conditions (a mutation rate of one base per gene). For 
a protein of N amino acids (3N nucleotides), the probability of a mutation at any base (p) 
is 1/3N, the probability of any position being wild-type (q) is 1-p, and the probability of 
all positions being wild-type is q3N. The dependence of this equation on protein length is 
negligible for proteins > 100 amino acids. The probability of having only one base 
mutated is p*q(3N−1). The probability of having two or more mutations is 1 – wild-type 
probability – single-mutant probability. 
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Chapter V – Systematic analysis of ubiquitin point mutants  
under temperature stress 
 
Benjamin P. Roscoe and Daniel N. Bolon 
 
The experimental results presented in this chapter are currently unpublished. I performed 
all of the experiments herein, and Dan Bolon and I analyzed the data and generated 
figures. Further experiments, including biochemical and biophysical analysis of single 
substitution ubiquitin variants as well as a repeat of the bulk competition experiments is 
necessary before preparation of a final manuscript. 
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Rationale: 
Chapter II of this dissertation describes the effect all ubiquitin point mutants on 
yeast growth rate under permissive conditions (30º C) in synthetic dextrose media.169 A 
major conclusion from this study is that many single amino acid substitutions were 
tolerated throughout the protein sequence, negatively correlated with client interaction 
density that we defined by analysis of the average surface burial of ubiquitin in 44 co-
crystal structures.169  That finding could not be predicted from phylogenetic comparisons, 
as ubiquitin is ultra-highly conserved with respect to protein sequence in eukaryotes 
(Figure 3.5a). The discrepancies between tolerated amino acid substitutions to a protein 
sequence in laboratory conditions versus that sampled over evolutionary time can have 
multiple explanations.  First, measurement errors in our experimental bulk competition 
fitness measurements (chapter III,) are higher than the minimum fitness defects that will 
cause purifying selection in a natural population (s≈10-6).74,141 A second explanation is 
that under different growth conditions there will be less tolerance for mutational change. 
In previous work from our lab, Ryan Hietpas, Ph.D. et al found that a 9 amino acid 
stretch of hsp90 was less tolerant to amino acid substitution under conditions of high 
salinity or temperature stress.170 
 In order to determine the effect of temperature stress on the tolerance of ubiquitin 
to amino acid substitutions, I performed a bulk competition experiment using the same 
randomized libraries and strategy described in chapter II169  at 36º C, a temperature that 
induces stress in yeast.171  
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Results and Discussion 
Comparison of ubiquitin amino acid substitutions at 30º C vs. 36º C 
 The tolerance of yeast  to ubiquitin amino acid substitutions was markedly 
reduced in bulk competition experiments at 36º C compared to growth competitions at 
30º C, with 141 tolerant substitutions (fitness > 0.9) at 30º C becoming deleterious 
(fitness < 0.5) at elevated temperature (table 5.1, figure 5.1&5.2a). Wild type synonyms 
all remained universally fit and stop codons were all deleterious. The overall pattern of 
amino acid position tolerance to mutation remained similar, with notable exceptions at 
positions K6 and K63, with neither tolerating any substitutions at elevated temperature. 
Lysine 63-linked ubiquitin is involved in DNA damage repair, and the K63R mutant as 
well as deletions of the Rsp5 HECT domain responsible for K63 linkage specificity in 
DNA repair have both previously been demonstrated to cause a temperature sensitive (ts) 
phenotype at 36º C in S. cerevisae (figure 5.1b, dashed red line).172   
 Temperature sensitive mutations were distributed throughout the protein, with 
similar fractions of temperature sensitive mutants in both the solvent-accessible 
surface/boundary residues and the solvent-inaccessible core residues (Figure 5.2b&c). 
This suggests that intermolecular interactions with binding partners as well as 
intramolecular structural perturbations are both likely mechanisms of temperature 
sensitive phenotypes. 
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 Figure 5.1. Heatmaps of ubiquitin point mutant effects on yeast growth rates at 30º and 
36º C. a) The ubiquitin gene was divided into eight separate libraries for bulk growth 
competition and deep sequencing analysis (described in chapter II). b) Heatmaps 
representing the amino acid substitution average relative growth rate scaled from null-
like (blue) to WT-like yellow at each temperature. Lysine linkage sites (K6 and K63) that 
were found to be critical at elevated temperatures are highlighted by red dashed 
rectangles. 
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Figure 5.1. Comparison of ubiquitin mutant fitness effects at 30º C vs. 36º C. 
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Figure 5.2. Comparison of ubiquitin point mutant effects on yeast growth at  
30º vs. 36º C. A. Correlation plot of ubiquitin point mutant relative growth rate at 30º vs. 
36º C. B. Pie chart representing fraction of temperature sensitive point mutants on the 
solvent-exposed surface and boundary residues of ubiquitin. C. Pie chart representing 
fraction of temperature sensitive point mutants in the solvent-inaccessible core of 
ubiquitin. D. Difference map of ubiquitin point mutant fitness classifications at 30º vs. 
36º C.  
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Figure 5.2. Comparison of ubiquitin point mutant effects on yeast growth at  
30º vs. 36º C. 
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Mapping temperature sensitive mutants to structure 
 We tabulated the number of temperature sensitive substitutions at each amino acid 
position of ubiquitin and mapped them to the crystal structure of monoubiquitin (figure 
5.3 a&b). Temperature sensitive substitutions appeared to be fairly evenly distributed 
across the structure (figure 5.3b).  This result was unexpected given the sensitivity of a 
common ubiquitin binding interface described in chapters II+III. Biochemical analysis of 
individual temperature sensitive mutants for folding defects, binding of known partner 
proteins (e.g. proteasome receptors) and in vivo polyubiqutin formation in yeast at both 
temperatures will be necessary to further investigate this finding.   
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Figure 5.3. Mapping temperature sensitive ubiquitin mutants to structure. A. Number of 
temperature sensitive mutants at each position of ubiquitin. B) Location of temperature 
sensitive mutants on the ubiquitin crystal structure 1UBQ.pdb. Positions with 1-4 
temperature sensitive mutants are colored in green, and positions with >4 temperature 
sensitive mutants are colored in blue. 
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Figure 5.3. Mapping temperature sensitive ubiquitin mutants to structure 
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Conclusions and future directions 
 This preliminary investigation clearly demonstrates the power of utilizing 
saturation mutagenesis and deep sequencing to discover temperature sensitive mutations 
in a single protein in yeast. We identified 141 temperature sensitive amino acid 
substitutions distributed in both the solvent-accessible surface/boundary residues and 
solvent-inaccessible core. This suggests that both inter- and intramolecular interactions 
likely contribute to observed temperature sensitive phenotypes. Future experiments to 
delineate these effects will be necessary to specify the specific causes of the temperature 
sensitive phenotype of individual mutants. For example, panels of both core and surface 
recombinant temperature sensitive mutants should be purified and analyzed by circular 
dichroism under chemical denaturation for changes in folding properties.  Analysis of 
previously reported thermodynamic folding defects and computational predictions of 
changes in free energy of ubiquitin point mutants did not correlate strongly with 
temperature sensitive mutants. Immunoblotting and/or immunoprecipitation of specific 
complexes for polyubiquitin accumulation of specific mutants at both temperatures may 
also help pinpoint specific defects.   
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Chapter VI – Discussion 
The research presented throughout this dissertation is unified by a single 
underlying experimental strategy, systematic mutagenesis of proteins focused on 
obtaining rich information on biochemical and cellular function through a deep-
sequencing readout. The two different biological systems studied in this work (yeast 
ubiquitin and BRAF V600E from human melanoma) are both supported by a rich body of 
mechanistic and structural studies, allowing us to comprehensively apply our data to give 
new insights into function in light of known biochemical mechanisms. This supports the 
value of systematic mutagenesis and focused deep sequencing as a way to explore the 
physical and chemical space requirements of the amino acid sequence of a protein. The 
strong correlation of residue tolerance to mutation in these systems in light of previously 
described functions in the literature suggests that extending this methodology to other 
lesser understood systems can result in rich interpretable data. Ongoing work in our 
group focused on the evolution of drug resistance in viral targets strongly supports this 
prediction. 
 The original research presented in chapter II reports the fitness effects of all 
possible point mutations to ubiquitin in yeast. Perhaps the most intriguing finding from 
this study is that ubiquitin tolerates many amino acid substitutions under the reported 
experimental conditions (30º C, synthetic dextrose media). These results demonstrate that 
it is possible for ubiquitin to acquire many neutral or near neutral amino acid 
substitutions in permissive conditions, adding to the body of literature supporting the 
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theory of near-neutral mutations providing a mechanism of adaptation under 
environmental selective pressures.13,21,22,76,173 
 A second finding from the systematic analysis of ubiquitin point mutants is that 
specific residue tolerance to mutation correlates strongly with the interaction surfaces of 
ubiquitin with binding partners (from ASA burial of 44 co-crystal structures in the PDB). 
This lends strong support to the theory that the mutational tolerance of a a specific 
residue in a protein is restrained by its molecular contacts, as proposed by E. Zuckerlandl 
in 1976.23 While this finding may seem intuitive, because of the previous technical 
challenges in generating and testing thousands of amino acid substitutions, our studies in 
ubiquitin are some of the most comprehensive analyses of the fitness effects of amino 
acid substitutions at each position in a gene. For other proteins with less characterized 
cellular interaction, these strategies will likely be very useful for discovering regions of 
proteins involved in previously unidentified processes. 
 The work in chapter III presents findings from examining the effect of all possible 
point mutants in ubiquitin residues 2-76 on the essential activation by the yeast E1 
ubiquitin activating protein (Uba1p). Because ubiquitin is a multifunctional protein with 
many steps to activation even for the canonical function of targeting client proteins to the 
26S proteasome for degradation,32 it is near impossible to predict which defects in 
function explain fitness defects. It can be inferred that because activation of ubiquitin by 
E1 is essential, that defects that prevent this activation will prevent cellular growth. 
However, the relationship between partial defects and the rate of growth defects was 
found to be complex. Mutants that had no discernible E1 activation activity were indeed 
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very deleterious for growth, however the yeast tolerated a reduction in ubiquitin 
activation by 98% in at least one mutant (R72S). Many other mutants had smaller but 
measurable defects in E1 activation, yet most were unable to grow. These results strongly 
suggests that while E1 activation is not rate limiting for yeast fitness, competitive defects 
in E1 activation predict downstream functional defects. Analysis of the available yeast E1 
: ubiquitin co-crystal structure56 indicated that E1 has a very large interaction surface 
compared to many other ubiquitin binding partners downstream. This led us to posit that 
E1 is sensitive to small competitive defects in ubiquitin activation, consistent with a 
model that suggests E1 molecules without this filtering capacity may be selected against 
in a natural yeast population. 
 Chapter IV of this dissertation describes a collaborative effort of the 
Daniel N. Bolon and Michael R. Green research groups to extend high throughput 
mutational screening to predict inhibitor resistant mutants in the oncogenic bRAF V600E 
kinase from human melanoma. Single point mutations are a common method of drug 
resistance in drug-binding targets.  Therefore, we used the structure of the inhibitor 
bound to bRAF V600E to target the drug binding portions of bRAF V600E mutagenesis. 
By selecting mutant library cell lines that were able to grow in the presence of the 
inhibitor, we were able to discover over a dozen novel mutants that conferred drug 
resistance. The findings from the high-throughput screen were validated by cell-based 
screens, probing of the kinase phosphorylation pathway, and tumor resistance in mice. 
One particularly resistant mutant, V600E L505H is acquirable through a single base 
substitution, and was recently discovered in a human melanoma cell line (Choi J., 
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Landrette S., Wang T., Evans P., Bacchiocchi A., Bjornson R., Cheng E., Stiegler A.L., 
Gathiaka S., Acevedo O., Boggon T.J., Krauthammer M., Halaban R., Xu T., 
unpublished data). These findings clearly demonstrate the power of our experimental 
approach for the prospective identification of drug-resistant mutants. 
Selection pressure over evolutionary time encompasses all environmental and 
competitive pressure to the ancestors of an organism over billions of years.  I believe it is 
presumptuous to believe that we can ever perfectly reconstruct the changing environment 
and timescales of evolutionary time, but I do believe that directed evolution experiments 
within the laboratory are able to provide strong evidence into how proteins can evolve 
under changing environments. In chapter V, the tolerance of ubiquitin in yeast to single 
point mutations is greatly reduced by a simple change in experimental conditions from 
permissive to heat stress temperatures. This suggests that the evolutionary conservation 
of ubiquitin may be able to be explained partially by changing environmental conditions, 
a hypothesis that is testable using these methods and a current direction of our research. 
Integrating the fitness effects of many point mutants across many conditions will likely 
help support population genetics models, especially as the mutational tolerance of many 
proteins is reported. Ryan Hietpas’ work in Hsp90 demonstrated a similar result, 
including some mutations that were more fit than wild type under conditions of high 
salinity.170 It should also be noted that many other factors lead to organismal fitness, 
including the genetic background of the organism that leads to its entire network of 
function, including factors such as relative expression level.111 
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 While the experiments described in the preceding chapters focus on amino acid 
substitutions at the protein level, many other applications can be imagined. The 
increasing throughput we demonstrated by introducing all point mutants to the ubiquitin 
gene in yeast can be applied to studies of codon preference in organisms, all well as 
studies of RNA machinery including ribosomal subunits and enzymes composed of RNA. 
It is also possible to apply these mutagenesis and sequencing strategies to nucleic acid 
regions of unknown or poorly understood function and test the effects on cells or 
organisms under many different conditions or genetic backgrounds, potentially 
discovering epigenetic effects of changes to chromosomal DNA. 
 In summary, I believe that our work, as well as the discoveries of other 
researchers investigating the role of amino acid sequence in function, will help bridge the 
divides between theoretical models of protein evolution and biochemistry. This 
dissertation provides evidence that this methodology has the potential to be applicable to 
human medicine in the context of drug resistance in cancer, a mechanism driven by 
mutation,20 often leading to amino acid substitutions in proteins involved in cellular 
signaling. Technology is paramount to furthering discovery in all of the scientific 
disciplines, but the most important part is applying the proper technology and 
methodology to the most important scientific problems. 
“Be technique agnostic.”  -Dean Tony Carruthers to the incoming GSBS class during 
orientation 2008. 
 
200 
 
Bibliography 
1. Anfinsen, C.B. (1972). The formation and stabilization of protein structure. 
Biochem. J. 128, 737–49 
2. Khorana, H.G. (1959). Synthesis and structural analysis of polynucleotides. J. 
Cell. Comp. Physiol. 54, 5–15 
3. Holley, R.W., Apgar, J. & Doctor, B.P. (1960). Separation of amino acid-specific 
“soluble”-fraction ribonucleic acids. Ann. N. Y. Acad. Sci. 88, 745–51 
4. Leder, P., Clark, B.F., Sly, W.S., Pestka, S. & Nirenberg, M.W. (1963). Cell-free 
peptide synthesis dependent upon synthetic oligodeoxynucleotides. Proc. Natl. 
Acad. Sci. U. S. A. 50, 1135–43 
5. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., 
Shindyalov, I.N. & Bourne, P.E. (2000). The Protein Data Bank. Nucleic Acids 
Res. 28, 235–42 
6. Radivojac, P., Clark, W.T., Oron, T.R., Schnoes, A.M., Wittkop, T., Sokolov, A., 
Graim, K., Funk, C., Verspoor, K., Ben-Hur, A., Pandey, G., Yunes, J.M., 
Talwalkar, A.S., Repo, S., Souza, M.L., Piovesan, D., Casadio, R., Wang, Z., 
Cheng, J., Fang, H., Gough, J., Koskinen, P., Törönen, P., Nokso-Koivisto, J., 
Holm, L., Cozzetto, D., Buchan, D.W.A., Bryson, K., Jones, D.T., Limaye, B., 
Inamdar, H., Datta, A., Manjari, S.K., Joshi, R., Chitale, M., Kihara, D., Lisewski, 
A.M., Erdin, S., Venner, E., Lichtarge, O., Rentzsch, R., Yang, H., Romero, A.E., 
Bhat, P., Paccanaro, A., Hamp, T., Kaßner, R., Seemayer, S., Vicedo, E., Schaefer, 
C., Achten, D., Auer, F., Boehm, A., Braun, T., Hecht, M., Heron, M., 
Hönigschmid, P., Hopf, T.A., Kaufmann, S., Kiening, M., Krompass, D., 
Landerer, C., Mahlich, Y., Roos, M., Björne, J., Salakoski, T., Wong, A., Shatkay, 
H., Gatzmann, F., Sommer, I., Wass, M.N., Sternberg, M.J.E., Škunca, N., Supek, 
F., Bošnjak, M., Panov, P., Džeroski, S., Šmuc, T., Kourmpetis, Y.A.I., van Dijk, 
A.D.J., ter Braak, C.J.F., Zhou, Y., Gong, Q., Dong, X., Tian, W., Falda, M., 
Fontana, P., Lavezzo, E., Di Camillo, B., Toppo, S., Lan, L., Djuric, N., Guo, Y., 
Vucetic, S., Bairoch, A., Linial, M., Babbitt, P.C., Brenner, S.E., Orengo, C., Rost, 
B., Mooney, S.D. & Friedberg, I. (2013). A large-scale evaluation of 
computational protein function prediction. Nat. Methods 10, 221–7 
7. Harms, M.J. & Thornton, J.W. (2013). Evolutionary biochemistry: revealing the 
historical and physical causes of protein properties. Nat. Rev. Genet. 14, 559–71 
8. Pannekoek, H., van Meijer, M., Schleef, R.R., Loskutoff, D.J. & Barbas, C.F. 
(1993). Functional display of human plasminogen-activator inhibitor 1 (PAI-1) on 
201 
 
phages: novel perspectives for structure-function analysis by error-prone DNA 
synthesis. Gene 128, 135–40 
9. Loeb, D.D., Swanstrom, R., Everitt, L., Manchester, M., Stamper, S.E. & 
Hutchison, C.A. (1989). Complete mutagenesis of the HIV-1 protease. Nature 340, 
397–400 
10. Rennell, D., Bouvier, S.E., Hardy, L.W. & Poteete, A.R. (1991). Systematic 
mutation of bacteriophage T4 lysozyme. J. Mol. Biol. 222, 67–88 
11. Fishman, A., Tao, Y., Bentley, W.E. & Wood, T.K. (2004). Protein engineering of 
toluene 4-monooxygenase of Pseudomonas mendocina KR1 for synthesizing 4-
nitrocatechol from nitrobenzene. Biotechnol. Bioeng. 87, 779–90 
12. Fowler, D.M., Araya, C.L., Fleishman, S.J., Kellogg, E.H., Stephany, J.J., Baker, 
D. & Fields, S. (2010). High-resolution mapping of protein sequence-function 
relationships. Nat. Methods 7, 741–6 
13. Hietpas, R.T., Jensen, J.D. & Bolon, D.N.A. (2011). Experimental illumination of 
a fitness landscape. Proc. Natl. Acad. Sci. U. S. A. 108, 7896–901 
14. Hietpas, R., Roscoe, B., Jiang, L. & Bolon, D.N.A. (2012). Fitness analyses of all 
possible point mutations for regions of genes in yeast. Nat. Protoc. 7, 1382–96 
15. McLaughlin, R.N., Poelwijk, F.J., Raman, A., Gosal, W.S. & Ranganathan, R. 
(2012). The spatial architecture of protein function and adaptation. Nature 491, 
138–42 
16. Araya, C.L., Fowler, D.M., Chen, W., Muniez, I., Kelly, J.W. & Fields, S. (2012). 
A fundamental protein property, thermodynamic stability, revealed solely from 
large-scale measurements of protein function. Proc. Natl. Acad. Sci. U. S. A. 109, 
16858–63 
17. Whitehead, T.A., Chevalier, A., Song, Y., Dreyfus, C., Fleishman, S.J., De Mattos, 
C., Myers, C.A., Kamisetty, H., Blair, P., Wilson, I.A. & Baker, D. (2012). 
Optimization of affinity, specificity and function of designed influenza inhibitors 
using deep sequencing. Nat. Biotechnol. 30, 543–8 
18. Starita, L.M., Pruneda, J.N., Lo, R.S., Fowler, D.M., Kim, H.J., Hiatt, J.B., 
Shendure, J., Brzovic, P.S., Fields, S. & Klevit, R.E. (2013). Activity-enhancing 
mutations in an E3 ubiquitin ligase identified by high-throughput mutagenesis. 
Proc. Natl. Acad. Sci. U. S. A. 110, E1263–72 
202 
 
19. Dean, A.M. & Thornton, J.W. (2007). Mechanistic approaches to the study of 
evolution: the functional synthesis. Nat. Rev. Genet. 8, 675–88 
20. Hochhaus, A., Schenk, T., Erben, P., Ernst, T., La Rosée, P. & Müller, M.C. 
(2009). Cause and management of therapy resistance. Best Pract. Res. Clin. 
Haematol. 22, 367–79 
21. Nei, M. (2007). The new mutation theory of phenotypic evolution. Proc. Natl. 
Acad. Sci. U. S. A. 104, 12235–42 
22. Kimura, M. (1983). Rare variant alleles in the light of the neutral theory. Mol. Biol. 
Evol. 1, 84–93 
23. Zuckerkandl, E. (1976). Evolutionary processes and evolutionary noise at the 
molecular level. I. Functional density in proteins. J. Mol. Evol. 7, 167–83 
24. Jones, S. & Thornton, J.M. (1997). Analysis of protein-protein interaction sites 
using surface patches. J. Mol. Biol. 272, 121–32 
25. Clark, W.T. & Radivojac, P. (2011). Analysis of protein function and its prediction 
from amino acid sequence. Proteins 79, 2086–96 
26. Clackson, T., Hoogenboom, H.R., Griffiths, A.D. & Winter, G. (1991). Making 
antibody fragments using phage display libraries. Nature 352, 624–8 
27. Lowman, H.B., Bass, S.H., Simpson, N. & Wells, J.A. (1991). Selecting high-
affinity binding proteins by monovalent phage display. Biochemistry 30, 10832–8 
28. Boder, E.T. & Wittrup, K.D. (1997). Yeast surface display for screening 
combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553–7 
29. Kacser, H. & Burns, J.A. The molecular basis of dominance. Genetics 97, 639–66 
30. Grossniklaus, U., Madhusudhan, M.S. & Nanjundiah, V. (1996). Nonlinear 
enzyme kinetics can lead to high metabolic flux control coefficients: implications 
for the evolution of dominance. J. Theor. Biol. 182, 299–302 
31. Hershko, A. & Ciechanover, A. (1998). The ubiquitin system. Annu. Rev. 
Biochem. 67, 425–79 
32. Finley, D. (2009). Recognition and processing of ubiquitin-protein conjugates by 
the proteasome. Annu. Rev. Biochem. 78, 477–513 
203 
 
33. Thrower, J.S., Hoffman, L., Rechsteiner, M. & Pickart, C.M. (2000). Recognition 
of the polyubiquitin proteolytic signal. EMBO J. 19, 94–102 
34. Spence, J., Sadis, S., Haas, A.L. & Finley, D. (1995). A ubiquitin mutant with 
specific defects in DNA repair and multiubiquitination. Mol. Cell. Biol. 15, 1265–
73 
35. Messick, T.E. & Greenberg, R.A. (2009). The ubiquitin landscape at DNA double-
strand breaks. J. Cell Biol. 187, 319–26 
36. Hicke, L., Schubert, H.L. & Hill, C.P. (2005). Ubiquitin-binding domains. Nat. 
Rev. Mol. Cell Biol. 6, 610–21 
37. Dikic, I., Wakatsuki, S. & Walters, K.J. (2009). Ubiquitin-binding domains - from 
structures to functions. Nat. Rev. Mol. Cell Biol. 10, 659–71 
38. Ye, Y. & Rape, M. (2009). Building ubiquitin chains: E2 enzymes at work. Nat. 
Rev. Mol. Cell Biol. 10, 755–64 
39. Hatakeyama, S., Yada, M., Matsumoto, M., Ishida, N. & Nakayama, K.I. (2001). 
U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276, 
33111–20 
40. Kim, H.C. & Huibregtse, J.M. (2009). Polyubiquitination by HECT E3s and the 
determinants of chain type specificity. Mol. Cell. Biol. 29, 3307–18 
41. Petroski, M.D. (2008). The ubiquitin system, disease, and drug discovery. BMC 
Biochem. 9 Suppl 1, S7 
42. Wintrode, P.L., Makhatadze, G.I. & Privalov, P.L. (1994). Thermodynamics of 
ubiquitin unfolding. Proteins 18, 246–53 
43. Sierra, J.R., Cepero, V. & Giordano, S. (2010). Molecular mechanisms of acquired 
resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75 
44. Giaever, G., Chu, A.M., Ni, L., Connelly, C., Riles, L., Véronneau, S., Dow, S., 
Lucau-Danila, A., Anderson, K., André, B., Arkin, A.P., Astromoff, A., El-
Bakkoury, M., Bangham, R., Benito, R., Brachat, S., Campanaro, S., Curtiss, M., 
Davis, K., Deutschbauer, A., Entian, K.-D., Flaherty, P., Foury, F., Garfinkel, D.J., 
Gerstein, M., Gotte, D., Güldener, U., Hegemann, J.H., Hempel, S., Herman, Z., 
Jaramillo, D.F., Kelly, D.E., Kelly, S.L., Kötter, P., LaBonte, D., Lamb, D.C., Lan, 
N., Liang, H., Liao, H., Liu, L., Luo, C., Lussier, M., Mao, R., Menard, P., Ooi, 
S.L., Revuelta, J.L., Roberts, C.J., Rose, M., Ross-Macdonald, P., Scherens, B., 
Schimmack, G., Shafer, B., Shoemaker, D.D., Sookhai-Mahadeo, S., Storms, R.K., 
204 
 
Strathern, J.N., Valle, G., Voet, M., Volckaert, G., Wang, C., Ward, T.R., 
Wilhelmy, J., Winzeler, E.A., Yang, Y., Yen, G., Youngman, E., Yu, K., Bussey, 
H., Boeke, J.D., Snyder, M., Philippsen, P., Davis, R.W. & Johnston, M. (2002). 
Functional profiling of the Saccharomyces cerevisiae genome. Nature 418, 387–91 
45. DeBartolo, J., Dutta, S., Reich, L. & Keating, A.E. (2012). Predictive Bcl-2 family 
binding models rooted in experiment or structure. J. Mol. Biol. 422, 124–44 
46. Pitt, J.N. & Ferré-D’Amaré, A.R. (2010). Rapid construction of empirical RNA 
fitness landscapes. Science 330, 376–9 
47. Fleishman, S.J., Whitehead, T.A., Ekiert, D.C., Dreyfus, C., Corn, J.E., Strauch, 
E.-M., Wilson, I.A. & Baker, D. (2011). Computational Design of Proteins 
Targeting the Conserved Stem Region of Influenza Hemagglutinin. Science (80-. ). 
332, 816–821 
48. Chau, V., Tobias, J.W., Bachmair, A., Marriott, D., Ecker, D.J., Gonda, D.K. & 
Varshavsky, A. (1989). A multiubiquitin chain is confined to specific lysine in a 
targeted short-lived protein. Science 243, 1576–83 
49. Rock, K.L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D. & 
Goldberg, A.L. (1994). Inhibitors of the proteasome block the degradation of most 
cell proteins and the generation of peptides presented on MHC class I molecules. 
Cell 78, 761–71 
50. Goldberg, A.L. (2007). Functions of the proteasome: from protein degradation and 
immune surveillance to cancer therapy. Biochem. Soc. Trans. 35, 12–7 
51. Goebl, M.G., Yochem, J., Jentsch, S., McGrath, J.P., Varshavsky, A. & Byers, B. 
(1988). The yeast cell cycle gene CDC34 encodes a ubiquitin-conjugating enzyme. 
Science 241, 1331–5 
52. Alkalay, I., Yaron, A., Hatzubai, A., Orian, A., Ciechanover, A. & Ben-Neriah, Y. 
(1995). Stimulation-dependent I kappa B alpha phosphorylation marks the NF-
kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. 
Natl. Acad. Sci. U. S. A. 92, 10599–603 
53. Dennissen, F.J.A., Kholod, N. & van Leeuwen, F.W. (2012). The ubiquitin 
proteasome system in neurodegenerative diseases: culprit, accomplice or victim? 
Prog. Neurobiol. 96, 190–207 
54. Orlowski, R.Z. & Kuhn, D.J. (2008). Proteasome inhibitors in cancer therapy: 
lessons from the first decade. Clin. Cancer Res. 14, 1649–57 
205 
 
55. Whitby, F.G., Xia, G., Pickart, C.M. & Hill, C.P. (1998). Crystal structure of the 
human ubiquitin-like protein NEDD8 and interactions with ubiquitin pathway 
enzymes. J. Biol. Chem. 273, 34983–91 
56. Lee, I. & Schindelin, H. (2008). Structural insights into E1-catalyzed ubiquitin 
activation and transfer to conjugating enzymes. Cell 134, 268–78 
57. Burch, T.J. & Haas, A.L. (1994). Site-directed mutagenesis of ubiquitin. 
Differential roles for arginine in the interaction with ubiquitin-activating enzyme. 
Biochemistry 33, 7300–8 
58. Miura, T., Klaus, W., Gsell, B., Miyamoto, C. & Senn, H. (1999). Characterization 
of the binding interface between ubiquitin and class I human ubiquitin-conjugating 
enzyme 2b by multidimensional heteronuclear NMR spectroscopy in solution. J. 
Mol. Biol. 290, 213–28 
59. Hurley, J.H., Lee, S. & Prag, G. (2006). Ubiquitin-binding domains. Biochem. J. 
399, 361–72 
60. Fushman, D. & Wilkinson, K.D. (2011). Structure and recognition of polyubiquitin 
chains of different lengths and linkage. F1000 Biol. Rep. 3, 26 
61. Hofmann, K. & Falquet, L. (2001). A ubiquitin-interacting motif conserved in 
components of the proteasomal and lysosomal protein degradation systems. Trends 
Biochem. Sci. 26, 347–50 
62. Fisher, R.D., Wang, B., Alam, S.L., Higginson, D.S., Robinson, H., Sundquist, 
W.I. & Hill, C.P. (2003). Structure and ubiquitin binding of the ubiquitin-
interacting motif. J. Biol. Chem. 278, 28976–84 
63. Hofmann, K. & Bucher, P. (1996). The UBA domain: a sequence motif present in 
multiple enzyme classes of the ubiquitination pathway. Trends Biochem. Sci. 21, 
172–3 
64. Ohno, A., Jee, J., Fujiwara, K., Tenno, T., Goda, N., Tochio, H., Kobayashi, H., 
Hiroaki, H. & Shirakawa, M. (2005). Structure of the UBA domain of Dsk2p in 
complex with ubiquitin molecular determinants for ubiquitin recognition. Structure 
13, 521–32 
65. Dieckmann, T., Withers-Ward, E.S., Jarosinski, M.A., Liu, C.F., Chen, I.S. & 
Feigon, J. (1998). Structure of a human DNA repair protein UBA domain that 
interacts with HIV-1 Vpr. Nat. Struct. Biol. 5, 1042–7 
206 
 
66. Beal, R., Deveraux, Q., Xia, G., Rechsteiner, M. & Pickart, C. (1996). Surface 
hydrophobic residues of multiubiquitin chains essential for proteolytic targeting. 
Proc. Natl. Acad. Sci. U. S. A. 93, 861–6 
67. Sloper-Mould, K.E., Jemc, J.C., Pickart, C.M. & Hicke, L. (2001). Distinct 
functional surface regions on ubiquitin. J. Biol. Chem. 276, 30483–9 
68. Went, H.M. & Jackson, S.E. (2005). Ubiquitin folds through a highly polarized 
transition state. Protein Eng. Des. Sel. 18, 229–37 
69. Benítez-Cardoza, C.G., Stott, K., Hirshberg, M., Went, H.M., Woolfson, D.N. & 
Jackson, S.E. (2004). Exploring sequence/folding space: folding studies on 
multiple hydrophobic core mutants of ubiquitin. Biochemistry 43, 5195–203 
70. Haririnia, A., Verma, R., Purohit, N., Twarog, M.Z., Deshaies, R.J., Bolon, D. & 
Fushman, D. (2008). Mutations in the hydrophobic core of ubiquitin differentially 
affect its recognition by receptor proteins. J. Mol. Biol. 375, 979–96 
71. Loladze, V. V, Ermolenko, D.N. & Makhatadze, G.I. (2002). Thermodynamic 
consequences of burial of polar and non-polar amino acid residues in the protein 
interior. J. Mol. Biol. 320, 343–57 
72. Pickart, C.M., Kasperek, E.M., Beal, R. & Kim, A. (1994). Substrate properties of 
site-specific mutant ubiquitin protein (G76A) reveal unexpected mechanistic 
features of ubiquitin-activating enzyme (E1). J. Biol. Chem. 269, 7115–23 
73. Lynch, M. & Conery, J.S. (2003). The origins of genome complexity. Science 302, 
1401–4 
74. Liti, G., Carter, D.M., Moses, A.M., Warringer, J., Parts, L., James, S.A., Davey, 
R.P., Roberts, I.N., Burt, A., Koufopanou, V., Tsai, I.J., Bergman, C.M., 
Bensasson, D., O’Kelly, M.J.T., van Oudenaarden, A., Barton, D.B.H., Bailes, E., 
Nguyen, A.N., Jones, M., Quail, M.A., Goodhead, I., Sims, S., Smith, F., 
Blomberg, A., Durbin, R. & Louis, E.J. (2009). Population genomics of domestic 
and wild yeasts. Nature 458, 337–41 
75. Sanjuán, R., Moya, A. & Elena, S.F. (2004). The distribution of fitness effects 
caused by single-nucleotide substitutions in an RNA virus. Proc. Natl. Acad. Sci. 
U. S. A. 101, 8396–401 
76. Carrasco, P., de la Iglesia, F. & Elena, S.F. (2007). Distribution of fitness and 
virulence effects caused by single-nucleotide substitutions in Tobacco Etch virus. 
J. Virol. 81, 12979–84 
207 
 
77. Domingo-Calap, P., Cuevas, J.M. & Sanjuán, R. (2009). The fitness effects of 
random mutations in single-stranded DNA and RNA bacteriophages. PLoS Genet. 
5, e1000742 
78. Perisic, O., Xiao, H. & Lis, J.T. (1989). Stable binding of Drosophila heat shock 
factor to head-to-head and tail-to-tail repeats of a conserved 5 bp recognition unit. 
Cell 59, 797–806 
79. Pursell, N.W., Mishra, P. & Bolon, D.N.A. (2012). Solubility-promoting function 
of Hsp90 contributes to client maturation and robust cell growth. Eukaryot. Cell 
11, 1033–41 
80. Wayne, N. & Bolon, D.N. (2010). Charge-rich regions modulate the anti-
aggregation activity of Hsp90. J. Mol. Biol. 401, 931–9 
81. Butt, T.R., Jonnalagadda, S., Monia, B.P., Sternberg, E.J., Marsh, J.A., Stadel, 
J.M., Ecker, D.J. & Crooke, S.T. (1989). Ubiquitin fusion augments the yield of 
cloned gene products in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 86, 2540–
4 
82. King, J.L. & Jukes, T.H. (1969). Non-Darwinian evolution. Science 164, 788–98 
83. Eddins, M.J., Varadan, R., Fushman, D., Pickart, C.M. & Wolberger, C. (2007). 
Crystal structure and solution NMR studies of Lys48-linked tetraubiquitin at 
neutral pH. J. Mol. Biol. 367, 204–11 
84. Varadan, R., Assfalg, M., Raasi, S., Pickart, C. & Fushman, D. (2005). Structural 
determinants for selective recognition of a Lys48-linked polyubiquitin chain by a 
UBA domain. Mol. Cell 18, 687–98 
85. Bolon, D.N., Marcus, J.S., Ross, S.A. & Mayo, S.L. (2003). Prudent modeling of 
core polar residues in computational protein design. J. Mol. Biol. 329, 611–22 
86. Bolon, D.N. & Mayo, S.L. (2001). Polar residues in the protein core of Escherichia 
coli thioredoxin are important for fold specificity. Biochemistry 40, 10047–53 
87. Cordes, M.H., Davidson, A.R. & Sauer, R.T. (1996). Sequence space, folding and 
protein design. Curr. Opin. Struct. Biol. 6, 3–10 
88. Krantz, B.A., Dothager, R.S. & Sosnick, T.R. (2004). Discerning the structure and 
energy of multiple transition states in protein folding using psi-analysis. J. Mol. 
Biol. 337, 463–75 
208 
 
89. Sims, J.J., Haririnia, A., Dickinson, B.C., Fushman, D. & Cohen, R.E. (2009). 
Avid interactions underlie the Lys63-linked polyubiquitin binding specificities 
observed for UBA domains. Nat. Struct. Mol. Biol. 16, 883–9 
90. Massi, F., Grey, M.J. & Palmer, A.G. (2005). Microsecond timescale backbone 
conformational dynamics in ubiquitin studied with NMR R1rho relaxation 
experiments. Protein Sci. 14, 735–42 
91. Fushman, D., Varadan, R., Assfalg, M. & Walker, O. (2004). Determining domain 
orientation in macromolecules by using spin-relaxation and residual dipolar 
coupling measurements. Prog. Nucl. Magn. Reson. Spectrosc. 44, 189–214 
92. Zhang, Y., Zhou, L., Rouge, L., Phillips, A.H., Lam, C., Liu, P., Sandoval, W., 
Helgason, E., Murray, J.M., Wertz, I.E. & Corn, J.E. (2013). Conformational 
stabilization of ubiquitin yields potent and selective inhibitors of USP7. Nat. 
Chem. Biol. 9, 51–8 
93. Gietz, R.D. & Woods, R.A. (2002). Transformation of yeast by lithium 
acetate/single-stranded carrier DNA/polyethylene glycol method. Methods 
Enzymol. 350, 87–96 
94. Scanlon, T.C., Gray, E.C. & Griswold, K.E. (2009). Quantifying and resolving 
multiple vector transformants in S. cerevisiae plasmid libraries. BMC Biotechnol. 
9, 95 
95. Dahiyat, B.I. & Mayo, S.L. (1997). De novo protein design: fully automated 
sequence selection. Science 278, 82–7 
96. Connolly, M.L. (1983). Solvent-accessible surfaces of proteins and nucleic acids. 
Science 221, 709–13 
97. (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallogr. 
D. Biol. Crystallogr. 50, 760–3 
98. Sahni, N., Yi, S., Zhong, Q., Jailkhani, N., Charloteaux, B., Cusick, M.E. & Vidal, 
M. (2013). Edgotype: a fundamental link between genotype and phenotype. Curr. 
Opin. Genet. Dev. 23, 649–57 
99. Vidal, M., Cusick, M.E. & Barabási, A.-L. (2011). Interactome networks and 
human disease. Cell 144, 986–98 
100. Ideker, T. & Sharan, R. (2008). Protein networks in disease. Genome Res. 18, 644–
52 
209 
 
101. Stearns, F.W. (2010). One hundred years of pleiotropy: a retrospective. Genetics 
186, 767–73 
102. Schuldiner, M., Collins, S.R., Thompson, N.J., Denic, V., Bhamidipati, A., Punna, 
T., Ihmels, J., Andrews, B., Boone, C., Greenblatt, J.F., Weissman, J.S. & Krogan, 
N.J. (2005). Exploration of the function and organization of the yeast early 
secretory pathway through an epistatic miniarray profile. Cell 123, 507–19 
103. Tong, A.H., Evangelista, M., Parsons, A.B., Xu, H., Bader, G.D., Pagé, N., 
Robinson, M., Raghibizadeh, S., Hogue, C.W., Bussey, H., Andrews, B., Tyers, 
M. & Boone, C. (2001). Systematic genetic analysis with ordered arrays of yeast 
deletion mutants. Science 294, 2364–8 
104. Uetz, P., Giot, L., Cagney, G., Mansfield, T.A., Judson, R.S., Knight, J.R., 
Lockshon, D., Narayan, V., Srinivasan, M., Pochart, P., Qureshi-Emili, A., Li, Y., 
Godwin, B., Conover, D., Kalbfleisch, T., Vijayadamodar, G., Yang, M., Johnston, 
M., Fields, S. & Rothberg, J.M. (2000). A comprehensive analysis of protein-
protein interactions in Saccharomyces cerevisiae. Nature 403, 623–7 
105. Gavin, A.-C., Bösche, M., Krause, R., Grandi, P., Marzioch, M., Bauer, A., 
Schultz, J., Rick, J.M., Michon, A.-M., Cruciat, C.-M., Remor, M., Höfert, C., 
Schelder, M., Brajenovic, M., Ruffner, H., Merino, A., Klein, K., Hudak, M., 
Dickson, D., Rudi, T., Gnau, V., Bauch, A., Bastuck, S., Huhse, B., Leutwein, C., 
Heurtier, M.-A., Copley, R.R., Edelmann, A., Querfurth, E., Rybin, V., Drewes, 
G., Raida, M., Bouwmeester, T., Bork, P., Seraphin, B., Kuster, B., Neubauer, G. 
& Superti-Furga, G. (2002). Functional organization of the yeast proteome by 
systematic analysis of protein complexes. Nature 415, 141–7 
106. Ho, Y., Gruhler, A., Heilbut, A., Bader, G.D., Moore, L., Adams, S.-L., Millar, A., 
Taylor, P., Bennett, K., Boutilier, K., Yang, L., Wolting, C., Donaldson, I., 
Schandorff, S., Shewnarane, J., Vo, M., Taggart, J., Goudreault, M., Muskat, B., 
Alfarano, C., Dewar, D., Lin, Z., Michalickova, K., Willems, A.R., Sassi, H., 
Nielsen, P.A., Rasmussen, K.J., Andersen, J.R., Johansen, L.E., Hansen, L.H., 
Jespersen, H., Podtelejnikov, A., Nielsen, E., Crawford, J., Poulsen, V., Sørensen, 
B.D., Matthiesen, J., Hendrickson, R.C., Gleeson, F., Pawson, T., Moran, M.F., 
Durocher, D., Mann, M., Hogue, C.W. V, Figeys, D. & Tyers, M. (2002). 
Systematic identification of protein complexes in Saccharomyces cerevisiae by 
mass spectrometry. Nature 415, 180–3 
107. Vidal, M., Brachmann, R.K., Fattaey, A., Harlow, E. & Boeke, J.D. (1996). 
Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-
protein and DNA-protein interactions. Proc. Natl. Acad. Sci. U. S. A. 93, 10315–20 
210 
 
108. Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R. & Ishioka, C. 
(2003). Understanding the function-structure and function-mutation relationships 
of p53 tumor suppressor protein by high-resolution missense mutation analysis. 
Proc. Natl. Acad. Sci. U. S. A. 100, 8424–9 
109. Dreze, M., Charloteaux, B., Milstein, S., Vidalain, P.-O., Yildirim, M.A., Zhong, 
Q., Svrzikapa, N., Romero, V., Laloux, G., Brasseur, R., Vandenhaute, J., Boxem, 
M., Cusick, M.E., Hill, D.E. & Vidal, M. (2009). “Edgetic” perturbation of a C. 
elegans BCL2 ortholog. Nat. Methods 6, 843–9 
110. Kacser, H. & Burns, J.A. (1995). The control of flux. Biochem. Soc. Trans. 23, 
341–66 
111. Jiang, L., Mishra, P., Hietpas, R.T., Zeldovich, K.B. & Bolon, D.N. a (2013). 
Latent effects of Hsp90 mutants revealed at reduced expression levels. PLoS 
Genet. 9, e1003600 
112. Liberles, D.A., Teichmann, S.A., Bahar, I., Bastolla, U., Bloom, J., Bornberg-
Bauer, E., Colwell, L.J., de Koning, A.P.J., Dokholyan, N. V, Echave, J., Elofsson, 
A., Gerloff, D.L., Goldstein, R.A., Grahnen, J.A., Holder, M.T., Lakner, C., 
Lartillot, N., Lovell, S.C., Naylor, G., Perica, T., Pollock, D.D., Pupko, T., Regan, 
L., Roger, A., Rubinstein, N., Shakhnovich, E., Sjölander, K., Sunyaev, S., Teufel, 
A.I., Thorne, J.L., Thornton, J.W., Weinreich, D.M. & Whelan, S. (2012). The 
interface of protein structure, protein biophysics, and molecular evolution. Protein 
Sci. 21, 769–85 
113. Fraser, J.S., Gross, J.D. & Krogan, N.J. (2013). From systems to structure: 
bridging networks and mechanism. Mol. Cell 49, 222–31 
114. Zhu, G., Golding, G.B. & Dean, A.M. (2005). The selective cause of an ancient 
adaptation. Science 307, 1279–82 
115. Bridgham, J.T., Carroll, S.M. & Thornton, J.W. (2006). Evolution of hormone-
receptor complexity by molecular exploitation. Science 312, 97–101 
116. Linnen, C.R., Poh, Y.-P., Peterson, B.K., Barrett, R.D.H., Larson, J.G., Jensen, 
J.D. & Hoekstra, H.E. (2013). Adaptive evolution of multiple traits through 
multiple mutations at a single gene. Science 339, 1312–6 
117. Dekel, E. & Alon, U. (2005). Optimality and evolutionary tuning of the expression 
level of a protein. Nature 436, 588–92 
118. Eames, M. & Kortemme, T. (2012). Cost-benefit tradeoffs in engineered lac 
operons. Science 336, 911–5 
211 
 
119. Weinreich, D.M., Delaney, N.F., Depristo, M.A. & Hartl, D.L. (2006). Darwinian 
evolution can follow only very few mutational paths to fitter proteins. Science 312, 
111–4 
120. Lunzer, M., Miller, S.P., Felsheim, R. & Dean, A.M. (2005). The biochemical 
architecture of an ancient adaptive landscape. Science 310, 499–501 
121. Dean, A.M., Dykhuizen, D.E. & Hartl, D.L. (1986). Fitness as a function of beta-
galactosidase activity in Escherichia coli. Genet. Res. 48, 1–8 
122. Haas, A.L., Warms, J. V, Hershko, A. & Rose, I.A. (1982). Ubiquitin-activating 
enzyme. Mechanism and role in protein-ubiquitin conjugation. J. Biol. Chem. 257, 
2543–8 
123. McGrath, J.P., Jentsch, S. & Varshavsky, A. (1991). UBA 1: an essential yeast 
gene encoding ubiquitin-activating enzyme. EMBO J. 10, 227–36 
124. Tokuriki, N. & Tawfik, D.S. (2009). Stability effects of mutations and protein 
evolvability. Curr. Opin. Struct. Biol. 19, 596–604 
125. Gangadhara, B.N., Laine, J.M., Kathuria, S. V, Massi, F. & Matthews, C.R. 
(2013). Clusters of branched aliphatic side chains serve as cores of stability in the 
native state of the HisF TIM barrel protein. J. Mol. Biol. 425, 1065–81 
126. Dill, K.A. (1990). Dominant forces in protein folding. Biochemistry 29, 7133–55 
127. Lee, S.Y., Pullen, L., Virgil, D.J., Castañeda, C.A., Abeykoon, D., Bolon, D.N.A. 
& Fushman, D. (2013). Alanine Scan of Core Positions in Ubiquitin Reveals Links 
between Dynamics, Stability, and Function. J. Mol. Biol. 426, 1377–1389 
128. Matyskiela, M.E., Lander, G.C. & Martin, A. (2013). Conformational switching of 
the 26S proteasome enables substrate degradation. Nat. Struct. Mol. Biol. 20, 781–
8 
129. Phillips, A.H., Zhang, Y., Cunningham, C.N., Zhou, L., Forrest, W.F., Liu, P.S., 
Steffek, M., Lee, J., Tam, C., Helgason, E., Murray, J.M., Kirkpatrick, D.S., 
Fairbrother, W.J. & Corn, J.E. (2013). Conformational dynamics control ubiquitin-
deubiquitinase interactions and influence in vivo signaling. Proc. Natl. Acad. Sci. 
U. S. A. 110, 11379–84 
130. Zhao, B., Bhuripanyo, K., Schneider, J., Zhang, K., Schindelin, H., Boone, D. & 
Yin, J. (2012). Specificity of the E1-E2-E3 enzymatic cascade for ubiquitin C-
terminal sequences identified by phage display. ACS Chem. Biol. 7, 2027–35 
212 
 
131. Patel, L.R., Curran, T. & Kerppola, T.K. (1994). Energy transfer analysis of Fos-
Jun dimerization and DNA binding. Proc. Natl. Acad. Sci. U. S. A. 91, 7360–4 
132. Walden, H., Podgorski, M.S. & Schulman, B.A. (2003). Insights into the ubiquitin 
transfer cascade from the structure of the activating enzyme for NEDD8. Nature 
422, 330–4 
133. Swanson, K.A., Kang, R.S., Stamenova, S.D., Hicke, L. & Radhakrishnan, I. 
(2003). Solution structure of Vps27 UIM-ubiquitin complex important for 
endosomal sorting and receptor downregulation. EMBO J. 22, 4597–606 
134. Peschard, P., Kozlov, G., Lin, T., Mirza, I.A., Berghuis, A.M., Lipkowitz, S., Park, 
M. & Gehring, K. (2007). Structural basis for ubiquitin-mediated dimerization and 
activation of the ubiquitin protein ligase Cbl-b. Mol. Cell 27, 474–85 
135. Clackson, T. & Wells, J.A. (1995). A hot spot of binding energy in a hormone-
receptor interface. Science 267, 383–6 
136. Hendsch, Z.S. & Tidor, B. (1994). Do salt bridges stabilize proteins? A continuum 
electrostatic analysis. Protein Sci. 3, 211–26 
137. Drummond, D.A. & Wilke, C.O. (2009). The evolutionary consequences of 
erroneous protein synthesis. Nat. Rev. Genet. 10, 715–24 
138. Khoury, G.A., Baliban, R.C. & Floudas, C.A. (2011). Proteome-wide post-
translational modification statistics: frequency analysis and curation of the swiss-
prot database. Sci. Rep. 1,  
139. Kramer, E.B., Vallabhaneni, H., Mayer, L.M. & Farabaugh, P.J. (2010). A 
comprehensive analysis of translational missense errors in the yeast 
Saccharomyces cerevisiae. RNA 16, 1797–808 
140. Tsai, I.J., Bensasson, D., Burt, A. & Koufopanou, V. (2008). Population genomics 
of the wild yeast Saccharomyces paradoxus: Quantifying the life cycle. Proc. Natl. 
Acad. Sci. U. S. A. 105, 4957–62 
141. Ohta, T. (1973). Slightly deleterious mutant substitutions in evolution. Nature 246, 
96–8 
142. Geiler-samerotte, K.A., Dion, M.F., Budnik, B.A., Wang, S.M. & Hartl, D.L. 
(2010). Misfolded proteins impose a dosage-dependent fitness cost and trigger a 
cytosolic unfolded protein response in yeast. doi:10.1073/pnas.1017570108/-
/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1017570108 
213 
 
143. Joshi, K.K., Chen, L., Torres, N., Tournier, V. & Madura, K. (2011). A 
proteasome assembly defect in rpn3 mutants is associated with Rpn11 instability 
and increased sensitivity to stress. J. Mol. Biol. 410, 383–99 
144. Yao, T. & Cohen, R.E. (2002). A cryptic protease couples deubiquitination and 
degradation by the proteasome. Nature 419, 403–7 
145. Verma, R., Aravind, L., Oania, R., McDonald, W.H., Yates, J.R., Koonin, E. V & 
Deshaies, R.J. (2002). Role of Rpn11 metalloprotease in deubiquitination and 
degradation by the 26S proteasome. Science 298, 611–5 
146. Shusta, E. V, Holler, P.D., Kieke, M.C., Kranz, D.M. & Wittrup, K.D. (2000). 
Directed evolution of a stable scaffold for T-cell receptor engineering. Nat. 
Biotechnol. 18, 754–9 
147. Duffy, S., Tsao, K.L. & Waugh, D.S. (1998). Site-specific, enzymatic biotinylation 
of recombinant proteins in Spodoptera frugiperda cells using biotin acceptor 
peptides. Anal. Biochem. 262, 122–8 
148. Chen, I., Howarth, M., Lin, W. & Ting, A.Y. (2005). Site-specific labeling of cell 
surface proteins with biophysical probes using biotin ligase. Nat. Methods 2, 99–
104 
149. Li, M.Z. & Elledge, S.J. (2007). Harnessing homologous recombination in vitro to 
generate recombinant DNA via SLIC. Nat. Methods 4, 251–6 
150. Mumberg, D., Müller, R. & Funk, M. (1994). Regulatable promoters of 
Saccharomyces cerevisiae: comparison of transcriptional activity and their use for 
heterologous expression. Nucleic Acids Res. 22, 5767–8 
151. Dhomen, N. & Marais, R. (2007). New insight into BRAF mutations in cancer. 
Curr. Opin. Genet. Dev. 17, 31–9 
152. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., 
Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., 
Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., 
Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., 
Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., 
Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., 
Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W.C., Leung, S.Y., Yuen, S.T., 
Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., 
Wooster, R., Stratton, M.R. & Futreal, P.A. (2002). Mutations of the BRAF gene 
in human cancer. Nature 417, 949–54 
214 
 
153. Bollag, G., Tsai, J., Zhang, J., Zhang, C., Ibrahim, P., Nolop, K. & Hirth, P. 
(2012). Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat. Rev. 
Drug Discov. 11, 873–86 
154. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P.N., Cho, H., Spevak, W., 
Zhang, C., Zhang, Y., Habets, G., Burton, E.A., Wong, B., Tsang, G., West, B.L., 
Powell, B., Shellooe, R., Marimuthu, A., Nguyen, H., Zhang, K.Y.J., Artis, D.R., 
Schlessinger, J., Su, F., Higgins, B., Iyer, R., D’Andrea, K., Koehler, A., Stumm, 
M., Lin, P.S., Lee, R.J., Grippo, J., Puzanov, I., Kim, K.B., Ribas, A., McArthur, 
G.A., Sosman, J.A., Chapman, P.B., Flaherty, K.T., Xu, X., Nathanson, K.L. & 
Nolop, K. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade 
in BRAF-mutant melanoma. Nature 467, 596–9 
155. Dummer, R. & Flaherty, K.T. (2012). Resistance patterns with tyrosine kinase 
inhibitors in melanoma: new insights. Curr. Opin. Oncol. 24, 150–4 
156. Shi, H., Moriceau, G., Kong, X., Lee, M.-K., Lee, H., Koya, R.C., Ng, C., Chodon, 
T., Scolyer, R.A., Dahlman, K.B., Sosman, J.A., Kefford, R.F., Long, G. V, 
Nelson, S.F., Ribas, A. & Lo, R.S. (2012). Melanoma whole-exome sequencing 
identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor 
resistance. Nat. Commun. 3, 724 
157. Poulikakos, P.I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., 
Shi, H., Atefi, M., Titz, B., Gabay, M.T., Salton, M., Dahlman, K.B., Tadi, M., 
Wargo, J.A., Flaherty, K.T., Kelley, M.C., Misteli, T., Chapman, P.B., Sosman, 
J.A., Graeber, T.G., Ribas, A., Lo, R.S., Rosen, N. & Solit, D.B. (2011). RAF 
inhibitor resistance is mediated by dimerization of aberrantly spliced 
BRAF(V600E). Nature 480, 387–90 
158. Tsai, J., Lee, J.T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, 
S., Kong, J., Haass, N.K., Sproesser, K., Li, L., Smalley, K.S.M., Fong, D., Zhu, 
Y.-L., Marimuthu, A., Nguyen, H., Lam, B., Liu, J., Cheung, I., Rice, J., Suzuki, 
Y., Luu, C., Settachatgul, C., Shellooe, R., Cantwell, J., Kim, S.-H., Schlessinger, 
J., Zhang, K.Y.J., West, B.L., Powell, B., Habets, G., Zhang, C., Ibrahim, P.N., 
Hirth, P., Artis, D.R., Herlyn, M. & Bollag, G. (2008). Discovery of a selective 
inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. 
Acad. Sci. U. S. A. 105, 3041–6 
159. Mitsiades, N., Chew, S.A., He, B., Riechardt, A.I., Karadedou, T., Kotoula, V. & 
Poulaki, V. (2011). Genotype-dependent sensitivity of uveal melanoma cell lines 
to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. 
Invest. Ophthalmol. Vis. Sci. 52, 7248–55 
215 
 
160. Whittaker, S., Kirk, R., Hayward, R., Zambon, A., Viros, A., Cantarino, N., 
Affolter, A., Nourry, A., Niculescu-Duvaz, D., Springer, C. & Marais, R. (2010). 
Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci. Transl. 
Med. 2, 35ra41 
161. Smalley, K.S.M., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T. & Herlyn, 
M. (2006). Multiple signaling pathways must be targeted to overcome drug 
resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5, 
1136–44 
162. Favata, M.F., Horiuchi, K.Y., Manos, E.J., Daulerio, A.J., Stradley, D.A., Feeser, 
W.S., Van Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F., Copeland, R.A., Magolda, 
R.L., Scherle, P.A. & Trzaskos, J.M. (1998). Identification of a novel inhibitor of 
mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623–32 
163. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B. & Rosen, N. 
(2009). (V600E)BRAF is associated with disabled feedback inhibition of RAF-
MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. 
Acad. Sci. U. S. A. 106, 4519–24 
164. Warmuth, M., Kim, S., Gu, X., Xia, G. & Adrián, F. (2007). Ba/F3 cells and their 
use in kinase drug discovery. Curr. Opin. Oncol. 19, 55–60 
165. Forbes, S.A., Bindal, N., Bamford, S., Cole, C., Kok, C.Y., Beare, D., Jia, M., 
Shepherd, R., Leung, K., Menzies, A., Teague, J.W., Campbell, P.J., Stratton, 
M.R. & Futreal, P.A. (2011). COSMIC: mining complete cancer genomes in the 
Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945–50 
166. Barbieri, C.E., Baca, S.C., Lawrence, M.S., Demichelis, F., Blattner, M., 
Theurillat, J.-P., White, T.A., Stojanov, P., Van Allen, E., Stransky, N., Nickerson, 
E., Chae, S.-S., Boysen, G., Auclair, D., Onofrio, R.C., Park, K., Kitabayashi, N., 
MacDonald, T.Y., Sheikh, K., Vuong, T., Guiducci, C., Cibulskis, K., Sivachenko, 
A., Carter, S.L., Saksena, G., Voet, D., Hussain, W.M., Ramos, A.H., Winckler, 
W., Redman, M.C., Ardlie, K., Tewari, A.K., Mosquera, J.M., Rupp, N., Wild, 
P.J., Moch, H., Morrissey, C., Nelson, P.S., Kantoff, P.W., Gabriel, S.B., Golub, 
T.R., Meyerson, M., Lander, E.S., Getz, G., Rubin, M.A. & Garraway, L.A. 
(2012). Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 
mutations in prostate cancer. Nat. Genet. 44, 685–9 
167. King, A.J., Patrick, D.R., Batorsky, R.S., Ho, M.L., Do, H.T., Zhang, S.Y., Kumar, 
R., Rusnak, D.W., Takle, A.K., Wilson, D.M., Hugger, E., Wang, L., Karreth, F., 
Lougheed, J.C., Lee, J., Chau, D., Stout, T.J., May, E.W., Rominger, C.M., 
Schaber, M.D., Luo, L., Lakdawala, A.S., Adams, J.L., Contractor, R.G., Smalley, 
K.S.M., Herlyn, M., Morrissey, M.M., Tuveson, D.A. & Huang, P.S. (2006). 
216 
 
Demonstration of a genetic therapeutic index for tumors expressing oncogenic 
BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 11100–5 
168. Hansen, J.D., Grina, J., Newhouse, B., Welch, M., Topalov, G., Littman, N., 
Callejo, M., Gloor, S., Martinson, M., Laird, E., Brandhuber, B.J., Vigers, G., 
Morales, T., Woessner, R., Randolph, N., Lyssikatos, J. & Olivero, A. (2008). 
Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg. Med. 
Chem. Lett. 18, 4692–5 
169. Roscoe, B.P., Thayer, K.M., Zeldovich, K.B., Fushman, D. & Bolon, D.N.A. 
(2013). Analyses of the effects of all ubiquitin point mutants on yeast growth rate. 
J. Mol. Biol. 425, 1363–77 
170. Hietpas, R.T., Bank, C., Jensen, J.D. & Bolon, D.N.A. (2013). Shifting fitness 
landscapes in response to altered environments. Evolution 67, 3512–22 
171. Finley, D., Ozkaynak, E. & Varshavsky, A. (1987). The yeast polyubiquitin gene 
is essential for resistance to high temperatures, starvation, and other stresses. Cell 
48, 1035–46 
172. Kee, Y., Muñoz, W., Lyon, N. & Huibregtse, J.M. (2006). The deubiquitinating 
enzyme Ubp2 modulates Rsp5-dependent Lys63-linked polyubiquitin conjugates 
in Saccharomyces cerevisiae. J. Biol. Chem. 281, 36724–31 
173. DePristo, M.A., Weinreich, D.M. & Hartl, D.L. (2005). Missense meanderings in 
sequence space: a biophysical view of protein evolution. Nat. Rev. Genet. 6, 678–
87  
 
